Non-Self-Administered Prior Authorization Approval Criteria

Effective Date: 10/01/2022
Standard Non-Self-Administered Prior Authorization Guidelines
1. **Formulary Agents**
   Drug products that are listed in the Formulary as Prior Authorization (PA) require evaluation, per MedImpact Pharmacy and Therapeutics Committee guidelines, when the member presents a prescription to a network pharmacy. Each request will be reviewed on individual patient need. If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

2. **Non-Formulary Agents**
   Any product not found in the Formulary listing, or any Formulary updates published by MedImpact, shall be considered a Non-Formulary drug. Coverage for non-formulary agents may be applied for in advance. When a member gives a prescription order for a non-formulary drug to a pharmacist, the pharmacist will evaluate the patient’s drug history and contact the physician to determine if there is a legitimate medical need for a non-formulary drug. Each request will be reviewed on individual patient need. The following basic criteria are used:
   a. The use of Formulary Drug Products is contraindicated in the patient.
   b. The patient has failed an appropriate trial of Formulary or related agents.
   c. The choices available in the Drug Formulary are not suited for the present patient care need, and the drug selected is required for patient safety.
   d. The use of a Formulary drug may provoke an underlying condition, which would be detrimental to patient care.

   If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

3. **Obtaining Coverage**
   Coverage may be obtained by:
   a. Faxing a completed Prior Authorization Request to DHMP at (303) 602-2081.
   b. Contacting DHMP Pharmacy Department at (303) 602-2070 and providing all necessary information requested.

   Non-approved requests may be appealed. The prescriber must provide information to support the appeal on the basis of medical necessity.
ABATACEPT - IV (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABATACEPT/MALTOSE</td>
<td>ORENCIA - IV</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ABATACEPT - IV (Orencia - IV) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   3. Psoriatic arthritis (PsA: a type of skin and joint condition)
   4. Prophylaxis (prevention) of acute graft versus host disease (aGVHD: a short-term type of immune disorder)

B. If the request is for moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Enbrel, Humira, Rinvoq, Xeljanz immediate/extended release
      b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
ABATACEPT - IV (NSA)

INITIAL CRITERIA (CONTINUED)

C. If the request is for moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Enbrel, Humira, Actemra, Xeljanz immediate release

D. If the request is for psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Cosentyx, Enbrel, Humira, Stelara, Xeljanz immediate/extended release, Otezla, Tremfya, Rinoq, Skyrizi

E. If the request is for prophylaxis of acute graft versus host disease, approval also requires:
   1. You are 2 years of age or older
   2. You are undergoing hematopoietic stem cell transplantation (HSCT: a type of cell transplantation) from a matched or one allele (version of a gene)-mismatched unrelated donor
   3. Orencia will be used in combination with a calcineurin inhibitor (such as cyclosporine or tacrolimus) and methotrexate

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
ABATACEPT - IV (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named ABATACEPT - IV (ORENCIA - IV) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   3. Psoriatic arthritis (PsA: a type of skin and joint condition)

B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Commercial Effective: 03/14/22
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADO-TRASTUZUMAB EMTANSINE (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADO-TRASTUZUMAB EMTANSINE</td>
<td>KADCYLA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ADO-TRASTUZUMAB EMTANSINE (Kadcyla) requires the following rule(s) be met for approval:
A. You have metastatic breast cancer (cancer has spread to other parts of body) or early breast cancer
B. **If you have metastatic breast cancer, approval also requires:**
   1. Your breast cancer is HER2-positive (it has a protein that causes breast cancer cells to grow)
   2. You have previously received trastuzumab and a taxane (class of cancer medication), separately or in combination
   3. You have received prior therapy for metastatic disease (disease has spread) OR developed disease recurrence (disease returns) during or within six months of completing adjuvant (add-on) therapy
C. **If you have early breast cancer, approval also requires:**
   1. Your breast cancer is HER2-positive (it has a protein that causes breast cancer cells to grow)
   2. You have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment (disease is still present after using certain types of cancer drugs)

Commercial Effective: 05/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADUCANUMAB-AVWA (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADUCANUMAB-AVWA</td>
<td>ADUHELM</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ADUCANUMAB-AVWA (Aduhelm)** requires the following rule(s) be met for approval:

A. You have mild Alzheimer's disease (progressive brain disorder that slowly destroys memory and thinking skills) or mild cognitive impairment (decreased ability to process, understand, store and remember information) due to Alzheimer's disease

B. Therapy is prescribed by or given in consultation with a neurologist (doctor who specializes in the brain), geriatrician (doctor who specializes in health care of elderly people), or psychiatrist (doctor who specializes in mental disorders)

C. You have a radiology report (type of imaging) or chart notes documenting the presence of amyloid-beta plaques (an indicator of Alzheimer's disease)

D. You have a Clinical Dementia Rating (CDR: a tool for evaluating memory loss) global score of 0.5 or 1.0 OR Mini Mental Status Exam (MMSE: a test used to evaluate memory, thinking, and understanding) score of 24 to 30

E. You have documentation confirming a baseline brain MRI (Magnetic resonance imaging) within one year prior to treatment

F. You do not have a history of a clotting disorder (illness that interferes with the blood’s ability to clot)

G. You are participating in an FDA (Federal Drug Administration)/NIH (National Institute of Health) approved clinical trial

H. You are not concurrently (at the same time) using any anticoagulant or antiplatelet therapy (except for aspirin at 81 mg daily or less) (such as rivaroxaban, dabigatran, clopidogrel, prasugrel)

CONTINUED ON NEXT PAGE
ADUCANUMAB-AVWA (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named ADUCANUMAB-AVWA (Aduhelm) requires the following rule(s) be met for renewal:

A. You have mild Alzheimer's disease (progressive brain disorder that slowly destroys memory and thinking skills) or mild cognitive impairment (decreased ability to process, understand, store and remember information) due to Alzheimer's disease

B. Your cognitive decline has slowed or stopped

C. You are not experiencing any severe, unstable, or symptomatic amyloid-related imaging abnormalities (ARIA: abnormal differences seen in magnetic resonance imaging [MRI: a medical imaging technique] of the brain)

D. You are not concurrently (at the same time) using any anticoagulant or antiplatelet therapy (except for aspirin at 81 mg daily or less) (such as rivaroxaban, dabigatran, clopidogrel, prasugrel)

Commercial Effective: 07/01/22
Our guideline named AFAMELANOTIDE (Scenesse) requires the following rule(s) be met for approval:
A. You have erythropoietic protoporphyria (EPP: a rare disorder that makes exposure to light extremely painful)
B. You are 18 years of age or older
C. You have a history of phototoxic reactions (damage to the skin)
D. The requested medication will be used to increase pain free light exposure

Commercial Effective: 07/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AFLIBERCEPT (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFLIBERCEPT</td>
<td>EYLEA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named AFLIBERCEPT (Eylea) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Neovascular (wet) age-related macular degeneration (nAMD: a type of eye disease)
   2. Macular edema following retinal vein occlusion (RVO: a type of eye condition)
   3. Diabetic macular edema (DME: a type of eye condition caused by high blood sugar)
   4. Diabetic retinopathy (DR: a type of eye condition caused by high blood sugar)

B. Therapy is prescribed by or in consultation with an ophthalmologist (eye doctor) or retina (a part of the eye) specialist

C. If you have diabetic macular edema, approval also requires:
   1. You will NOT use Eylea concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Lucentis, Vabysmo)

D. If you have neovascular (wet) age-related macular degeneration, approval also requires:
   1. You will NOT use Eylea concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Lucentis, Susvimo, Beovu)

RENEWAL CRITERIA

NOTE: For the diagnoses of diabetic retinopathy or macular edema following retinal vein occlusion, please refer to the initial criteria section.

Our guideline named AFLIBERCEPT (Eylea) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Diabetic macular edema (DME: a type of eye condition caused by high blood sugar)
   2. Neovascular (wet) age-related macular degeneration (nAMD: a type of eye disease)

B. If you have diabetic macular edema, renewal also requires:
   1. You have maintenance or improvement of visual acuity (vision clarity or sharpness)
   2. You will NOT use Eylea concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Lucentis, Vabysmo)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE
AFLIBERCEPT (NSA)

RENEWAL CRITERIA (CONTINUED)

C. If you have neovascular (wet) age-related macular degeneration, renewal also requires:
   1. You have maintenance or improvement of visual acuity (vision clarity or sharpness)
   2. You will NOT use Eylea concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Lucentis, Susvimo, Beovu)

Commercial Effective: 07/01/22
AGALSIDASE BETA (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGALSIDASE BETA</td>
<td>FABRAZYME</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named AGALSIDASE BETA (Fabrazyme) requires the following rule(s) be met for approval:

A. You have Fabry disease (a rare genetic disease)
B. You are 2 years of age or older
C. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor), cardiologist (heart doctor), or specialist physician in genetics or inherited metabolic disorders
D. You are NOT concurrently (taking at the same time) using an alpha-galactosidase A (a-Gal A: a type of protein) pharmacological chaperone (a molecule that helps correct other bad proteins) Galafold (migalastat)
E. You are symptomatic OR have evidence of injury from GL-3 (Globotriaosylceramide: a type of fat) to the kidney, heart, or central nervous system recognized by laboratory, histological (viewed by microscope), or imaging findings. Evidence of injury would include decreased glomerular filtration rate (GFR: a tool for evaluating kidney function) for age, persistent albuminuria (protein in urine), cerebral white matter lesions on brain MRI (magnetic resonance imaging: type of imaging lab), cardiac fibrosis (abnormal thickening of heart valves) on contrast cardiac MRI
F. You meet ONE of the following:
   1. Female patients: There is confirmation of Fabry disease via genetic test documenting galactosidase alpha gene (GLA) mutation
   2. Male patients: There is confirmation of Fabry disease via enzyme assay (type of lab test) showing you do not have enough alpha galactosidase A (a-Gal –A), OR genetic test documenting galactosidase alpha gene (GLA) mutation

CONTINUED ON NEXT PAGE
AGALSIDASE BETA (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named AGALSIDASE BETA (Fabrazyme) requires the following rule(s) be met for renewal:

A. You have a diagnosis of Fabry disease (a rare genetic disease)

B. You have demonstrated improvement or maintenance/stabilization while on Fabrazyme therapy in regard to at least ONE of the following:

1. Symptoms which include pain, hypohidrosis/anhidrosis (less sweating or no sweating), exercise intolerance, GI (gastrointestinal) symptoms, angiokeratomas (dark red/purple raised spots), abnormal cornea, tinnitus (ringing in the ears)/hearing loss

2. Imaging such as brain/cardiac MRI (magnetic resonance imaging: type of imaging lab), DEXA (test to measure bone density), renal (kidney) ultrasound

3. Laboratory or histological (viewed by microscope) testing such as GL-3 (globotriaosylceramide: a type of fat) in plasma/urine, renal biopsy

C. You are NOT concurrently (taking at the same time) using an alpha-galactosidase A (a-Gal A: a type of protein) pharmacological chaperone (a molecule that helps correct other bad proteins) Galafold (migalastat)

Commercial Effective: 07/01/22
Alemtuzumab (NSA)

Generic  | Brand  
----------|--------
ALEMTUZUMAB  | LEMTRADA  

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ALEMTUZUMAB (Lemtrada)** requires the following rules be met for approval:

A. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), to include relapsing-remitting disease (symptoms go away and return) and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

C. You have previously tried TWO drugs that have been FDA (Food and Drug Administration) approved for the treatment of relapsing forms of multiple sclerosis (MS) *(Please note: The following agents are preferred and may also require prior authorization: Avonex, Copaxone/Glatiramer/Glatopa, Gilenya, Plegridy, Rebif, Betaseron, dimethyl fumarate, Mavenclad, Mayzent, Vumerity, Aubagio, Kesimpta)*

RENEWAL CRITERIA

Our guideline named **ALEMTUZUMAB (Lemtrada)** requires the following rules be met for renewal:

A. You have a relapsing form of multiple sclerosis (MS: an illness where immune system eats away at the protective covering of the nerves), to include relapsing-remitting disease (symptoms go away and return) and active secondary progressive disease (advanced disease)

B. At least 12 months have passed since you received the most recent course of Lemtrada

Commercial Effective: 01/01/21
GUIDELINES FOR USE

Our guideline named ALGLUCOSIDASE ALFA (Lumizyme) requires that the following rules be met:

A. You have Pompe's disease (an inherited condition where complex sugar (glycogen) builds up in your body's cells because your body cannot make a type of enzyme called acid alpha-glucosidase) for approval.
AMIVANTAMAB-VMJW (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMIVANTAMAB-VMJW</td>
<td>RYBREVANT</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline name AMIVANTAMAB-VMJW (Rybrevant) requires the following rule(s) be met for approval:

A. You have locally advanced or metastatic non-small cell lung cancer (NSCLC) (type of lung cancer that has grown outside the organ it started in but has not spread to other parts of the body or lung cancer that has spread to other parts of the body)

B. You are 18 years of age or older

C. You have epidermal growth factor receptor (EGFR) exon 20 insertion mutations (type of gene mutation), as detected by a Food and Drug Administration (FDA)-approved test

D. Your disease has progressed on or after platinum-based chemotherapy (type of treatment for NSCLC)

CommercialEffective: 10/01/21
ANIFROLUMAB-FNIA (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANIFROLUMAB-FNIA</td>
<td>SAPHNELO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ANIFROLUMAB-FNIA (Saphnelo) requires the following rule(s) be met for approval:
A. You have moderate to severe systemic lupus erythematosus (SLE: a condition where the immune system attacks its own tissues)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a rheumatologist (a doctor who specializes in conditions that affects the muscles and skeletal system, especially the joints)
D. You are receiving standard SLE therapy (types of medication to suppress your immune system, such as oral corticosteroids, antimalarials, or immunosuppressants)

RENEWAL CRITERIA

Our guideline named ANIFROLUMAB-FNIA (Saphnelo) requires the following rule(s) be met for renewal:
A. You have moderate to severe systemic lupus erythematosus (SLE: a condition where the immune system attacks its own tissues)
B. You have had clinical improvement while on Saphnelo

Commercial Effective: 08/30/21
Drugs listed in this document do not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

**ASPARAGINASE (NSA)**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPARAGINASE (ERWINIA CHRYSAN)</td>
<td>ERWINAZE</td>
</tr>
<tr>
<td>PEGASPARGASE</td>
<td>ONCASPAR</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named ASPARAGINASE (Erwinaze, Oncaspar) requires the following rule(s) be met for approval:

A. You have a diagnosis of acute lymphoblastic leukemia (ALL: type of blood and bone marrow cancer)

B. The requested medication will be used as a part of a chemotherapeutic treatment plan with multiple drugs

C. **If you are requesting Oncaspar, approval also requires ONE of the following:**
   1. Oncaspar will be used as a first-line therapy
   2. You have hypersensitivity to native forms of L-asparaginase (you are allergic to natural forms of a type of enzyme/protein)

D. **If you are requesting Erwinaze, approval also requires:**
   1. You have developed a hypersensitivity to a E. Coli-derived asparaginase (you are allergic to an enzyme/protein that is from a type of bacteria)

Commercial Effective: 07/01/20
Our guideline named ATEZOLIZUMAB (Tecentriq) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Locally advanced or metastatic (disease has spread to other parts of the body) urothelial carcinoma (cancer that occurs in the urinary system)
   2. Stage II to IIIA non-small cell lung cancer (NSCLC: a type of lung cancer)
   3. Metastatic non-squamous non-small cell lung cancer (NSq NSCLC: a type of lung cancer that originates in peripheral lung tissue)
   4. Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
   5. Extensive-stage small cell lung cancer (ES-SCLC: type of lung cancer)
   6. Unresectable or metastatic hepatocellular carcinoma (HCC: type of liver cancer that cannot be removed by surgery or has spread to other parts of the body)
   7. Unresectable or metastatic melanoma (skin cancer that has spread or cannot be completely removed with surgery)

B. If you have locally advanced or metastatic urothelial carcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. You are not eligible to receive cisplatin-containing chemotherapy AND has a tumor that expresses PD-L1 (Programmed death-ligand 1 sustained tumor-infiltrating immune cells [IC] covering 5% or more of the tumor area), as determined by a Food and Drug Administration approved test
      b. You are not eligible to receive any platinum containing chemotherapy regardless of PD-L1 status

C. If you have stage II to IIIA non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used as a single agent and as adjuvant treatment (as part of a regimen) following resection (cutting out part of tissue or organ) and platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
   3. Your tumor(s) express PD-L1 (programmed death-ligand 1: type of protein) on 1% or more of tumor cells, as determined by an FDA-approved test

(Criteria continued on next page)
ATEZOLIZUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

D. **If you have metastatic non-squamous non-small cell lung cancer, approval also requires:**
   1. You are 18 years of age or older
   2. You do not have EGFR (epidermal growth factor receptor- a type of protein) or ALK (anaplastic lymphoma kinase- a type of protein) genomic tumor abnormalities
   3. The requested medication will be given in combination with ONE of the following regimens as a first-line treatment:
      a. Bevacizumab, paclitaxel, and carboplatin, OR
      b. Paclitaxel protein-bound and carboplatin

E. **If you have metastatic non-small cell lung cancer, approval also requires:**
   1. You are 18 years of age or older
   2. The requested medication will be used as a single-agent
   3. You meet ONE of the following:
      a. You do not have an EGFR (epidermal growth factor receptor- a type of protein) or ALK (anaplastic lymphoma kinase- a type of protein) mutation AND your disease has gotten worse during or after treatment with a platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
      b. You do not have an EGFR (epidermal growth factor receptor- a type of protein) or ALK (anaplastic lymphoma kinase- a type of protein) mutation, AND the requested medication will be used as first line treatment, AND you have tumors that have high PD-L1 (programmed death-ligand 1: type of protein) expression (PD-L1 stained 50% or more of tumor cells, or PD-L1 stained tumor infiltrating immune cells covering 10% or more of the tumor area) as determined by an Food and Drug Administration (FDA) approved test
      c. You have an ALK mutation and your disease has gotten worse during or after treatment with a platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin), AND ALK-directed therapy [such as Xalkori (crizotinib), Zy kadia (ceritinib)]
      d. You have an EGFR mutation and your disease has gotten worse during or after treatment with a platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin), AND EGFR-directed therapy [such as Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib)]

F. **If you have extensive-stage small cell lung cancer, approval also requires:**
   1. You are 18 years of age or older
   2. The requested medication will be used in combination with carboplatin and etoposide as a first-line treatment

*(Criteria continued on next page)*
ATEZOLIZUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

G. If you have unresectable or metastatic hepatocellular carcinoma, approval also requires:
   1. You have not previously been treated with systemic therapy
   2. The requested medication will be used in combination with bevacizumab

H. If you have unresectable or metastatic melanoma, approval also requires:
   1. The requested medication will be used in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf)
   2. You have a BRAF V600 mutation (type of gene mutation)

Commercial Effective: 11/22/21
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AVALGLUCOSIDASE ALFA-NGPT (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVALGLUCOSIDASE ALFA-NGPT</td>
<td>NEXVIAZYMЕ</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named AVALGLUCOSIDASE ALFA-NGPT (Nexviazyme) requires the following rule(s) be met for approval:

A. You have late-onset Pompe disease (an inherited condition where complex sugar [glycogen] builds up in the body's cells because the body cannot make a type of enzyme called lysosomal acid alpha-glucosidase [GAA])
B. You are 1 year of age or older

Commercial Effective: 01/01/22
Our guideline named AVELUMAB (Bavencio) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic Merkel cell carcinoma (MCC: a type of skin cancer)
   2. Locally advanced or metastatic (disease that has spread) urothelial carcinoma (UC: type of urinary system cancer)
   3. Advanced renal cell carcinoma (RCC: type of kidney cancer)

B. If you have metastatic Merkel Cell Carcinoma, approval also requires:
   1. You are 12 years of age or older

C. If you have locally advanced or metastatic urothelial carcinoma, approval also requires ONE of the following:
   1. Your disease has worsened during or after platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
   2. Your disease has worsened within 12 months of neoadjuvant (treatment given before a main treatment) or adjuvant treatment (add-on to a main treatment) with platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
   3. Your disease has not worsened with first-line platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
      a. The requested medication will be used as first-line maintenance treatment

D. If you have advanced renal cell carcinoma, approval also requires:
   1. The requested medication will be used as first-line treatment
   2. The requested medication will be used in combination with axitinib
AXICABTAGENE CILOLEUCEL (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXICABTAGENE CILOLEUCEL</td>
<td>YESCARTA</td>
</tr>
</tbody>
</table>
GUIDELINES FOR USE (CONTINUED)

C. If you have large B-cell lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by a Yescarta-certified hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   3. Yescarta will be administered at a treatment center that is certified to administer Yescarta
   4. You have not previously tried Yescarta
   5. You have not had any prior anti-CD19 therapy (such as Kymriah, Breyanzi)
   6. You meet ONE of the following:
      a. Your disease is refractory (disease did not respond to treatment) to first-line chemoimmunotherapy (a type of cancer treatment such as R-CHOP [rituximab cyclophosphamide, doxorubicin, vincristine, prednisone])
      b. Your disease has relapsed (disease that has returned) within 12 months of first-line chemoimmunotherapy (a type of cancer treatment such as R-CHOP [rituximab cyclophosphamide, doxorubicin, vincristine, prednisone])

D. If you have relapsed or refractory follicular lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by a Yescarta-certified hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   3. You have received two or more lines of systemic therapy (treatment that targets the entire body)
   4. Yescarta will be administered at a treatment center that is certified to administer Yescarta
   5. You have not previously tried Yescarta
   6. You have not had any prior anti-CD19 therapy (such as Kymriah, Breyanzi)

Commercial Effective: 10/01/22
BELANTAMAB MAFODOTIN-BLMF (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BELANTAMAB MAFODOTIN-BLMF</td>
<td>BLENREP</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **BELANTAMAB MAFODOTIN-BLMF (Blenrep)** requires the following rule(s) be met for approval:

A. You have relapsed or refractory multiple myeloma (type of blood cancer that has returned or did not respond to previous treatment)

B. You are 18 years of age or older

C. You have received at least four prior therapies, including an anti-CD38 monoclonal antibody (such as daratumumab, isatuximab), a proteasome inhibitor (such as ixazomib, carfilzomib), and an immunomodulatory agent (such as lenalidomide, pomalidomide)

Commercial Effective: 04/10/21
BELIMUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BELIMUMAB</td>
<td>BENLYSTA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named BELIMUMAB IV (Benlysta) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Autoantibody-positive systemic lupus erythematosus (SLE: a type of immune condition)
   2. Active lupus nephritis (LN: a type of immune condition that affects the kidneys)

B. If you have autoantibody-positive systemic lupus erythematosus (SLE), approval also requires:
   1. You are 5 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using corticosteroids, antimalarials (drug that treat parasites), nonsteroidal anti-inflammatory drugs (NSAIDS), or immunosuppressives (drugs that weaken your immune system)

C. If you have active lupus nephritis, approval also requires:
   1. You are 5 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)
   3. You are receiving standard treatment (such as steroids, antimalarials, nonsteroidal anti-inflammatory drugs, immunosuppressives [drugs that weaken your immune system])

CONTINUED ON NEXT PAGE
BELIMUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **BELIMUMAB IV (Benlysta)** requires the following rule(s) be met for renewal:

A. You have **ONE** of the following diagnoses:
   1. Autoantibody-positive systemic lupus erythematosus (SLE: a type of immune condition)
   2. Active lupus nephritis (LN: a type of immune condition that affects the kidneys)

B. **If you have autoantibody-positive systemic lupus erythematosus (SLE), renewal also requires:**
   1. You have had clinical improvement while on Benlysta

C. **If you have active lupus nephritis, renewal also requires:**
   a. You have had clinical improvement in renal response as compared to baseline laboratory values (eGFR [measurement of kidney function] or proteinuria [level of protein in urine]), and/or clinical parameters (such as fluid retention, use of rescue drugs, glucocorticoid dose)

Commercial Effective: 08/29/22
BELINOSTAT (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BELINOSTAT</td>
<td>BELEODAQ</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named BELINOSTAT (Beleodaq) requires that the following rule be met for approval:

A. You have a diagnosis of relapsed or refractory (your condition has gotten worse after improving) peripheral T-cell lymphoma (PTCL; cancer that affects a type of immune system cells)

B. You are 18 years of age or older

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BENRALIZUMAB (Fasenra)** requires the following rule(s) be met for approval:

A. You have severe asthma with an eosinophilic phenotype (type of inflammatory asthma)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a physician specializing in pulmonary (lung/breathing) medicine or allergy medicine
D. You have a documented blood eosinophil level (type of white blood cell) of at least 150 cells/mcL within the past 12 months
E. You are being treated with medium, high-dose, or a maximally tolerated dose of an inhaled corticosteroid AND at least one other maintenance medication which includes a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), long-acting muscarinic antagonist (such as tiotropium), leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid
F. You have ONE of the following:
   1. Experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
   2. Poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      a. Daytime asthma symptoms more than twice per week
      b. Any night waking due to asthma
      c. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      d. Any activity limitation due to asthma
G. You will NOT use Fasenra concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Cinqair) when used for the treatment asthma

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

Our guideline named BENRALIZUMAB (Fasenra) requires the following rule(s) be met for renewal:

A. You will continue to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid

B. You will NOT use Fasenra concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Cinqair) when used for the treatment asthma

C. You have shown a clinical response as evidenced by ONE of the following:
   1. Reduction in asthma exacerbation (worsening of symptoms) from baseline
   2. Decreased use of rescue medications
   3. Increase in percent predicted FEV1 (amount of air exhaled in one second) from pretreatment baseline
   4. Reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing, etc.)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named BEVACIZUMAB (Avastin) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic colorectal cancer (mCRC: colon cancer that has spread in the body)
   2. Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC: type of lung cancer that cannot be completely removed with surgery or has spread/returned)
   3. Recurrent glioblastoma (GBM: type of brain tumor)
   4. Metastatic renal cell carcinoma (mRCC: type of kidney cancer)
   5. An ophthalmic (eye) indication listed in Micromedex/Drugdex (drug database) with Class I, IIa, or IIb recommendation
   6. Persistent, recurrent, or metastatic cervical cancer (type of uterus cancer)
   7. Platinum-resistant recurrent epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer
   8. Platinum-sensitive recurrent epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer
   9. Stage III or IV epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer
   10. Unresectable or metastatic hepatocellular carcinoma (HCC: type of liver cancer that cannot be completely removed with surgery or has spread to other parts of the body)

B. If you have metastatic colorectal cancer, approval also requires:
   1. You meet ONE of the following:
      a. Avastin is being used in combination with intravenous (given into the vein) 5-fluorouracil based chemotherapy for first or second-line treatment
      b. Your disease has progressed (gotten worse) on a first-line Avastin product-containing regimen AND Avastin is being used in combination with fluoropyrimidine-irinotecan- (for example FOLFIRI) or fluoropyrimidine-oxaliplatin- (for example FOLFOX, CapeOx) based chemotherapy as a second-line treatment
   2. You have tried ONE of the following preferred medications, unless you have a contraindication (harmful for) to: Mvasi or Zirabev

(Initial criteria continued on next page)
C. If you have unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, approval also requires:
   1. Avastin is being used in combination with carboplatin and paclitaxel for first-line treatment
   2. You have tried ONE of the following preferred medications, unless you have a contraindication (harmful for) to: Mvasi or Zirabev

D. If you have recurrent glioblastoma, approval also requires:
   1. You are 18 years of age or older
   2. You have tried ONE of the following preferred medications, unless you have a contraindication (harmful for) to: Mvasi or Zirabev

E. If you have metastatic renal cell carcinoma, approval also requires:
   1. Avastin is being used in combination with interferon-alfa
   2. You have tried ONE of the following preferred medications, unless you have a contraindication (harmful for) to: Mvasi or Zirabev

F. If you have any ophthalmic indication listed in Micromedex/Drugdex with Class I, Ila, or IIb recommendation, approval also requires:
   1. Therapy is prescribed by or in consultation with an ophthalmologist (eye doctor) or retina (a part of the eye) specialist
   2. You are NOT concurrently (at the same time) using other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Susvimo, Lucentis, Beovu) for any ophthalmic indication

G. If you have persistent, recurrent, or metastatic cervical cancer, approval also requires:
   1. Avastin is being used in combination with paclitaxel and cisplatin OR paclitaxel and topotecan
   2. You have tried ONE of the following preferred medications, unless you have a contraindication (harmful for) to: Mvasi or Zirabev

H. If you have platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, approval also requires:
   1. Avastin is being used in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan
   2. You have received no more than two prior chemotherapy regimens
   3. You have tried ONE of the following preferred medications, unless you have a contraindication (harmful for) to: Mvasi or Zirabev

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
BEVACIZUMAB (NSA)

INITIAL CRITERIA (CONTINUED)

I. If you have platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, approval also requires:
   1. You meet ONE of the following:
      a. Avastin is being used in combination with carboplatin and paclitaxel, OR with carboplatin and gemcitabine
      b. Avastin is being used as a single agent after previous use in combination with one of the carboplatin-containing chemotherapy regimens listed above
   2. You have tried ONE of the following preferred medications, unless you have a contraindication (harmful for) to: Mvasi or Zirabe

J. If you have Stage III or IV epithelial ovarian/fallopian tube or primary peritoneal cancer, approval also requires:
   1. Avastin is being used following initial surgical resection (removal)
   2. Avastin is being used in combination with carboplatin and paclitaxel, OR as a single agent after previous use in combination with carboplatin and paclitaxel
   3. You have tried ONE of the following preferred medications, unless you have a contraindication (harmful for) to: Mvasi or Zirabe

K. If you have unresectable or metastatic hepatocellular carcinoma, approval also requires:
   1. Avastin will be used in combination with atezolizumab
   2. You have not received prior systemic therapy (treatment that spreads throughout the body)

RENEWAL CRITERIA

NOTE: For diagnoses other than ophthalmic indication listed in Micromedex/Drugdex with Class I, IIa, or IIb recommendation, please refer to the initial criteria section.

Our guideline named BEVACIZUMAB (Avastin) requires the following rule(s) be met for renewal:
A. You have an ophthalmic (eye) indication listed in Micromedex/Drugdex (drug database) with Class I, IIa, or IIb recommendations
B. You have maintenance or improvement of visual acuity (vision clarity or sharpness)
C. You are NOT concurrently (at the same time) using other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Susvimo, Lucentis, Beovu) for any ophthalmic indication

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named **BEVACIZUMAB-AWWB (Mvasi)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic colorectal cancer (mCRC: colon cancer that has spread in the body)
   2. Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC: type of lung cancer that cannot be completely removed with surgery or has spread/returned)
   3. Recurrent glioblastoma (GBM: type of brain tumor)
   4. Metastatic renal cell carcinoma (mRCC: type of kidney cancer)
   5. Persistent, recurrent, or metastatic cervical cancer (type of uterus cancer)
   6. Stage III or IV epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer
   7. Platinum-resistant recurrent epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer
   8. Platinum-sensitive recurrent epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer

B. If you have metastatic colorectal cancer, approval also requires ONE of the following:
   1. Mvasi is being used in combination with intravenous (given into the vein) 5-fluorouracil based chemotherapy for first or second-line treatment
   2. Mvasi is being used in combination with fluoropyrimidine-irinotecan (for example FOLFIRI) or fluoropyrimidine-oxaliplatin (for example FOLFOX, CAPeOX) based chemotherapy as a second-line treatment AND your disease has progressed (gotten worse) on a first-line bevacizumab product-containing regimen

C. If you have unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, approval also requires:
   1. Mvasi is being used in combination with carboplatin and paclitaxel for first-line treatment

*Criteria continued on the next page*
GUIDELINES FOR USE (CONTINUED)

D. If you have recurrent glioblastoma, approval also requires:
   1. You are 18 years of age or older

E. If you have metastatic renal cell carcinoma, approval also requires:
   1. Mvasi is being used in combination with interferon-alfa

F. If you have persistent, recurrent, or metastatic cervical cancer, approval also requires:
   1. Mvasi is being used in combination with paclitaxel and cisplatin OR paclitaxel and topotecan

G. If you have Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:
   1. Mvasi is being used following initial surgical resection (removal)
   2. Mvasi is being used in combination with carboplatin and paclitaxel, OR as a single agent after previous use in combination with carboplatin and paclitaxel

H. If you have platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:
   1. Mvasi is being used in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan
   2. You have received no more than two prior chemotherapy regimens

I. If you have platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires ONE of the following:
   1. Mvasi is being used in combination with carboplatin and paclitaxel, OR with carboplatin and gemcitabine
   2. Mvasi is being used as a single agent after previous use in combination with one of the carboplatin-containing chemotherapy regimens listed above

Commercial Effective: 01/01/22
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

**BEVACIZUMAB-BVZR (NSA)**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BEVACIZUMAB-BVZR</td>
<td>ZIRABEV</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **BEVACIZUMAB-BVZR (Zirabev)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic colorectal cancer (mCRC: colon cancer that has spread in the body)
   2. Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC: type of lung cancer that cannot be completely removed with surgery or has spread/returned)
   3. Recurrent glioblastoma (GBM: type of brain tumor)
   4. Metastatic renal cell carcinoma (mRCC: type of kidney cancer)
   5. Persistent, recurrent, or metastatic cervical cancer (type of uterus cancer)
   6. Stage III or IV epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer
   7. Platinum-resistant recurrent epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer
   8. Platinum-sensitive recurrent epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer

B. **If you have metastatic colorectal cancer**, approval also requires ONE of the following:
   1. The requested medication is being used in combination with intravenous (given into the vein) 5-fluorouracil based chemotherapy for first or second-line treatment
   2. The requested medication is being used in combination with fluoropyrimidine- irinotecan- (for example, FOLFIRI) or fluoropyrimidine-oxaliplatin- (for example, FOLFOX, CAPEOX) based chemotherapy as a second-line treatment AND your disease has progressed (gotten worse) on a first-line bevacizumab product-containing regimen

C. **If you have unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer**, approval also requires:
   1. The requested medication is being used in combination with carboplatin and paclitaxel for first-line treatment

D. **If you have recurrent glioblastoma**, approval also requires:
   1. You are 18 years of age or older

E. **If you have metastatic renal cell carcinoma**, approval also requires:
   1. The requested medication is being used in combination with interferon-alfa

F. **If you have persistent, recurrent, or metastatic cervical cancer**, approval also requires:
   1. The requested medication is being used in combination with paclitaxel and cisplatin OR paclitaxel and topotecan

*(Criteria continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

G. **If you have Stage III or IV epithelial ovarian/fallopian tube or primary peritoneal cancer**, approval also requires:
   1. The requested medication is being used following initial surgical resection (removal)
   2. The requested medication is being used in combination with carboplatin and paclitaxel, OR as a single agent after previous use in combination with carboplatin and paclitaxel

H. **If you have platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer**, approval also requires:
   1. The requested medication is being used in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan
   2. You have received no more than two prior chemotherapy regimens

I. **If you have platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer**, approval also requires **ONE of the following**:
   1. The requested medication is being used in combination with carboplatin and paclitaxel, OR with carboplatin and gemcitabine
   2. The requested medication is being used as a single agent after previous use in combination with one of the carboplatin-containing chemotherapy regimens listed above

Commercial Effective: 03/22/21
GUIDELINES FOR USE

Our guideline named **BEVACIZUMAB-MALY (Alymsys)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic colorectal cancer (mCRC: colon cancer that has spread in the body)
   2. Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC: type of lung cancer that cannot be completely removed with surgery or has spread/returned)
   3. Recurrent glioblastoma (GBM: type of brain tumor)
   4. Metastatic renal cell carcinoma (mRCC: type of kidney cancer)
   5. Persistent, recurrent, or metastatic cervical cancer (type of uterus cancer)
   6. Platinum-resistant recurrent epithelial ovarian/fallopian tube (female sex organs) or primary peritoneal (abdomen) cancer

B. **If you have metastatic colorectal cancer, approval also requires:**
   1. You meet ONE of the following:
      a. Alymsys is being used in combination with intravenous (given into the vein) 5-fluorouracil based chemotherapy for first or second-line treatment
      b. Your disease has progressed (gotten worse) on a first-line bevacizumab product-containing regimen AND Alymsys is being used in combination with fluoropyrimidine-irinotecan- (for example FOLFIRI) or fluoropyrimidine-oxaliplatin- (for example FOLFOX, CapeOx) based chemotherapy as a second-line treatment
   2. You have tried or have a contraindication (harmful for) to ONE of the following preferred agents: Mvasi, Zirabev

C. **If you have unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, approval also requires:**
   1. Alymsys is being used in combination with carboplatin and paclitaxel for first-line treatment
   2. You have tried or have a contraindication (harmful for) to ONE of the following preferred agents: Mvasi, Zirabev

*(Criteria continued on next page)*
GUIDELINES FOR USE (CONTINUED)

D. If you have recurrent glioblastoma, approval also requires:
   1. You are 18 years of age or older
   2. You have tried or have a contraindication (harmful for) to ONE of the following preferred agents: Mvasi, Zirabev

E. If you have metastatic renal cell carcinoma, approval also requires:
   1. Alymsys is being used in combination with interferon-alfa
   2. You have tried or have a contraindication (harmful for) to ONE of the following preferred agents: Mvasi, Zirabev

F. If you have persistent, recurrent, or metastatic cervical cancer, approval also requires:
   1. Alymsys is being used in combination with paclitaxel and cisplatin OR paclitaxel and topotecan
   2. You have tried or have a contraindication (harmful for) to ONE of the following preferred agents: Mvasi, Zirabev

G. If you have platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, approval also requires:
   1. Alymsys is being used in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan
   2. You have received no more than two prior chemotherapy regimens
   3. You have tried or have a contraindication (harmful for) to ONE of the following preferred agents: Mvasi, Zirabev

Commercial Effective: 07/18/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named BLINATUMOMAB (Blincyto) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL: a type of blood cancer that has returned or is resistant to treatment)
   2. Minimal residual disease (MRD)-positive, CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL: a type of blood cancer)

B. If you have minimal residual disease-positive, CD19-positive B-cell precursor acute lymphoblastic leukemia, approval also requires:
   1. You are in first or second complete remission (no symptoms or signs of disease)
   2. You have minimal residual disease (small number of cancer cells that remain after treatment) greater than or equal to 0.1%

RENEWAL CRITERIA

Our guideline named BLINATUMOMAB (Blincyto) requires the following rule(s) be met for renewal:

A. You have one of the following diagnoses:
   a. Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL: a type of blood cancer that has returned or resistant to treatment)
   b. Minimal residual disease (MRD)-positive, CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL: a type of blood cancer)

B. If you have relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia, renewal also requires:
   1. You have achieved complete remission (CR) (no symptoms or signs of disease) or CR with partial recovery of peripheral blood counts (CPh) after two cycles of induction (starter) treatment (cycle 1 and 2) with Blincyto
   2. You have NOT received an allogeneic hematopoietic stem-cell transplant (stem cells from a genetically similar, but not identical, donor)

(Renewal criteria continued on next page)
BLINATUMOMAB (NSA)

RENEWAL CRITERIA (CONTINUED)

C. If you have minimal residual disease-positive, CD19-positive B-cell precursor acute lymphoblastic leukemia, renewal also requires:
   1. You have no detectable level of minimal residual disease (small number of cancer cells that remain after treatment) within one cycle of Blincyto treatment
   2. You are relapse-free (your disease does not come back after being gone) which includes hematological (relating to blood) or extramedullary relapse, or secondary leukemia (cancer)

Commercial Effective: 04/01/22
Our guideline named BORTEZOMIB (Velcade) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Multiple myeloma (a type of blood cancer)
   2. Mantle cell lymphoma (a type of blood cancer)
B. You are 18 years of age or older
C. If you are requesting bortezomib 2.5mg or 1mg strength, approval also requires:
   1. You have received at least one prior therapy for mantle cell lymphoma
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BOTULINUM NEUROTOXIN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ONABOTULINUM TOXIN A</td>
<td>BOTOX, BOTOX COSMETIC</td>
</tr>
<tr>
<td>ABOBOTULINUM TOXIN A</td>
<td>DYSPORT</td>
</tr>
<tr>
<td>RIMABOTULINUM TOXIN B</td>
<td>MYOBLOC</td>
</tr>
<tr>
<td>INCOBOTULINUM TOXIN A</td>
<td>XEOMIN</td>
</tr>
</tbody>
</table>

** Please use the criteria for the specific drug requested **

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

BOTOX

Our guideline named BOTULINUM NEUROTOXIN (Botox) requires the following rule(s) be met for approval:

A. You are using the requested medication for ONE of the following conditions:
   1. Prevention of chronic migraine headaches (at least 15 days per month with headache lasting 4 hours a day or longer)
   2. Overactive bladder (OAB: problem with the bladder function that causes the sudden need to urinate)
   3. Urinary incontinence (uncontrolled leakage of urine)
   4. Neurogenic detrusor overactivity (NDO: nerve related bladder dysfunction)
   5. Spasticity (stiffness or tightness of your muscles)
   6. Cervical dystonia (spasmodic torticollis or involuntary contracting of the neck muscles)
   7. Severe axillary hyperhidrosis (excessive underarm sweating)
   8. Blepharospasm (involuntary forcible closure of the eyelid)
   9. Strabismus (cross-eyed)

(Botox criteria text continued on next page)

CONTINUED ON NEXT PAGE
BOTULINUM NEUROTOXIN (NSA)

INITIAL CRITERIA - BOTOX (CONTINUED)

B. If you have overactive bladder (OAB), approval also requires:
   1. You are 18 years of age or older.
   2. You had a trial of or contraindication (harmful for) to an anticholinergic medication such as oxybutynin, Ditropan XL, Detrol, Detrol LA, Enablex, Toviaz, Vesicare, Sanctura

C. If you have urinary incontinence, approval also requires:
   1. You are 18 years of age or older.
   2. You have detrusor (bladder muscle) overactivity associated with a neurologic (nervous system) condition such as: spinal cord injury (SCI) or multiple sclerosis (MS).
   3. You had a trial of or contraindication (harmful for) to an anticholinergic medication such as oxybutynin, Ditropan XL, Detrol, Detrol LA, Enablex, Toviaz, Vesicare, Sanctura

D. If you have neurogenic detrusor overactivity (NDO), approval also requires:
   1. You are 5 years of age or older
   2. You did not have an adequate response or are not able to take anticholinergic medications

E. If you have chronic migraine headaches (at least 15 days per month with headache lasting 4 hours a day or longer), approval also requires:
   1. You are 18 years of age or older
   2. Botox is prescribed for the prophylaxis (prevention) of headaches
   3. You have tried TWO of the following migraine prevention treatments: Valproic acid/divalproex sodium, topiramate, propranolol, timolol, amitriptyline, venlafaxine, atenolol, nadolol, metoprolol

F. If you have cervical dystonia or severe axillary hyperhidrosis, approval also requires:
   1. You are 18 years of age or older

G. If you have spasticity, approval also requires:
   1. You are 2 years of age or older

H. If you have blepharospasm and strabismus, approval also requires:
   1. You are 12 years of age or older

NOTE: This medication will not be approved for a cosmetic indication (for example wrinkles - glabellar lines, lateral canthal lines, forehead lines).

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

DYSPORT

1. Is our guideline named BOTULINUM NEUROTOXIN (Dysport) requires the following rule(s) be met for approval:
   A. You have ONE of the following conditions:
      1. Cervical dystonia also called spasmodic torticollis (involuntary contracting of the neck muscles)
      2. Spasticity (stiffness or tightness of your muscles)
   B. If you have cervical dystonia, approval also requires:
      1. You are 18 years of age or older
   C. If you have spasticity, approval also requires:
      1. You are 2 years of age or older

   NOTE: This medication will not be approved for a cosmetic indication (for example wrinkles - glabellar lines, lateral canthal lines, forehead lines).

MYOBLOC

Our guideline named BOTULINUM NEUROTOXIN (Myobloc) requires the following rule(s) be met for approval:
A. You have ONE of the following conditions:
   1. Cervical dystonia (spasmodic torticollis or involuntary contracting of the neck muscles)
   2. Chronic sialorrhea (drooling or excessive salivation)
B. You are 18 years of age or older

NOTE: This medication will not be approved for a cosmetic indication (for example wrinkles - glabellar lines, lateral canthal lines, forehead lines).

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

XEOMIN

Our guideline named BOTULINUM NEUROTOXIN (Xeomin) requires the following rule(s) be met for approval:

A. You have ONE of the following conditions:
   1. Chronic sialorrhea (drooling or excessive salivation)
   2. Cervical dystonia (spasmodic torticollis or involuntary contracting of the neck muscles)
   3. Blepharospasm (involuntary forcible closure of the eyelid)
   4. Upper limb spasticity (stiffness or tightness of your muscles)

B. If you have chronic sialorrhea, approval also requires:
   1. You are 2 years of age or older

C. If you have cervical dystonia or blepharospasm, approval also requires:
   1. You are 18 years of age or older

D. If you have upper limb spasticity, approval also requires ONE of the following:
   1. You are 18 years of age or older
   2. You are 2 to 17 years of age and do not have spasticity caused by cerebral palsy (an illness that affects movement, muscle tone or posture)

NOTE: This medication will not be approved for a cosmetic indication (for example wrinkles - glabellar lines, lateral canthal lines, forehead lines).

CONTINUED ON NEXT PAGE
BOTULINUM NEUROTOXIN (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For requests of Dysport, Myobloc or Xeomin, please refer to the initial criteria section.

BOTOX

NOTE: For diagnoses other than migraine, please refer to the initial criteria section.

Our guideline named BOTULINUM NEUROTOXIN (Botox) requires the following rule(s) be met for renewal:

A. You have chronic migraine headaches (at least 15 days per month with headache lasting 4 hours a day or longer)

B. You have experienced ONE of the following:
   a. A reduction in migraine or headache frequency of at least 2 days per month
   b. A reduction in migraine severity
   c. A reduction in migraine duration (length)

NOTE: This medication will not be approved for a cosmetic indication (such as wrinkles - glabellar lines, lateral canthal lines, forehead lines).

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named BRENTUXIMAB (Adcetris) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Classical Hodgkin lymphoma (cHL: a type of blood cancer)
   2. Relapsed systemic anaplastic large cell lymphoma (sALCL: a type of blood cancer that has returned)
   3. Systemic anaplastic large cell lymphoma (sALCL: a type of blood cancer)
   4. Other CD30-expressing peripheral T-cell lymphomas (a type of blood cancer)
   5. Primary cutaneous anaplastic large cell lymphoma (pcALCL: cancer that presents in the skin affecting immune system cells)
   6. CD30-expressing mycosis fungoides (MF: rare form of immune system cancer affecting the skin)
   7. Stage III or IV classical Hodgkin lymphoma (cHL: a type of blood cancer)

B. If you have classical Hodgkin lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. You have failed autologous hematopoietic stem cell transplant (auto-HSCT: transplant cells are from your own body)
      b. You are not an auto-HSCT candidate AND have failed at least two multi-agent chemotherapy regimens, which include but are not limited to: ABVD [doxorubicin, bleomycin, vinblastine, dacarbazine], Stanford V [doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, prednisone], BEACOPP [bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone]
      c. You are considered high risk of relapse or disease progression (disease comes back or gets worse) after having auto-HSCT (defined as refractory [disease does not respond to treatment], relapse within 12 months, or relapse at least 12 months with extranodal [area outside of the lymph node] disease) AND you have obtained complete/partial remission (little or no sign of cancer in your body), or stable disease to most recent pre-auto-HSCT salvage therapy

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

C. If you have relapsed systemic anaplastic large cell lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. You have failed at least one multi-agent chemotherapy regimen, which includes but are not limited to: CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] or CHOEP [cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone]

D. If you have systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, approval also requires:
   1. You are 18 years of age or older
   2. You have not received previous treatment for sALCL or other CD30-expressing PTCL
   3. The requested medication will be used in combination with cyclophosphamide, doxorubicin, and prednisone

E. If you have primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides, approval also requires:
   1. You are 18 years of age or older
   2. You have received prior systemic therapy (treatment that targets the entire body)

F. If you have Stage III or IV classical Hodgkin lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used in combination with doxorubicin, vinblastine, and dacarbazine
   3. You have not received previous treatment for Stage III or IV classical Hodgkin Lymphoma (cHL)

Commercial Effective: 04/01/22
GUIDELINES FOR USE

Our guideline named BREXUCABTAGENE AUTOLEUCEL (Tecartus) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Relapsed or refractory mantle cell lymphoma (MCL: type of white blood cell cancer that has returned or does not respond to treatment)
   2. Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL: a type of blood cancer that has returned or does not respond to treatment)

B. You are 18 years of age or older

Commercial Effective: 10/25/21
GUIDELINES FOR USE

Our guideline named **BUPRENORPHINE EXTENDED-RELEASE (Sublocade)** requires the following rule(s) be met for approval:

A. You have a diagnosis of moderate to severe opioid use disorder (mis-use of a type of pain medication)

B. You previously started treatment with a transmucosal (medication that enters body through a mucous layer like those in the mouth) buprenorphine-containing product, which was followed by dose adjustment for a minimum of 7 days

Commercial Effective: 07/01/20
BROLCIZUMAB-DBLL (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BROLCIZUMAB-DBLL</td>
<td>BEOVU</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named BROLCIZUMAB-DBLL (Beovu) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Neovascular (wet) age-related macular degeneration (nAMD: a type of eye disease)
   2. Diabetic macular edema (DME: a type of eye condition caused by high blood sugar)

B. **If you have neovascular age-related macular degeneration, approval also requires:**
   1. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist
   2. You are NOT using Beovu at the same time with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis, Susvimo)

C. **If you have diabetic macular edema, approval also requires:**
   1. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist
   2. You are NOT using Beovu at the same time with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis, Vabysmo)

RENEWAL CRITERIA

Our guideline named BROLCIZUMAB-DBLL (Beovu) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Neovascular (wet) age-related macular degeneration (nAMD: a type of eye disease)
   2. Diabetic macular edema (DME: a type of eye condition caused by high blood sugar)

B. **If you have neovascular age-related macular degeneration, renewal also requires:**
   1. You have maintained or improved visual acuity (vision clarity or sharpness)
   2. You are NOT using Beovu at the same time with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis, Susvimo)

C. **If you have diabetic macular edema, renewal also requires:**
   1. You have maintained or improved visual acuity (vision clarity or sharpness)
   2. You are NOT using Beovu at the same time with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis, Vabysmo)
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BUPRENORPHINE IMPLANT (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUPRENORPHINE</td>
<td>PROBUPHINE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **BUPRENORPHINE IMPLANT (Probuphine)** requires the following rule(s) be met for approval:

A. You have NOT previously received ONE Probuphine treatment course in EACH arm (for a maximum of TWO 6-month treatment courses)

B. You have achieved and continued to have clinical stability on low to moderate doses of transmucosal buprenorphine (such as Subutex, Suboxone, Bunavail, or Zubsolv) defined as 8 mg per day or less of Subutex/Suboxone or a transmucosal buprenorphine equivalent for a minimum of 3 months without any need for additional dosing or adjustments

C. The requested medication is prescribed by a physician certified with the Probuphine REMS (Risk Evaluation and Mitigation Strategy) program to prescribe, insert, and remove Probuphine implants as confirmed by checking probuphinerems.com

Commercial Effective: 07/01/20
Our guideline named BUROSUMAB (Crysvita) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. X-linked hypophosphatemia (XLH: inherited disorder with low phosphate blood levels)
   2. Fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia (TIO: a rare disease characterized by the development of tumors that cause weakened and softened bones. The tumors release hormones known as fibroblast growth factor 23 that lowers your phosphate levels)

B. If you have X-linked hypophosphatemia (XLH), approval also requires:
   1. Your diagnosis is confirmed by ONE of the following:
      a. You have XLH symptoms such as osteomalacia (bone softening), excessive fractures, bowed legs, impaired growth and ONE of the following:
         i. If you are less than 18 years of age, your serum phosphate level is less than 3.2 mg/dL with normal vitamin D levels
         ii. If you are 18 years of age or older, your serum phosphate level is less than 2.5 mg/dL with normal vitamin D levels
         iii. You have more than normal amount of FGF23 protein on assay (type of lab analysis)
         iv. You have a family history of X-linked hypophosphatemia
      b. You have a PHEX mutation (Phosphate-regulating neutral endopeptidase, X-linked) confirmed by a genotyping (type of test)
   2. You are 6 months of age or older
   3. Therapy is prescribed by or given in consultation with an endocrinologist (hormone doctor), nephrologist (kidney doctor), orthopedic surgeon (surgeon that deals with skeletal deformities), or medical geneticist
   4. You will not be taking oral phosphate salt or active vitamin D analog supplementation with the requested medication
   5. You meet ONE of the following:
      a. You previously had a trial of or failure to phosphate/vitamin D analog therapy (such as calcitriol, paricalcitol)
      b. Your disease condition, severity, and/or other factors indicate phosphate/vitamin D analog therapy is not preferable/advisable for you compared to anticipated outcomes with Crysvita

(Initial criteria continued on next page)
BUROSUMAB-TWZA (NSA)

INITIAL CRITERIA (CONTINUED)

C. If you have FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO), approval also requires:
   1. Your diagnosis is confirmed by the following:
      a. You have symptoms of tumor-induced osteomalacia (such as osteomalacia [softening of the bones], excessive fractures, muscle weakness, fatigue, bone pain)
   2. You are 2 years of age or older
   3. Therapy is prescribed by or given in consultation with an endocrinologist (hormone doctor), nephrologist (kidney doctor), orthopedic surgeon (surgeon that deals with skeletal deformity), or medical geneticist
   4. Your tumors cannot be curatively resected (surgically removed) or localized
   5. You have stopped oral phosphate and/or active vitamin D analogs (such as calcitriol, paricalcitol) at least 1 week prior to starting Crysvita
   6. You meet ONE of the following:
      o You previously had a trial of or failure to phosphate/vitamin D analog therapy
      o Your disease condition, severity, and/or other factors indicate phosphate/vitamin D analog therapy is not preferable/advisable for you compared to anticipated outcomes with Crysvita

RENEWAL CRITERIA

Our guideline named BUROSUMAB (Crysvita) requires the following rules be met for renewal:
A. You have ONE of the following diagnoses:
   1. X-linked hypophosphatemia (XLH; inherited disorder with low phosphate blood levels)
   2. Fibroblast growth factor 23 (FGF23) -related hypophosphatemia in tumor-induced osteomalacia (TIO: a rare disease characterized by the development of tumors that cause weakened and softened bones. The tumors release hormones known as fibroblast growth factor 23 that lowers your phosphate levels)
B. If you have X-linked hypophosphatemia (XLH), renewal also requires:
   1. You have achieved normal blood phosphate levels as defined by the reference range for your age
C. If you have Fibroblast growth factor 23 (FGF23) - related hypophosphatemia in tumor-induced osteomalacia, renewal also requires:
   1. You have achieved normal fasting blood phosphate levels (around or above the lower end of the reference range for age and below 5 mg/dL)

Commercial Effective: 10/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CALASPARGASE PEGOL (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CALASPARGASE PEGOL-MKNL</td>
<td>ASPARLAS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named CALASPARGASE PEGOL (Asparlas) requires the following rule(s) be met for approval:

1. You have a diagnosis of acute lymphoblastic leukemia (type of blood and bone marrow cancer)
2. You are 1 month to 21 years of age
3. Asparlas will be used as a part of a chemotherapeutic treatment plan that contains multiple drugs

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named CANAKINUMAB (Ilaris) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Cryopyrin-Associated Periodic Syndromes such as Familial Cold Autoinflammatory Syndrome (FCAS: inherited inflammatory disorder that is triggered with cold) or Muckle-Wells Syndrome (MWS: disorder characterized by periodic episodes of skin rash, fever, and joint pain)
   2. Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS: genetic disease that causes recurrent episodes of fever)
   3. Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) (genetic disorders that have recurrent fever episodes and inflammation)
   4. Familial Mediterranean Fever (FMF: genetic disorder that causes recurrent episodes of fever and pain in the abdomen, chest, or joints)
   5. Systemic Juvenile Idiopathic Arthritis (SJIA: swelling and stiffness in joints in children that can affect organs)
   6. Adult-Onset Still's Disease (AOSD: rare autoinflammatory disease caused by abnormalities of the immune system)

B. If you have Cryopyrin-Associated Periodic Syndromes (CAPS) such as Familial Cold Autoinflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS), approval also requires:
   1. You are 4 years of age or older
   2. Therapy is prescribed by or given in consultation with a rheumatologist (doctor who specializes in conditions that affect the muscles and skeletal system, especially the joints)

C. If you have Systemic Juvenile Idiopathic Arthritis (SJIA), approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or given in consultation with a rheumatologist (doctor who specializes in conditions that affect the muscles and skeletal system, especially the joints), dermatologist (skin doctor), or immunologist (immune system doctor)
   3. You had a previous trial of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine, unless there is a medical reason why you cannot (contraindication)
   4. You had a previous trial of the preferred immunomodulator: Actemra, unless there is a medical reason why you cannot (contraindication)

(Initial criteria continued on next page)
INITIAL CRITERIA (CONTINUED)

D. If you have Adult-Onset Still's Disease (AOSD), approval also requires:
   1. Therapy is prescribed by or given in consultation with a rheumatologist (doctor who specializes in conditions that affect the muscles and skeletal system, especially the joints) dermatologist (skin doctor), or immunologist (immune system doctor)
   2. You had a previous trial of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine, unless there is a medical reason why you cannot (contraindication)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

Our guideline named CANAKINUMAB (Ilaris) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Cryopyrin-Associated Periodic Syndromes such as Familial Cold Autoinflammatory Syndrome (FCAS: inherited inflammatory disorder that is triggered with cold) or Muckle-Wells Syndrome (MWS: disorder characterized by periodic episodes of skin rash, fever, and joint pain)
   2. Systemic Juvenile Idiopathic Arthritis (SJIA: swelling and stiffness in joints in children that can affect organs)
   3. Adult-Onset Still's Disease (AOSD: rare autoinflammatory disease caused by abnormalities of the immune system)

B. If you have Systemic Juvenile Idiopathic Arthritis (SJIA) or Adult-Onset Still's Disease (AOSD), renewal also requires ONE of the following:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You have shown maintained or improved systemic inflammatory disease (e.g., fevers, pain, rash, arthritis)

Commercial Effective: 04/01/21
CARFILZOMIB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARFILZOMIB</td>
<td>KYPROLIS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named CARFILZOMIB (Kyprolis) requires the following rule(s) be met for approval:

A. You have relapsed or refractory multiple myeloma (plasma cell cancer that has returned or is not completely responsive to treatment)
B. You are 18 years of age or older
C. You meet ONE of the following criteria:
   1. You have previously received one to three lines of therapy AND will be using Kyprolis in combination with ONE of the following regimens:
      a. Lenalidomide and dexamethasone
      b. Dexamethasone
      c. Daratumumab and dexamethasone
      d. Daratumumab-hyaluronidase-fihi and dexamethasone
   2. You have previously received one or more lines of multiple myeloma therapy AND will be using Kyprolis alone

Commercial Effective: 01/17/22
CASIMERSEN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CASIMERSEN</td>
<td>AMONDYS-45</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named CASIMERSEN (Amondys-45) requires the following rule(s) be met for approval:

A. You have Duchenne muscular dystrophy (DMD: inherited disorder where your muscles get weaker over time)
B. You have a confirmed mutation in the DMD gene that is responsive to exon 45 skipping (a process that allows a protein to still function with sections of faulty genetic code)

Commercial Effective: 07/01/21
Our guideline named **CEMIPLIMAB-RWLC (Libtayo)** requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC: type of skin cancer that has spread or has highly developed)
   2. Metastatic or locally advanced basal cell carcinoma (BCC: type of skin cancer that has spread or has highly developed)
   3. Metastatic or locally advanced non-small cell lung cancer (NSCLC: type of lung cancer that has spread or you are not a candidate for surgical resection or chemoradiation)

B. **If you have metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), approval also requires:**
   1. You are not a candidate for curative surgery or curative radiation

C. **If you have metastatic or locally advanced basal cell carcinoma (BCC), approval also requires:**
   1. You have previously been treated with a hedgehog pathway inhibitor (such as Erivedge, Odomzo) or a hedgehog pathway inhibitor is not appropriate for you

D. **If you have metastatic or locally advanced non-small cell lung cancer (NSCLC), approval also requires:**
   1. The requested medication will be used as first-line treatment
   2. Your tumor is high PD-L1 (programmed death-ligand: type of protein) expression [Tumor Proportion Score (TPS) at least 50%] as determined by an FDA (Food and Drug Administration)-approved test
   3. Your tumors must not have EGFR, ALK or ROS1 aberrations (type of gene mutations)

---

Commercial Effective: 04/10/21
CERLIPONASE ALFA (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERLIPONASE ALFA</td>
<td>BRINEURA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named CERLIPONASE ALFA (Brineura) requires the following rule(s) be met for approval:

A. You have a diagnosis of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2; group of severe diseases that affect the nervous system, including mental and movement skills), also known as tripeptidyl peptidase 1 (TPP1) deficiency
B. Your diagnosis is confirmed by TPP1 enzyme deficiency test or TPP1/CLN2 genotyping
C. You are ambulatory (able to walk) and experiencing symptoms such as instability, intermittent falls, requires assistance to walk, or can crawl only
D. You have a documented CLN2 Clinical Rating Scale Score (test to measure the severity of ceroid lipofuscinosis type 2) of 3 to 5, with a minimum score of 1 in each of the motor and language category
E. You are 3 years of age or older
F. Therapy is prescribed by or given in consultation with a neurologist (nerve doctor) or pediatric ceroid lipofuscinosis type 2 specialist

RENEWAL CRITERIA

Our guideline named CERLIPONASE ALFA (Brineura) requires the following rule(s) be met for renewal:

A. You have improved or maintained baseline motor function (such as ambulation, walking, crawling) or demonstrated a less-than-expected decline in motor function (such as ambulation, walking or crawling) from baseline
B. You have a ceroid lipofuscinosis type 2 (CLN2) motor score of at least 1 (such as you are not bedridden or immobile)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named CETUXIMAB (Erbitux) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Locally or regionally advanced squamous cell carcinoma (type of skin cancer) of the head and neck
   2. Recurrent locoregional disease or metastatic (cancer that has spread to other parts of the body) squamous cell carcinoma of the head and neck
   3. Recurrent or metastatic squamous cell carcinoma of the head and neck
   4. Metastatic colorectal cancer (mCRC: colon/rectum cancer that has spread to other parts of the body)

B. If you have locally or regionally advanced squamous cell carcinoma of the head and neck, approval also requires:
   1. The requested medication will be used in combination with radiation therapy

C. If you have recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck, approval also requires:
   1. The requested medication will be used in combination with platinum-based therapy (such as cisplatin, carboplatin, or oxaliplatin) and 5-fluorouracil (5-FU) as first-line treatment

D. If you have recurrent or metastatic squamous cell carcinoma of the head and neck, approval also requires:
   1. The requested medication will be used as a single agent
   2. You have previously failed platinum-based therapy (such as cisplatin, carboplatin, or oxaliplatin)

E. If you have metastatic colorectal cancer (mCRC), approval also requires ONE of the following:
   1. Your cancer is KRAS wild-type (a type of gene with no mutation), epidermal growth factor receptor (EGFR)-expressing as determined by an FDA (Food and Drug Administration)-approved test
      a. You meet ONE of the following:
         i. The requested medication is being used in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment
         ii. The requested medication is being used in combination with irinotecan and you are refractory (resistant) to irinotecan-based chemotherapy
         iii. The requested medication is being used as a single agent AND you have failed oxaliplatin-based and irinotecan-based chemotherapy unless you are intolerant to irinotecan

(Criteria continued on next page)
CETUXIMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

2. Your cancer has a BRAF V600 mutation (a type of mutation) as determined by an FDA (Food and Drug Administration)-approved test
   a. You are 18 years of age or older
   b. The requested medication is being used in combination with encorafenib after prior therapy

Commercial Effective: 10/25/21
GUIDELINES FOR USE

Our guideline named **CILTACABTAGENE AUTOLEUCEL (Carvykti)** requires the following rule(s) be met for approval:

A. You have relapsed or refractory multiple myeloma (a type of blood cancer that has returned or did not respond to treatment)
B. You are 18 years of age or older
C. You have received four or more prior lines of therapy, including a proteasome inhibitor (such as Velcade, Kyprolis), an immunomodulatory agent (such as Revlimid, Pomalyst), and an anti-CD38 monoclonal antibody (such as Darzalex)

Commercial Effective: 07/01/22
Our guideline named **COPANLISIB (Aliqopa)** requires the following rule(s) be met for approval:

A. You have relapsed follicular lymphoma (FL: a type of blood cancer)

B. You are 18 years of age or older

C. You have received at least two prior systemic therapies (therapy that travels through the blood) for follicular lymphoma

---

Commercial Effective: 07/01/20
CRIZANLIZUMAB-TMCA (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRIZANLIZUMAB-TMCA</td>
<td>ADAKVEO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named CRIZANLIZUMAB-TMCA (Adakveo) requires the following rule(s) be met for approval:
A. You have sickle cell disease (type of red blood cell disorder)
B. You are at least 16 years old
C. The medication is prescribed by or given in consultation with a hematologist (blood doctor specialist)
D. You have previously tried hydroxyurea, unless there is a medical reason why you cannot (contraindication)
E. If you are 18 years of age or older, approval also requires ONE of the following:
   1. You had at least 2 sickle cell crises in the past year. (A sickle cell crises is defined as a visit to an emergency room/medical facility for sickle cell disease-related pain which was treated with a parenterally administered (given into the vein) narcotic or parenterally administered ketorolac, the occurrence of acute chest syndrome, priapism (prolonged erection of penis), or splenic sequestration [suppressing of spleen])
   2. You are having sickle cell associated symptoms (such as pain or anemia) which are interfering with activities of daily living
   3. You have a history of or have recurrent acute chest syndrome (ACS: chest pain, cough, fever and low oxygen levels)

RENEWAL CRITERIA

Our guideline named CRIZANLIZUMAB-TMCA (Adakveo) requires the following rule(s) be met for renewal:
A. You have sickle cell disease (type of red blood cell disorder)
B. You have maintained or experienced a reduction in acute (sudden and severe) complications of sickle cell disease (SCD) (such as a reduction in number of sickle cell crises, hospitalizations, acute chest syndrome [ACS: chest pain, cough, fever and low oxygen levels]).

Commercial Effective: 04/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DARATUMUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DARATUMUMAB</td>
<td>DARZALEX</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named DARATUMUMAB (Darzalex) requires the following rule(s) be met for approval:

A. You have multiple myeloma (plasma cell cancer)
B. You are 18 years of age or older
C. You meet ONE of the following criteria:
   1. You have newly diagnosed multiple myeloma and are not eligible for autologous stem cell transplant (cells from your own body) and will receive daratumumab in combination with lenalidomide and dexamethasone
   2. You have relapsed or refractory multiple myeloma (plasma cell cancer that has returned or is not completely responsive to treatment) and received at least one prior therapy AND will receive daratumumab in combination with lenalidomide and dexamethasone
   3. You are newly diagnosed with multiple myeloma, not eligible for autologous stem cell transplant (cells from your own body), AND will receive daratumumab in combination with bortezomib, melphalan and prednisone
   4. You are newly diagnosed with multiple myeloma, are eligible for autologous stem cell transplant (cells from your own body), AND will receive daratumumab in combination with bortezomib, thalidomide and prednisone
   5. You have received at least one prior therapy AND will receive daratumumab in combination with bortezomib and dexamethasone
   6. You have relapsed or refractory multiple myeloma (plasma cell cancer that has returned or is not completely responsive to treatment) and received one to three prior lines of therapy AND will receive daratumumab in combination with carfilzomib and dexamethasone
   7. You have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI: class of drug for myeloma cancer) AND will receive daratumumab in combination with pomalidomide and dexamethasone
   8. You have received at least three prior lines of therapy, including a proteasome inhibitor (class of drug for myeloma) and an immunomodulatory agent (drug that changes the immune response or the functioning of the immune system) AND you will receive daratumumab as monotherapy (single drug to treat condition)
   9. You are refractory (resistant) to both a proteasome inhibitor and an immunomodulatory agent AND will receive daratumumab as monotherapy

**Note:** Proteasome inhibitors examples include: bortezomib, carfilzomib, or ixazomib and Immunomodulatory agent examples include: lenalidomide, pomalidomide, or thalidomide.

Commercial Effective: 04/10/21

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/16/2022
GUIDELINES FOR USE

Our guideline named DARATUMUMAB-HYALURONIDASE-FIJH (Darzalex Faspro) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Multiple myeloma (type of blood cancer)
   2. Newly diagnosed light chain (AL) amyloidosis (a buildup of proteins in the tissues causing organ dysfunction)

B. You are 18 years of age or older

C. If you have multiple myeloma, approval also requires ONE of the following:
   1. You have newly diagnosed multiple myeloma, are not eligible for autologous stem cell transplant (cells from your own body), AND will receive Darzalex Faspro in combination with bortezomib (Velcade), melphalan and prednisone
   2. You have newly diagnosed multiple myeloma, are not eligible for autologous stem cell transplant (cells from your own body), AND will receive Darzalex Faspro in combination with lenalidomide (Revlimid) and dexamethasone
   3. You have newly diagnosed multiple myeloma, are eligible for autologous stem cell transplant (cells from your own body), AND will receive Darzalex Faspro in combination with bortezomib (Velcade), thalidomide and dexamethasone
   4. You have relapsed or refractory multiple myeloma (type of blood cancer that has returned or is not completely responsive to treatment), received at least one prior therapy AND will receive Darzalex Faspro in combination with lenalidomide (Revlimid) and dexamethasone
   5. You have relapsed or refractory multiple myeloma (type of blood cancer that has returned or is not completely responsive to treatment), received one to three prior lines of therapy, AND Darzalex Faspro will be used in combination with carfilzomib (Kyprolis) and dexamethasone
   6. You have received at least one prior therapy AND will receive Darzalex Faspro in combination with bortezomib (Velcade) and dexamethasone
   7. You have received at least one prior line of therapy, including lenalidomide (Revlimid) and a proteasome inhibitor (class of drug for multiple myeloma) AND Darzalex Faspro will be used in combination with pomalidomide (Pomalyst) and dexamethasone

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

8. You have received at least three prior lines of therapy, including a proteasome inhibitor (class of drug for multiple myeloma) AND an immunomodulatory agent (drug that changes the immune response or the functioning of the immune system) AND you will receive Darzalex Faspro as monotherapy (will not be used in combination with another drug)

9. You are refractory (resistant) to both a proteasome inhibitor (class of drug for multiple myeloma) AND an immunomodulatory agent AND you will receive Darzalex Faspro as monotherapy (will not be used in combination with another drug)

D. If you have newly diagnosed light chain amyloidosis, approval also requires:
   1. Darzalex Faspro will be used in combination with bortezomib (Velcade), cyclophosphamide and dexamethasone

Note: Proteasome inhibitors include: bortezomib (Velcade), carfilzomib (Kyprolis), or ixazomib (Ninlaro); immunomodulatory agents include: lenalidomide (Revlimid), pomalidomide (Pomalyst), or thalidomide (Thalomid).

Commercial Effective: 01/17/22
GUIDELINES FOR USE

Our guideline named **DAUNORUBICIN/CYTARABINE LIPOSOME (Vyxeos)** requires the following rule(s) be met for approval:

A. You have a new diagnosis of therapy-related acute myeloid leukemia (type of white blood cell cancer) OR acute myeloid leukemia with myelodysplasia-related changes (type of blood and bone marrow cancer that affects production of blood cells)

B. You are 1 year of age or older

---

**Commercial Effective: 05/01/21**
DENOSUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DENOSUMAB</td>
<td>PROLIA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named DENOSUMAB (Prolia) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Postmenopausal osteoporosis (a type of bone condition)
   2. Osteoporosis in a male patient
   3. Glucocorticoid-induced osteoporosis (a type of bone condition caused by steroids)
   4. Bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer (using the medication to lower hormone levels for prostate cancer that has not spread to other parts of the body)
   5. Bone loss in women receiving adjuvant aromatase inhibitor therapy (type of breast cancer drug) for breast cancer.

B. If you have postmenopausal osteoporosis, approval also requires ONE of the following:
   1. You are at high risk for fracture defined as ONE of the following:
      a. History of osteoporotic (fragility, low trauma) fracture(s)
      b. 2 or more risk factors for fracture. Some risk factors are history of multiple recent low trauma fractures, bone mineral density T-score (measurement of bone density) less than or equal to -2.5, corticosteroid use, or use of gonadotropin-releasing hormone analogs such as nafarelin
      c. No prior treatment for osteoporosis AND FRAX score (tool to measure your fracture risk) greater than or equal to 20% for any major fracture OR greater than or equal to 3% for hip fracture
   2. You had a trial of bisphosphonates such as Fosamax, Actonel, Boniva, Reclast, unless there is a medical reason why you cannot (contraindication)
   3. You are unable to use oral therapy (for example, due to upper gastrointestinal [GI] problems - unable to tolerate oral medication, lower GI problems - unable to absorb oral medications, trouble remembering to take oral medications or coordinating an oral bisphosphonate with other oral medications or your daily routine)

C. If you have glucocorticoid-induced osteoporosis OR are a male with osteoporosis, approval also requires:
   1. You are at high risk for fractures defined as ONE of the following:
      a. History of osteoporotic (fragility, low trauma) fracture(s)
      b. Two or more risk factors for fracture. Some risk factors are history of multiple recent low trauma fractures, bone mineral density T-score (measurement of bone density) less than or equal to -2.5, corticosteroid use, or use of gonadotropin-releasing hormone analogs such as nafarelin
   2. You had a trial of bisphosphonates such as Fosamax, Actonel, Boniva, Reclast, unless there is a medical reason why you cannot (contraindication)

(Criteria continued on next page)

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
DENOSUMAB-PROLIA (NSA)

GUIDELINES FOR USE (CONTINUED)

D. If you are a man with bone loss who is receiving androgen deprivation therapy for non-metastatic prostate cancer, OR you are a woman with bone loss who is receiving adjuvant aromatase inhibitor therapy for breast cancer, approval also requires:

1. You are at high risk for fracture. Some risk factors include history of osteoporotic fracture, history of multiple recent low trauma fractures, corticosteroid use, or use of gonadotropin releasing hormone analogs such as nafarelin

2. You had a trial of bisphosphonates such as Fosamax, Actonel, Boniva, Reclast, unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 04/18/22
DENOSUMAB-XGEVA (NSA)

GUIDELINES FOR USE

Our guideline named DENOSUMAB (Xgeva) requires you meet ONE of the following criteria:

A. You have multiple myeloma (plasma cell cancer) OR bone metastases from solid tumors (cancer has spread to bones from solid tumors) AND the requested medication is being used to prevent skeletal-related events (such as bone fractures or bone pain requiring radiation)

B. You have giant cell tumor of bone that is unresectable (tumor cannot be removed completely through surgery) or where surgical resection is likely to result in severe morbidity (illness)

C. You have hypercalcemia (higher than normal levels of calcium in blood) of malignancy that does not respond to bisphosphonate therapy (such as Fosamax, Actonel, or Boniva)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named DIFELIKEFALIN (Korsuva) requires the following rule(s) be met for approval:
A. You have moderate to severe pruritus (itching) associated with chronic kidney disease
B. You are 18 years of age or older
C. You are undergoing hemodialysis (HD: a process of removing excess water and toxins from the blood)

Commercial Effective: 07/01/22
DINUTUXIMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DINUTUXIMAB</td>
<td>UNITUXIN</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named DINUTUXIMAB (Unituxin) requires the following rule(s) be met for approval:

A. You have high-risk neuroblastoma (a type of cancer that usually affects glands above the kidneys)
B. You are 17 years of age or younger
C. You have received an autologous (cells are from your own body) stem cell transplant
D. You had a partial response to chemotherapy given before you had an autologous stem cell transplant
E. You have not undergone 5 cycles of dinutuximab in the past
F. Dinutuximab will be used concurrently (at the same time) with isotretinoin and either Leukine or Proleukin

Commercial Effective: 04/10/21
GUIDELINES FOR USE

Our guideline named DOSTARLIMAB-GXLY (Jemperli) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Mismatch repair deficient (dMMR) recurrent (returning) or advanced endometrial cancer (EC: cancer that starts in the lining of the uterus), as determined by a Food and Drug Administration (FDA) approved test
   2. Mismatch repair deficient (dMMR) recurrent (returning) or advanced solid tumors, as determined by a Food and Drug Administration (FDA) approved test

B. If you have dMMR recurrent or advanced endometrial cancer (EC), approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has progressed on or following previous treatment with a platinum-containing regimen (such as carboplatin)

C. If you have dMMR recurrent or advanced solid tumors, approval also requires:
   1. You are 18 years of age or older
   2. Your tumors have progressed on or following prior treatment
   3. You have no satisfactory alternative treatment options

Commercial Effective: 10/01/21
GUIDELINES FOR USE

Our guideline named DURVALUMAB (Imfinzi) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Unresectable stage III non-small cell lung cancer (NSCLC: lung cancer that cannot be completely removed with surgery)
   2. Extensive-stage small cell lung cancer (ES-SCLC: lung cancer that has spread widely throughout the lungs, or other parts of the body)
   3. Locally advanced or metastatic biliary tract cancer (BTC: biliary tract cancer that has spread from where it started to nearby tissue or lymph nodes or has spread to other parts of the body)
B. If you have unresectable Stage III non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your disease has not worsened after using concurrent (at the same time) platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin) and radiation therapy
C. If you have extensive-stage small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication is being used as first line of therapy
   3. The requested medication will be used in combination with etoposide and either carboplatin or cisplatin
D. If you have locally advanced or metastatic biliary tract cancer, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used in combination with gemcitabine and cisplatin

Commercial Effective: 10/01/22
GUIDELINES FOR USE

Our guideline named ECALLANTIDE (Kalbitor) requires the following rule(s) be met for approval:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You are 12 years of age or older
C. Your diagnosis is confirmed by complement testing (a type of lab test)
D. Kalbitor is being used for treatment of acute (sudden and severe) attacks of hereditary angioedema
E. Kalbitor is prescribed by or in consultation with an allergist, immunologist (allergy or immune system doctor), or hematologist (blood doctor)
F. Kalbitor will be administered by a healthcare professional with appropriate medical support to manage anaphylaxis (severe, possible life-threatening allergic reaction) and/or angioedema (a type of swelling)
G. You will NOT be using Kalbitor concurrently (at the same time) with other acute treatments for HAE attacks (such as Berinert, Ruconest, Firazyr)

Commercial Effective: 07/01/22
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECULIZUMAB</td>
<td>SOLIRIS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ECULIZUMAB (Soliris)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
   2. Atypical hemolytic uremic syndrome (aHUS: a condition that affects blood vessels in your kidneys)
   3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
   4. Neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)

B. Eculizumab (Soliris) is NOT being used for hemolytic uremic syndrome related to Shiga toxin E. coli

C. If you have paroxysmal nocturnal hemoglobinuria, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a hematologist (blood specialist)
   3. You have documented confirmation of PNH by flow cytometry (type of measurement of physical and chemical qualities of cells) demonstrating ALL of the following:
      a. At least 2 different GPI-protein deficiencies (you’re missing a certain type of protein such as CD55, CD59) on at least 2 cell lineages (types of cells such as erythrocytes, granulocytes)
      b. PNH granulocyte clone size of 10% or greater
   4. You are NOT concurrently (at the same time) using complement inhibitor therapy (such as Ultomiris or Empaveli)
   5. You meet ONE of the following:
      a. You are transitioning from Ultomiris
      b. You have documented evidence of intravascular hemolysis (blood cells break down within your blood stream) (such as lactate dehydrogenase [LDH] level greater than or equal to 1.5 times the upper limit of normal, hemoglobinuria [type of blood protein in urine]) AND presence of at least one PNH-related sign or symptom (such as a history of blood transfusion due to PNH, symptoms of anemia [low red blood cell level], history of major adverse vascular event from thromboembolism [blood clot])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
ECULIZUMAB (NSA)

INITIAL CRITERIA (CONTINUED)

D. If you have generalized myasthenia gravis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. Your diagnosis is confirmed by a positive anti-acetylcholine receptor antibody test (an indicator of myasthenia gravis)
   4. You have Myasthenia Gravis Foundation of America class II, III, or IV (types of severity of disease)
   5. You had a trial of or contraindication (harmful for) to ONE corticosteroid (such as prednisone)
   6. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
      b. You had a trial of or contraindication (harmful for) to ONE non-steroidal immunosuppressive therapy while on chronic plasmapheresis or plasma exchange (types of blood therapy)

E. If you have neuromyelitis optica spectrum disorder, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. Your diagnosis is confirmed by a positive serologic (blood) test for anti-aquaporin-4 (AQP4: type of protein) antibodies
   4. You have at least ONE of the following core clinical characteristics:
      a. Optic neuritis (a type of brain disorder)
      b. Acute myelitis (a type of brain disorder)
      c. Area postrema syndrome (a type of brain disorder)
      d. Acute brainstem syndrome (a type of brain disorder)
      e. Symptomatic narcolepsy (a type of sleep condition) or acute diencephalic clinical syndrome (tumor in a part of brain) with NMOSD-typical diencephalic MRI lesions (affected areas)
      f. Symptomatic cerebral syndrome with NMOSD-typical brain lesions
   5. You will NOT use rituximab, inebilizumab, or satralizumab concurrently (at the same time) with Soliris

CONTINUED ON NEXT PAGE
ECULIZUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named ECULIZUMAB (Soliris) requires the following rule(s) be met for renewal:

A. You have one of the following diagnoses:
   1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
   2. Atypical hemolytic uremic syndrome (aHUS: a condition that affects blood vessels in your kidneys)
   3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
   4. Neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)

B. **If you have paroxysmal nocturnal hemoglobinuria, renewal also requires:**
   1. You have had clinical benefit compared to baseline (before you started treatment), (such as reduction in number of blood transfusions [adding blood to your body], improvement/stabilization of lactate dehydrogenase [type of enzyme] and hemoglobin [type of blood cell] levels)
   2. You are NOT concurrently (at the same time) using complement inhibitor therapy (such as Ultomiris or Empaveli)

C. **If you have generalized myasthenia gravis, renewal also requires:**
   1. You have had clinical benefit compared to baseline according to validated gMG instruments (such as Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)

D. **If you have neuromyelitis optica spectrum disorder, renewal also requires:**
   1. You have had a reduction in relapse frequency compared to baseline
   2. You will NOT use rituximab, inebilizumab, or satralizumab concurrently (at the same time) with Soliris

Commercial Effective: 10/01/22
EDARAVONE (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDARAVONE</td>
<td>RADICAVA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named EDARAVONE (Radicava) requires the following rule(s) be met for approval:
A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
B. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or ALS specialist at an ALS Specialty Center or Care Clinic
C. You have the disease (from onset of symptoms) for 2 years or less
D. You have normal respiratory (breathing) function (such as Forced Vital Capacity [FVC: amount of air exhaled from lungs] of 80 percent or more)
E. You have mild to moderate ALS with a score of 2 or higher in all of the following 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revise (ALSFRS-R: a tool for evaluating functional status): speech, salivation, swallowing, handwriting, cutting food, dressing and hygiene, turning in bed, walking, climbing stairs, dyspnea (difficulty breathing), orthopnea (shortness of breath while lying down), respiratory insufficiency (a type of breathing condition)
F. You have tried riluzole OR are currently taking riluzole

RENEWAL CRITERIA

Our guideline named EDARAVONE (Radicava) requires the following rule(s) be met for renewal:
A. You do not require invasive ventilation (inserting a breathing tube into your throat)
B. You have improved baseline functional ability as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R: a tool for evaluating functional status) OR you have maintained a score of 2 or greater in all 12 items of the ALSFRS-R

Commercial Effective: 07/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named EFGARTIGIMOD ALFA-FCAB (VYVGART) requires the following rule(s) be met for approval:
A. You have generalized myasthenia gravis (gMG: chronic autoimmune disorder)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
D. Your diagnosis is confirmed by a positive serologic test for anti-acetylcholine receptor (AChR) antibody (an indicator of myasthenia gravis)
E. You have Myasthenia Gravis Foundation of America class II, III, or IV (types of severity of disease)
F. You had a trial of or contraindication (harmful for) to ONE corticosteroid (such as prednisone)
G. You meet ONE of the following:
   1. You had a trial of or contraindication (harmful for) to TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
   2. You had a trial of or contraindication (harmful for) to ONE non-steroidal immunosuppressive therapy while on chronic plasmapheresis or plasma exchange (types of blood therapy)

RENEWAL CRITERIA

Our guideline named EFGARTIGIMOD ALFA-FCAB (VYVGART) requires the following rule(s) be met for renewal:
A. You have generalized myasthenia gravis (gMG: chronic autoimmune disorder)
B. You have had clinical benefit compared to baseline according to validated gMG instruments (such as Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)

Commercial Effective: 10/01/22
ELOSULFASE ALFA (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELOSULFASE ALFA</td>
<td>VIMIZIM</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ELOSULFASE ALFA (Vimizim) requires you have Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome - rare metabolic condition that mainly affects the skeleton).

Commercial Effective: 07/01/20
ELOTUZUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELOTUZUMAB</td>
<td>EMPLICITI</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **ELOTUZUMAB (Empliciti)** requires the following rule(s) be met for approval:

A. You have multiple myeloma (plasma cell cancer)
B. You are 18 years of age or older
C. You meet ONE of the following criteria:
   1. Empliciti is used in combination with lenalidomide and dexamethasone if you have received one to three prior therapies such as bortezomb, thalidomide, lenalidomide, melphalan, or stem cell transplantation
   2. Empliciti is used in combination with pomalidomide and dexamethasone if you have received at least two prior therapies including lenalidomide and a proteasome inhibitor (such as bortezomb, carfilzomib, ixazomib)

Commercial Effective: 04/10/21
EMAPALUMAB-LZSG (NSA)

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named EMAPALUMAB-LZSG (Gamifant) requires the following rule(s) be met for approval:

A. You have primary hemophagocytic lymphohistiocytosis (HLH; inherited condition where you have too much of certain types of immune cells, causing inflammation)

B. Your diagnosis is confirmed by ONE of the following:
   1. You have undergone a genetic test identifying HLH-associated gene mutation such as PRF1 (type of gene), UNC13D (type of gene)
   2. You have at least five of the following eight diagnostic criteria for HLH: fever; splenomegaly (enlarged spleen); cytopenias (low number of a type of blood cell affecting at least 2 of 3 cell lineages); hypertriglyceridemia (type of high cholesterol) and/or hypofibrinogenemia (type of genetic disorder); hemophagocytosis (destruction of certain types of cells) in bone marrow or spleen or lymph nodes, and no evidence of malignancy; low or absent natural killer-cell activity; ferritin level of at least 500 mcg/L; soluble CD25 level of at least 2,400 U/mL

C. You have refractory, recurrent, or progressive disease (disease returns or does not respond to treatment and gets worse); OR you had a trial or intolerance to conventional hemophagocytic lymphohistiocytosis therapy (such as chemotherapy, steroids, immunotherapy)

D. The requested medication will be used at the same time with dexamethasone

E. Therapy is prescribed by or given in consultation with an immunologist (doctor who specializes in immune disorders), hematologist (blood doctor), or oncologist (cancer doctor)

RENEWAL CRITERIA

Our guideline named EMAPALUMAB-LZSG (Gamifant) requires the following rule(s) be met for renewal:

A. You have hemophagocytic lymphohistiocytosis (inherited condition where you have too much of certain types of immune cells, causing inflammation)

B. You have not received successful hematopoietic stem cell transplantation

C. You have demonstrated improved immune system response from baseline as shown by any of the following: your fever has gone away, decreased splenomegaly (spleen size has gotten smaller), improvement in central nervous system symptoms such as altered mental status, improved complete blood count, increased fibrinogen levels, reduced D-dimer, reduced ferritin, reduced soluble CD25 (type of protein) levels

Commercial Effective: 07/01/20
Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

Our guideline named **ENFORTUMAB (Padcev)** requires the following rule(s) be met for approval:

A. You have locally advanced or metastatic urothelial cancer (mUC: type of urinary system cancer that has spread to other parts of the body)

B. You are 18 years of age or older

C. You meet ONE of the following:
   1. You have previously received a medication that works against a type of protein called programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor AND you have previously received a platinum-containing chemotherapy (type of cancer medication)
   2. You are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy

**Commercial Effective: 08/30/21**
ENZYME REPLACEMENT THERAPY: GAUCHER DISEASE (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMIGLUCERASE</td>
<td>CEREZYME</td>
</tr>
<tr>
<td>TALIGLUCERASE ALFA</td>
<td>ELELYSO</td>
</tr>
<tr>
<td>VELAGLUCERASE ALFA</td>
<td>VPRIV</td>
</tr>
</tbody>
</table>

** Please use the criteria for the specific drug requested **

GUIDELINES FOR USE

ELELYSO

Our guideline named ENZYME REPLACEMENT THERAPY: GAUCHER DISEASE (Eleyso) requires the following rule(s) be met for approval:

A. You have type 1 Gaucher disease (genetic disorder where a type of fatty substance builds up in the body)
B. You are 4 years of age or older

VPRIV

Our guideline named ENZYME REPLACEMENT THERAPY: GAUCHER DISEASE (Vpriv) requires the following rule(s) be met for approval:

- You have type 1 Gaucher disease (genetic disorder where a type of fatty substance builds up in the body)
- You are 4 years of age or older
- You previously had a trial of Elelyso, unless there is a medical reason why you cannot (contraindication)

CEREZYME

Our guideline named ENZYME REPLACEMENT THERAPY: GAUCHER DISEASE (Cerezyme) requires the following rule(s) be met for approval:

A. You have type 1 Gaucher disease (genetic disorder where a type of fatty substance builds up in the body)
B. You are 18 years of age or older
C. You previously had a trial of Elelyso, unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 07/01/20
EPOPROSTENOL IV (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOPROSTENOL SODIUM</td>
<td>FLOLAN, EPOPROSTENOL SODIUM</td>
</tr>
<tr>
<td>(GLYCINE)</td>
<td></td>
</tr>
<tr>
<td>EPOPROSTENOL SODIUM</td>
<td>VELETRI, EPOPROSTENOL SODIUM</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named EPOPROSTENOL IV (Flolan, Veletri) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (type of high blood pressure in the arteries of the lungs, World Health Organization Group 1)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
C. You have documentation confirming your diagnosis of pulmonary arterial hypertension based on right heart catheterization (a test using a thin tube that is placed into the right side of your heart) with the following values:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
D. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class III-IV symptoms (a system to classify how severely limited you are in daily activities due to heart failure symptoms)

RENEWAL CRITERIA

Our guideline named EPOPROSTENOL IV (Flolan, Veletri) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (type of high blood pressure in the arteries of the lungs, World Health Organization Group 1)
B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You have remained stable in the 6-minute walk distance test AND your World Health Organization functional class has remained stable or improved (a system to classify how severely limited you are in daily activities due to heart failure symptoms)

Commercial Effective: 01/01/22
### GUIDELINES FOR USE

#### INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **EPTINEZUMAB-JJMR (Vyepti)** requires the following rule(s) be met for approval:

A. **You have migraines**

B. **If you have episodic migraines, approval also requires:**
   1. You are 18 years of age or older
   2. Vyepti is prescribed for the preventive treatment of migraines
   3. You will NOT use Vyepti concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Nurtec ODT, Qulipta) for migraine prevention
   4. You had a trial of ONE of the following preventive migraine treatments: Valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
   5. You had a trial of TWO of the following: Ajovy, Aimovig, Emgality, Nurtec ODT, Qulipta

C. **If you have chronic migraines, approval also requires:**
   1. You are 18 years of age or older
   2. Vyepti is prescribed for the preventive treatment of migraines
   3. You will NOT use Vyepti concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Nurtec ODT, Qulipta) for migraine prevention
   4. You had a trial of ONE of the following preventive migraine treatments: Valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox
   5. You had a trial of TWO of the following: Ajovy, Aimovig, Emgality, Nurtec ODT, Qulipta

CONTINUED ON NEXT PAGE
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EPTINEZUMAB-JJMR (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named EPTINEZUMAB-JJMR (Vyepti) requires the following rule(s) be met for renewal:

A. Vyepti is being prescribed for preventive treatment of migraines
B. You will NOT use Vyepti concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Nurtec ODT, Quilpta) for migraine prevention
C. You also meet ONE of the following:
   1. You have experienced a reduction in migraine or headache frequency by at least 2 days per month with Vyepti therapy
   2. You have experienced a reduction in migraine severity with Vyepti therapy
   3. You have experienced a reduction in migraine duration (length of time) with Vyepti therapy

Commercial Effective: 04/01/22
ERIBULIN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERIBULIN</td>
<td>HALAVEN</td>
</tr>
<tr>
<td>MESYLATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ERIBULIN (Halaven) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic (cancer has spread) breast cancer
   2. Unresectable or metastatic liposarcoma (cancer that starts in fat cells that has spread or cannot be completely removed by surgery)

B. **If you have metastatic breast cancer, approval also requires:**
   A. You had previous treatment with an anthracycline (class of medication for cancer such as daunorubicin, doxorubicin, etc)
   B. You had previous treatment with a taxane (such as paclitaxel and docetaxel)

C. **If you have unresectable or metastatic liposarcoma, approval also requires:**
   1. You had previous treatment with an anthracycline (class of medication for cancer such as daunorubicin, doxorubicin, etc)

Commercial Effective: 07/01/20
ESKETAMINE (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESKETAMINE</td>
<td>SPRAVATO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ESKETAMINE (Spravato) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Treatment-resistant depression (TRD: depressive symptoms are not responding to treatment)
   2. Major depressive disorder (MDD: a type of mental illness)

B. If you have treatment-resistant depression, approval also requires:
   1. You are 18 years of age or older
   2. Spravato will be used in combination with an oral antidepressant (a type of medication to treat depression)
   3. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
   4. You have non-psychotic, unipolar depression (you have no other mental health conditions except depression)
   5. You do NOT have active substance (drug) abuse
   6. You had a trial of TWO oral antidepressants from different classes for the treatment of depression [such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), bupropion, mirtazapine, serotonin modulator, tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs)] for an adequate time period of at least 6 weeks (unless you have shown little to no improvement after 4 weeks)

C. If you have major depressive disorder, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
   3. You have acute (short-term) suicidal ideation or behavior (thoughts of killing yourself)
   4. Spravato will be used in combination with an oral antidepressant (a type of medication to treat depression)
   5. You have non-psychotic, unipolar depression (you have no other mental health conditions except depression)
   6. You do NOT have active substance (drug) abuse

CONTINUED ON NEXT PAGE
ESKETAMINE (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **ESKETAMINE (Spravato)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Treatment-resistant depression (TRD: depressive symptoms are not responding to treatment)
   2. Major depressive disorder (MDD: a type of mental illness)

B. You have demonstrated clinical benefit (improvement in depression) compared to baseline

Commercial Effective: 04/01/22
ETELCALCETIDE (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETELCALCETIDE</td>
<td>PARSABIV</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **ETELCALCETIDE (Parsabiv)** requires the following rule(s) be met for approval:

A. You have secondary hyperparathyroidism (too much parathyroid hormone due to low blood calcium levels)
B. You are 18 years of age or older
C. You have chronic kidney disease
D. You are on hemodialysis (a way of removing toxins from your blood)
E. You are NOT taking another calcimimetic agent (a drug that acts like calcium in the body such as cinacalcet)

Commercial Effective: 07/01/20
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ETEPLIRSEN (Exondys-51) requires the following rule(s) be met for approval:
A. You have Duchenne muscular dystrophy (DMD: inherited disorder where your muscles get weaker over time)
B. You have documented genetic testing that confirms you have a mutation (change in DNA that make up your gene) in the DMD gene that is responsive to exon 51 skipping (a process that allows a protein to still function with sections of faulty genetic code)
C. Therapy is prescribed by or given in consultation with a neurologist (brain, spinal cord, nervous system doctor) specializing in treatment of Duchenne muscular dystrophy at a DMD treatment center
D. You are ambulatory (able to move and walk)
E. You are currently receiving treatment with corticosteroids (such as prednisone or prednisolone) unless there is a medical reason why you cannot (contraindication)

RENEWAL CRITERIA

Our guideline named ETEPLIRSEN (Exondys-51) requires ONE of the following rule(s) be met for renewal:
A. You have maintained or demonstrated less than expected decline in ambulatory ability (ability to move and walk) based on muscle function assessments (such as the 6-minute walk test)
B. You have maintained or demonstrated less than expected decline in other muscle function (such as pulmonary [lung] or cardiac [heart] function)
GUIDELINES FOR USE

Our guideline named **EVINACUMAB-DGNB (Evkeeza)** requires the following rule(s) be met for approval:

A. You have homozygous familial hypercholesterolemia (HoFH: type of inherited high cholesterol)
B. You are 12 years of age or older
C. Evkeeza will be used as an adjunct (add-on) to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies (such as statins, PCSK9 inhibitors, ezetimibe, lomitapide, lipoprotein apheresis)

Commercial Effective: 07/01/21
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FAM-TRASTUZUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAM-TRASTUZUMAB</td>
<td>ENHERTU</td>
</tr>
<tr>
<td>DERUXTECAN-NXKI</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **FAM-TRASTUZUMAB (Enhertu)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic HER2-positive breast cancer (a type of breast cancer that cannot be surgically removed or has spread to other parts of the body)
   2. Unresectable or metastatic HER2-low breast cancer (a type of breast cancer that cannot be surgically removed or has spread to other parts of the body)
   3. Unresectable or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that cannot be surgically removed or has spread to other parts of the body)
   4. Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma (a type of digestive system cancer that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)

B. **If you have unresectable or metastatic HER2-positive breast cancer, approval also requires:**
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. You have received a prior anti-HER2-based regimen (drug that works against a protein called human epidermal growth factor receptor 2) in the metastatic setting (cancer has spread to other parts of the body)
      b. You have received a prior anti-HER2-based regimen (drug that works against a protein called human epidermal growth factor receptor 2) in the neoadjuvant (given before main treatment) or adjuvant (additional treatment) setting AND the disease has returned during or within six months of completing therapy

C. **If you have unresectable or metastatic HER2-low breast cancer, approval also requires:**
   1. You are 18 years of age or older
   2. You have received a prior chemotherapy in the metastatic setting (cancer has spread to other parts of the body) OR developed disease recurrence (disease has returned) during or within 6 months of completing adjuvant (additional treatment) chemotherapy

*(Criteria continued on next page)*

CONTINUED ON NEXT PAGE
D. If you have unresectable or metastatic non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your tumors have activating HER2 (ERBB2) mutations (a type of mutation), as detected by a Food & Drug Administration (FDA)-approved test
   3. You have received a prior systemic therapy

E. If you have locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You have received a prior trastuzumab-based (type of medication) regimen

Commercial Effective: 09/12/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named FARICIMAB-SVOA (Vabysmo) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Neovascular (wet) age-related macular degeneration (nAMD: a type of eye disease)
   2. Diabetic macular edema (DME: a type of eye condition caused by high blood sugar)
B. If you have neovascular (wet) age-related macular degeneration, approval also requires:
   1. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist
   2. You are NOT using Vabysmo at the same time with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis, Beovu)
C. If you have diabetic macular edema, approval also requires:
   1. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist
   2. You are NOT using Vabysmo at the same time with other intravitreal (in the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis)

RENEWAL CRITERIA

Our guideline named FARICIMAB-SVOA (Vabysmo) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Neovascular (wet) age-related macular degeneration (nAMD: a type of eye disease)
   2. Diabetic macular edema (DME: a type of eye condition caused by high blood sugar)
B. If you have neovascular (wet) age-related macular degeneration, approval also requires:
   1. You have maintained or improved visual acuity (vision clarity or sharpness)
   2. You are NOT using Vabysmo at the same time with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis, Beovu)
C. If you have diabetic macular edema, approval also requires:
   1. You have maintained or improved visual acuity (vision clarity or sharpness)
   2. You are NOT using Vabysmo at the same time with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis)
FULVESTRANT (NSA)

GUIDELINES FOR USE

Our guideline named FULVESTRANT (Faslodex) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer
   2. HR-positive advanced breast cancer
   3. HR-positive, HER2-negative advanced or metastatic breast cancer (cancer that has spread)

B. If you have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, approval also requires:
   1. You are female and postmenopausal
   2. You have not previously been treated with endocrine (hormone) therapy
   3. The requested medication will be used as monotherapy (using a single drug to treat a condition)

C. If you have hormone receptor (HR)-positive advanced breast cancer, approval also requires:
   1. You are female and postmenopausal
   2. You have experienced disease progression (it has gotten worse) following endocrine (hormone) therapy
   3. The requested medication will be used as monotherapy (used alone)

D. If you have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, approval also requires ONE of the following:
   1. The requested medication will be used concurrently (at the same time) with Ibrance (palbociclib) or Verzenio (abemaciclib) and you are a female that has experienced disease progression (it has gotten worse) after endocrine (hormone) therapy
   2. The requested medication will be used in combination with Kisqali (ribociclib) and you meet ALL of the following:
      a. You are a female and postmenopausal
      b. You have not received prior endocrine based therapy for metastatic breast cancer (such as letrozole, anastrozole, tamoxifen, exemestane) OR you have experienced disease progression on endocrine therapy

Commercial Effective: 07/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GEMTUZUMAB OZOGAMICIN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEMTUZUMAB OZOGAMICIN</td>
<td>MYLOTARG</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named GEMTUZUMAB OZOGAMICIN (Mylotarg) requires that ONE of the following rule(s) be met for approval:

1. You have newly-diagnosed CD33 (type of molecule that is used as a marker to diagnose AML) – positive acute myeloid leukemia (AML: type of blood and bone marrow cancer with too many immature white blood cells) AND you are ≥ 1 month of age or older

2. You have relapsed (returning) or refractory (resistant) CD33 (type of molecule that is used as a marker to diagnose AML) - positive acute myeloid leukemia (AML) AND you are ≥ 2 years of age or older

Commercial Effective: 04/10/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named GIVOSIRAN (Givlaari) requires the following rule(s) be met for approval:
A. You have acute hepatic porphyria (enzyme deficiency which leads to buildup of materials in the liver) (to include acute intermittent porphyria [AIP], variegate porphyria [VP], hereditary coproporphyria [HCP], ALA dehydratase-deficient porphyria [ADP])
B. You are 18 years of age or older
C. You have genetic confirmation of AHP mutation (a change in your DNA that make up your gene), OR high (beyond reference range) urinary or plasma porphobilinogen (PBG), or aminolevulinic acid (ALA) (PBG and ALA: urine or blood tests that measure the level of porphyrins – a chemical that helps make hemoglobin in your body)
D. You have experienced two or more acute (sudden and severe) hepatic porphyria attacks in the past 12 months
E. The medication is prescribed by or given in consultation with a geneticist (doctor who specializes in conditions of gene disorders), hepatologist (doctor who specializes in treating the liver), hematologist (doctor who specializes in the study of blood, blood-forming organs and blood diseases), gastroenterologist (doctor who specializes in conditions of the stomach, intestine and related organs), neurologist (doctor who specializes in disorders of the nervous system), dermatologist (doctor who treats conditions of the skin, hair and nails), or a healthcare provider experienced in managing acute hepatic porphyria
F. Your doctor provided documentation of your weight

RENEWAL CRITERIA

Our guideline named GIVOSIRAN (Givlaari) requires the following rule(s) be met for renewal:
A. You have acute hepatic porphyria (AHP: enzyme deficiency which leads to buildup of materials in the liver) (to include acute intermittent porphyria [AIP], variegate porphyria [VP], hereditary coproporphyria [HCP], ALA dehydratase-deficient porphyria [ADP])
B. You have achieved or maintained clinical (medical) benefit compared to baseline (such as less hemin use, less AHP attacks, improvement of AHP symptoms, etc.)
C. You have not received a liver transplant (replaced your bad liver with a healthy liver from another person)
D. Your doctor provided documentation of your weight

Commercial Effective: 04/20/20
GOLIMUMAB - IV (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLIMUMAB - IV</td>
<td>SIMPONI ARIA - IV</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GOLIMUMAB - IV (Simponi Aria)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You are currently using methotrexate at the same time, unless there is a contraindication (harmful for)
   5. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
      b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz IR/XR) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

*(Initial criteria continued on next page)*

CONTINUED ON NEXT PAGE
C. If you have psoriatic arthritis, approval also requires:
   1. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   2. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   3. You meet ONE of the following criteria:
      a. You are 2 to 5 years old and had a trial of or contraindication (harmful for) to the preferred medication: Cosentyx
      b. You are 6 to 17 years of age and had a trial of or contraindication (harmful for) to BOTH of the following preferred medications: Cosentyx and Stelara
      c. You are 18 years of age or older and had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (IR or XR, immediate-release or extended-release), Otezla, Tremfya, Rinvoq, Skyrizi

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
   4. You had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Cosentyx, Enbrel, Humira, Xeljanz (IR or XR, immediate-release or extended-release), Rinvoq

E. If you have polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Enbrel, Humira, Actemra, Xeljanz immediate release

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

Our guideline named GOLIMUMAB - IV (Simponi Aria) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You are currently using methotrexate at the same time, unless there is a contraindication (harmful for)

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

D. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (diagnostic test to determine the effectiveness of drug therapy) while on therapy

E. If you have polyarticular juvenile idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GOLODIRSEN (Vyondys-53)** requires the following rule(s) be met for approval:

C. You have Duchenne muscular dystrophy (DMD: inherited disorder where your muscles get weaker over time)

D. You have documented genetic testing that confirms you have a mutation (change in DNA that make up your gene) in the DMD gene that is responsive to exon 53 skipping (a process that allows a protein to still function with sections of faulty genetic code)

E. Therapy is prescribed by or given in consultation with a neurologist (brain, spinal cord, nervous system doctor) specializing in treatment of Duchenne muscular dystrophy at a DMD treatment center

F. You are ambulatory (able to move and walk)

G. You are currently receiving treatment with corticosteroids (such as prednisone or prednisolone) unless there is a medical reason why you cannot (contraindication)

RENEWAL CRITERIA

Our guideline named **GOLODIRSEN (Vyondys-53)** requires ONE of the following rule(s) be met for renewal:

A. You have maintained or demonstrated less than expected decline in ambulatory ability (ability to move and walk) based on muscle function assessments (such as the 6-minute walk test)

B. You have maintained or demonstrated less than expected decline in other muscle function (such as pulmonary [lung] or cardiac [heart] function)

---

Commercial Effective: 01/01/21
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GONADOTROPIN RELEASING HORMONE (GNRH) AGONIST (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRIPTORELIN PAMOATE</td>
<td>TRIPTODUR, TRELSTAR</td>
</tr>
<tr>
<td>HISTRELIN ACETATE</td>
<td>SUPPRELIN LA, VANTAS</td>
</tr>
<tr>
<td>LEUPROLIDE ACETATE</td>
<td>LUPRON DEPOT–PED, LUPRON DEPOT, LUPANETA, FENSOLVI</td>
</tr>
<tr>
<td>GOSERELIN ACETATE</td>
<td>ZOLADEX</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named GONADOTROPIN RELEASING HORMONE (GNRH) AGONIST (Lupron Depot, Lupaneta, Zoladex, Supprelin LA, Vantas, Triptodur, Trelstar, Fensolvi) requires the following rule(s) be met for approval:

A. You have or are using the requested drug for ONE of the following:
   1. Advanced prostate cancer
   2. Moderate to severe pain from endometriosis (condition affecting the uterus)
   3. Central precocious puberty (CPP: early sexual development in girls and boys)
   4. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
   5. As an endometrial-thinning agent prior to endometrial ablation (surgical removal of body tissue) for dysfunctional uterine bleeding
   6. Palliative treatment (treatment for pain or discomfort) of advanced breast cancer
   7. Management of locally confined carcinoma (cancer) of the prostate
   8. Anemia caused by uterine leiomyomata (fibroids: small muscle tumor)

B. If you have advanced prostate cancer, approval also requires:
   1. The request is for Lupron Depot, Zoladex, Vantas, or Trelstar

(Initial criteria continued on next page)
C. If you have moderate to severe pain from endometriosis, approval also requires:
   1. The request is for Lupron Depot, Lupaneta, or Zoladex
   2. You are 18 years of age or older if the request is for Lupaneta or Zoladex
   3. Your diagnosis is confirmed by surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
   4. Therapy is prescribed by or in consultation with an obstetrician/gynecologist (a type of women's health doctor)
   5. You had a trial of or contraindication (harmful for) to a nonsteroidal anti-inflammatory drug (NSAID) AND a progestin-containing contraceptive preparation (such as combination hormonal contraceptive preparation, progestin-only contraceptive preparation)
   6. You are NOT using Lupron Depot, Lupaneta, or Zoladex concurrently (at the same time) with another gonadotropin-releasing hormone (GnRH)-modulating agent (such as elagolix, relugolix)
   7. If the request is for Zoladex, you have NOT received more than 6 months of treatment per lifetime
   8. If the request is for Lupron Depot or Lupaneta, you have NOT received more than 12 months of treatment per lifetime

D. If you are female and have central precocious puberty, approval also requires:
   1. The request is for Triptodur, Supprelin LA, Lupron Depot-Ped, or Fensolvi
   2. You are 2 years of age or older if the request is for Triptodur, Supprelin LA, or Fensolvi
   3. Therapy is prescribed by or in consultation with a pediatric endocrinologist (a type of hormone doctor)
   4. You have high levels of follicle-stimulating hormone (FSH) (level greater than 4.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
   5. You are/were younger than 8 years of age when your condition started
   6. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)

(Initial criteria continued on next page)
GONADOTROPIN RELEASING HORMONE (GNRH) AGONIST (NSA)

INITIAL CRITERIA (CONTINUED)

E. If you are male and have central precocious puberty, approval also requires:
1. The request is for Triptodur, Supprelin LA, Lupron Depot-Ped, or Fensolvi
2. You are 2 years of age or older if the request is for Triptodur, Supprelin LA, or Fensolvi
3. Therapy is prescribed by or in consultation with a pediatric endocrinologist (a type of hormone doctor)
4. You have high levels of follicle-stimulating hormone (FSH) (level greater than 5.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
5. You are/were younger than 9 years of age when your condition started
6. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

F. If you are using the requested medication as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding, approval also requires:
1. The request is for Zoladex

G. If you are using the requested medication for palliative treatment of advanced breast cancer, approval also requires:
1. The request is for Zoladex
2. You are a premenopausal or perimenopausal female

H. If you are using the requested medication for the management of locally confined carcinoma of the prostate, approval also requires:
1. The request is for Zoladex
2. The requested medication will be used in combination with flutamide

I. If you have anemia caused by uterine leiomyomata, approval also requires:
1. The request is for Lupron Depot
2. You are using the requested medication for preoperative hematologic (blood) improvement
3. The requested medication will be used with iron therapy

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE
GONADOTROPIN RELEASING HORMONE (GNRH) AGONIST (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For palliative treatment of advanced breast cancer, management of locally confined prostate carcinoma, preoperative hematologic improvement of anemia caused by uterine leiomyomata, or use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding, please refer to the Initial Criteria section.

Our guideline named GONADOTROPIN RELEASING HORMONE (GNRH) AGONIST (Lupron Depot, Lupaneta, Zoladex, Supprelin LA, Vantas, Triptodur, Trelstar, Fensolvi) requires the following rule(s) be met for renewal:

A. You have or are using the requested drug for ONE of the following:
   1. Advanced prostate cancer
   2. Moderate to severe pain from endometriosis (condition affecting the uterus)
   3. Central precocious puberty (CPP: early sexual development in girls and boys)
   4. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)

B. If you have moderate to severe pain associated with endometriosis, renewal also requires:
   1. The request is for Lupron Depot or Lupaneta
   2. You experienced improvement of pain related to endometriosis while on therapy
   3. You are receiving add-back therapy at the same time (combination estrogen-progestin or progestin-only contraceptive preparation)
   4. You have NOT received a total of 12 months of treatment with the requested medication per lifetime
   5. You are NOT using Lupron Depot or Lupaneta concurrently (at the same time) with another gonadotropin-releasing hormone (GnRH)-modulating agent (such as elagolix, relugolix)

C. If you have central precocious puberty, renewal also requires:
   1. The request is for Triptodur, Supprelin LA, Lupron Depot-Ped, or Fensolvi
   2. Tanner scale staging (scale of physical measurements of development based on external sex characteristics) at initial diagnosis of CPP has stabilized or regressed (lowered) during three separate medical visits in the previous year
   3. You have not reached actual age which corresponds to current pubertal age

D. If you have advanced prostate cancer, renewal also requires:
   1. The request is for Lupron Depot, Zoladex, Vantas, or Trelstar
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named HYALURONATE (Euflexxa, Gel-One, Gelsyn-3, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz FX, Synojoynt, Synvisc, Synvisc-One, Genvisc 850, Visco-3, Trivisc, Durolane, Triluron, Sodium Hyaluronate) requires the following rule(s) be met for approval:
A. You have osteoarthritis (a type of joint condition) of the knee
B. You are 21 years of age or older
C. You have failed a 6-week trial of non-pharmacologic (non-drug) therapy (such as education, exercise, use of insoles or braces, weight loss, physical therapy [exercises to restore health])

(Initial criteria continued on next page)
HYALURONATE (NSA)

INITIAL CRITERIA (CONTINUED)

D. You meet THREE of the following criteria:
   1. You had a trial of or contraindication (harmful for) to TWO intra-articular (injected within the joint) steroids (such as methylprednisolone acetate, triamcinolone acetonide)
   2. You had a trial of or contraindication (harmful for) to a topical non-steroidal anti-inflammatory drug (NSAID: such as diclofenac)
   3. You had a trial of or contraindication (harmful for) to TWO oral NSAIDs (such as meloxicam, diclofenac)
   4. You had a trial of or contraindication (harmful for) to acetaminophen

RENEWAL CRITERIA

Our guideline named HYALURONATE (Euflexxa, Gel-One, Gelsyn-3, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz FX, Synojoynt, Synvisc, Synvisc-One, Genvisc 850, Visco-3, Trivisc, Durolane, Triluron, Sodium Hyaluronate) requires the following rule(s) be met for renewal:
   A. It has been at least 6 months since your last treatment on the same knee

Commercial Effective: 10/01/22
### GUIDELINES FOR USE

Our guideline named **HYDROXYPROGESTERONE CAPROATE (Makena)** requires the following rule(s) be met for approval:

A. The medication will be used to lower the risk of preterm (early than normal 37 weeks) birth in a woman with a history of singleton spontaneous preterm birth

B. You do **NOT** have multiple gestations (twins, triplets, etc.)

C. You are at least 16 weeks pregnant but less than 37 weeks pregnant with a single gestation (embryo/fetus)

D. You have a history of delivery at less than 37 weeks of gestation following spontaneous preterm labor or premature rupture of membranes

Our guideline named **HYDROXYPROGESTERONE CAPROATE (Generic Delalutin)** requires you are a non-pregnant female and are using the medication for **ONE** of the following:

A. For treatment of advanced adenocarcinoma of the uterine corpus (uterine cancer/tumor Stage III or IV)

B. For the management of primary/secondary amenorrhea (lack of normal menstruation) and abnormal uterine bleeding caused by hormonal imbalance with no organic pathology (no disease from body/organs), such as submucous fibroids or uterine cancer

C. As a test for endogenous (within the body) estrogen production

D. For the production of secretory endometrium and desquamation (shedding of the tissue lining of the uterus)

**Commercial Effective: 07/01/20**
GUIDELINES FOR USE

Our guideline named **IBALIZUMAB-UIYK (Trogarzo)** requires the following rule(s) be met for approval:

A. You have human immunodeficiency virus type 1 (HIV-1) infection (a virus that attacks the body’s immune system and if untreated, can lead to AIDS [acquired immunodeficiency syndrome])

B. You are 18 years of age or older

C. The requested medication will be used in combination with other antiretroviral(s) (class of medication used to treat HIV)

D. You are treatment experienced (previously treated)

E. You have multidrug-resistant HIV-1 infection (your virus is resistant to more than one HIV medication)

F. You are failing your current antiretroviral regimen

Commercial Effective: 10/01/20
GUIDELINES FOR USE

Our guideline named IDECABTAGENE VICLEUCE (Abecma) requires the following rule(s) be met for approval:

A. You have relapsed or refractory multiple myeloma (plasma cell cancer that has returned or is not responsive to treatment)
B. You are 18 years of age or older
C. You have received four or more prior lines of therapy, including an immunomodulatory agent (such as Revlimid, Pomalyst), a proteasome inhibitor (such as Velcade, Kyprolis), and an anti-CD38 monoclonal antibody (such as Darzalex)

Commercial Effective: 07/01/21
IMMUNE GLOBULIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMMUNE GLOBULIN</td>
<td>BIVIGAM, CARIMUNE NF</td>
</tr>
<tr>
<td></td>
<td>NANOFILTERED, FLEBOGAMMA DIF</td>
</tr>
<tr>
<td></td>
<td>GAMASTAN S-D, GAMMAGARD S-D,</td>
</tr>
<tr>
<td></td>
<td>GAMMAPLEX, PRIVIGEN,</td>
</tr>
<tr>
<td></td>
<td>GAMMAGARD LIQUID, HIZENTRA</td>
</tr>
<tr>
<td>IMMUNE GLOB, GAM CAPRYLATE</td>
<td>GAMUNEX-C, GAMMAKED</td>
</tr>
<tr>
<td>IMMUNE GLOBULIN / MALTOSE</td>
<td>OCTAGAM</td>
</tr>
<tr>
<td>IGG/HYALURONIDASE, RECOMBINANT</td>
<td>HYQVIA</td>
</tr>
<tr>
<td>IMMUN GLOB G(IGG)/GLY/IGA OV50</td>
<td>CUVITRU</td>
</tr>
<tr>
<td>IMMUN GLOB G(IGG)-IFAS/GLYCINE</td>
<td>PANZYGA</td>
</tr>
<tr>
<td>IMMUN GLOB G(IGG)-HIPP/MALTOSE</td>
<td>CUTAQUG</td>
</tr>
<tr>
<td>IMMUNE GLOBULIN (HUMAN)-KLHW</td>
<td>XEMBIFY</td>
</tr>
<tr>
<td>IMMUNE GLOBULIN (HUMAN)-SLRA</td>
<td>ASCENIV</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named IMMUNE GLOBULIN requires the following rule(s) be met for approval:

A. **For Gammagard Liquid, Gamunex-C, gammaked, Bivigam, Carimune NF Nanofiltered, Flebogamma DIF, Gammagard S-D, Gammplex, Privigen, Octagam, or Panzyga for intravenous (IV) injection**, approval requires you to have ONE of the following diagnoses:

1. Primary Immunodeficiency Disease (genetic disease where your immune system is weak)
2. Idiopathic Thrombocytopenic Purpura (Low levels of the blood cells that prevent bleeding)
3. Chronic Inflammatory Demyelinating Polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)

*(Criteria continued on next page)*
GUIDELINES FOR USE (CONTINUED)

4. Multifocal Motor Neuropathy (nerve disorder with increasing muscle weakness and wasting)
5. Kawasaki Syndrome (inflammation in the walls of blood vessels in the body)
6. B-cell Chronic Lymphocytic Leukemia (blood and bone marrow cancer of immune cells) with Autoimmune Hemolytic Anemia (body destroys red blood cells more rapidly than it produces them), Immune Thrombocytopenic Purpura (decreased number of blood cells that prevent bleeding with increased easy bruising) OR Pure Red Cell Blood Aplasia (bone marrow stops making red blood cells)
7. Guillain-Barre Syndrome (immune system attacks the nerves)
8. Myasthenia Gravis (weakness and rapid fatigue of muscles under voluntary control)
9. Autoimmune Graves’ Ophthalmopathy (type of eye disease from having little to no thyroid)
10. Cytomegalovirus-induced Pneumonitis related to a solid organ transplant (lung tissue inflammation) related to a solid organ transplant
11. Prevention of bacterial infection in an HIV-infected child (human immunodeficiency virus)-infected child
12. Reduction of secondary infections in pediatric HIV infections
13. Dermatomyositis (inflammatory disease with muscle weakness and skin rash) or polymyositis (type of inflammatory muscle disease)
14. Autoimmune uveitis (Birdshot retinochoroidopathy; inflammation of the middle layer of the eye)
15. Lambert-Eaton myasthenic syndrome (nerve disease in which the immune system attacks the body’s own tissues)
16. IgM (Immunoglobulin M) anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathy (type of nerve damage)
17. Stiff-man syndrome (nerve disorder with increasing muscle stiffness (rigidity) and repeated episodes of painful muscle spasms)
18. Neonatal sepsis (blood infection in infants)
19. Rotaviral enterocolitis (severe diarrhea among infants and young children)
20. Toxic shock syndrome (life-threatening complication of certain bacterial infections)
21. Enteroviral meningoencephalitis (Inflammation of the brain and surrounding tissues caused by a virus)
22. Toxic Epidermal Necrolysis or Stevens-Johnson syndrome (both are types of serious skin bacterial infections)
23. Autoimmune Mucocutaneous Blistering Disease (group of serious skin conditions that start with blisters on the skin) such as pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, or epidermolysis bullosa acquisita

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

B. For Asceniv, approval requires:
   1. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)
   2. You are 12 years of age or older
   3. You have tried any other TWO immunoglobulin products

C. For Gamastan S-D, approval requires:
   1. You are using the requested drug for prophylaxis (prevention) or passive immunization (immune response where antibodies are obtained from outside the body) of hepatitis A, measles, varicella, or rubella

D. For Hizentra, approval requires:
   1. The medication is only for subcutaneous (under the skin) use
   2. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak) OR chronic Inflammatory Demyelinating Polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)

E. For Cuvitru, Hyqvia, Cutaquig, or Xembify, approval requires:
   1. The medication is only for subcutaneous (under the skin) use
   2. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)

F. For Gammagard Liquid, Gamunex-C, or Gammaked for subcutaneous use, approval requires:
   1. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)

Commercial Effective: 04/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INCLISIRAN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INCLISIRAN SODIUM</td>
<td>LEQVIO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named INCLISIRAN (Leqvio) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Heterozygous familial hypercholesterolemia (HeFH: type of inherited high cholesterol)
   2. Atherosclerotic cardiovascular disease (health problems related to narrow or blocked blood vessels of the heart), such as history of myocardial infarction (heart attack) or other acute coronary syndrome, coronary or other revascularization procedure (restoring blood flow to heart and other areas), transient ischemic attack (short, stroke-like attack), ischemic stroke (arteries to your brain become narrowed or blocked)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor), endocrinologist (a type of hormone doctor), or lipidologist (a type of cholesterol doctor)
D. You have a low density lipoprotein (LDL: bad cholesterol) cholesterol level greater than or equal to 70 mg/dL at initiation of Leqvio therapy
E. You had a trial of or contraindication (harmful for) to ezetimibe AND Praluent or Repatha
F. If you are statin tolerant, approval also requires:
   1. You will continue statin treatment in combination with Leqvio
   2. You meet ONE of the following:
      a. You are currently taking a high-intensity statin (atorvastatin 40-80 mg daily, rosvastatin 20-40 mg daily) AND have been taking it for a duration of at least 8 weeks
      b. You did not tolerate a high-intensity statin (atorvastatin 40-80 mg daily, rosvastatin 20-40 mg daily) but are currently taking a maximally tolerated dose of any statin AND have been taking it for a duration of at least 8 weeks
G. If you are statin intolerant, approval also requires ONE of the following:
   1. You have an absolute contraindication (harmful for) to statin therapy (such as active decompensated liver disease [symptoms related to liver damage], nursing female, pregnancy or plans to become pregnant, or hypersensitivity [allergic] reaction)
   2. You have complete statin intolerance as defined by severe and intolerable adverse effects that has occurred with trials of at least two separate statins, and the side effects have improved when you stopped each statin. Some adverse effects include: creatine kinase (type of protein) elevation greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis (severe muscle break down), severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group

CONTINUED ON NEXT PAGE

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
INCLISIRAN (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named INCLISIRAN (Leqvio) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Heterozygous familial hypercholesterolemia (HeFH: type of inherited high cholesterol)
   2. Atherosclerotic cardiovascular disease (health problems related to narrow or blocked blood vessels of the heart)

B. You meet ONE of the following:
   1. You have continued to take a high intensity statin (atorvastatin 40-80 mg daily, rosvuastatin 20-40 mg daily) along with the requested medication
   2. You have continued therapy with a maximally tolerated dose of any statin along with the requested medication
   3. You have an absolute contraindication (harmful for) to statin therapy
   4. You have complete statin intolerance (side effect)

Commercial Effective: 01/17/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

- You have neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)
- You are 18 years of age or older
- Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- Your diagnosis is confirmed by a positive serologic (blood) test for anti-aquaporin-4 (AQP4: type of protein) antibodies
- You have at least ONE of the following core clinical characteristics:
  1. Optic neuritis (type of brain disorder)
  2. Acute myelitis (type of brain disorder)
  3. Area postrema syndrome (type of brain disorder)
  4. Acute brainstem syndrome (type of brain disorder)
  5. Symptomatic narcolepsy (type of sleep condition) or acute diencephalic clinical syndrome (type of brain disorder) with NMOSD-typical diencephalic MRI lesions
  6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions
- You will NOT use rituximab, satralizumab, or eculizumab together with Uplizna

RENEWAL CRITERIA

- You have neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)
- You have shown clinical benefit (such as reduction in relapse frequency from baseline or a decrease in NMOSD-related hospitalizations) on therapy with Uplizna
- You will NOT use rituximab, satralizumab, or eculizumab together with Uplizna

Commercial Effective: 07/01/22
INFLIXIMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INFLIXIMAB</td>
<td>REMICADE,</td>
</tr>
<tr>
<td></td>
<td>INFLIXIMAB</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named INFLIXIMAB (Remicade) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using or have a contraindication (harmful for) to methotrexate
   4. You have tried at least 3 months of or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   5. You meet ONE of the following:
      a. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Enbrel, Humira, Rinoq, Xeljanz (immediate release/extended release)
      b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB (NSA)

INITIAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as, methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (immediate release/extended release), Otezla, Tremfya, Rinvoq, Skyrizi

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You have tried or have a contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Xeljanz (immediate release/extended release), Rinvoq

E. If you have severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
   4. You have tried or have a contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
   5. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
INFLIXIMAB (NSA)

INITIAL CRITERIA (CONTINUED)

F. If you have moderate to severe Crohn’s disease, approval also requires:
   1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   2. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   3. You meet ONE of the following:
      a. You are 6 to 17 years of age AND have tried or have a contraindication (harmful for) to the following preferred immunomodulatory: Humira
      b. You are 18 years of age or older AND have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Skyrizi

G. If you have moderate to severe ulcerative colitis, approval also requires:
   1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   2. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   3. You meet ONE of the following:
      a. You are 6 to 17 years of age AND have tried or have a contraindication (harmful for) to the following preferred immunomodulator: Humira
      b. You are 18 years of age or older AND have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Xeljanz (immediate release/extended release), Rinvoq

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

Our guideline named INFLIXIMAB (Remicade) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn’s disease (CD: a type of bowel disorder)
   6. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You are currently using or have a contraindication (harmful for) to methotrexate
C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
D. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy
E. If you have severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease OR you have experienced a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

Commercial Effective: 09/01/22
Our guideline named **INFLIXIMAB-ABDA (Renflexis)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using or have a contraindication (harmful for) to methotrexate
   4. You have tried or have a contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   5. You meet ONE of the following:
      a. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
      b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

*(Initial criteria continued on next page)*
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-ABDA (NSA)

INITIAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (immediate release/extended release), Otezla, Tremfya, Rinvoq, Skyrizi

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You have tried or have a contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Xeljanz (immediate release/extended release), Rinvoq

E. If you have severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
   4. You have tried or have a contraindication (harmful for) to ONE or more form of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
   5. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla

(Initial criteria continued on next page)
INITIAL CRITERIA (CONTINUED)

F. If you have moderate to severe Crohn's disease, approval also requires:
   1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   2. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   3. You meet ONE of the following:
      a. You are 6 to 17 years of age AND have tried or have a contraindication (harmful for) to the following preferred immunomodulatory: Humira
      b. You are 18 years of age or older AND have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Skyrizi

G. If you have moderate to severe ulcerative colitis, approval also requires:
   1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   2. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   3. You meet ONE of the following:
      a. You are 6 to 17 years of age AND have tried or have a contraindication (harmful for) to the following preferred immunomodulator: Humira
      b. You are 18 years of age or older AND have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Xeljanz (immediate release/extended release), Rinvoq

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

Our guideline named **INFLIXIMAB (Remicade)** requires the following rule(s) be met for renewal:

B. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

C. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You are currently using or have a contraindication (harmful for) to methotrexate

D. **If you have psoriatic arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

E. **If you have ankylosing spondylitis, renewal also requires:**
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy

F. **If you have severe plaque psoriasis, renewal also requires:**
   1. You have achieved or maintained clear or minimal disease OR you have experienced a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

---

Commercial Effective: 09/01/22
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-AXXQ (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INFLIXIMAB-AXXQ</td>
<td>AVSOLA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named INFLIXIMAB-AXXQ (Avsola) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using or have a contraindication (harmful for) to methotrexate
   4. You have tried or have a contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug) such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   5. You meet ONE of the following:
      a. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Enbrel, Humira, Rinvoq, Xeljanz immediate release/extended release
      b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
INFLIXIMAB-AXXQ (NSA)

INITIAL CRITERIA (CONTINUED)

C. **If you have psoriatic arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (immediate release/extended release), Otezla, Tremfya, Rinvoq, Skyrizi

D. **If you have ankylosing spondylitis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You have tried or have a contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Xeljanz (immediate release/extended release), Rinvoq

E. **If you have severe plaque psoriasis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
   4. You have tried or have a contraindication (harmful for) to ONE or more forms of the following standard therapies: PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
   5. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla

*(Initial criteria continued on next page)*

CONTINUED ON NEXT PAGE
INFLIXIMAB-AXXQ (NSA)

INITIAL CRITERIA (CONTINUED)

F. If you have moderate to severe Crohn's disease, approval also requires:
   1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   2. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   3. You meet ONE of the following:
      a. You are 6 to 17 years of age AND have tried or have a contraindication (harmful for) to the following preferred immunomodulator: Humira
      b. You are 18 years of age or older AND have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Skyrizi

G. If you have moderate to severe ulcerative colitis, approval also requires:
   1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   2. You have tried or have a contraindication (harmful for) to ONE standard therapy such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   3. You meet ONE of the following:
      a. You are 6 to 17 years of age AND have tried or have a contraindication (harmful for) to the following preferred immunomodulator: Humira
      b. You are 18 years of age or older AND have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Xeljanz (immediate release/extended release), Rinvoq

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
INFLIXIMAB-AXXQ (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named INFLIXIMAB-AXXQ (Avsola) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You are currently using or have a contraindication (harmful for) to methotrexate

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

D. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy

E. If you have severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease OR you have experienced a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

Commercial Effective: 09/01/22
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INFliximab-Dyyb</td>
<td>Inflectra</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named INFLIXIMAB- DYYB (Inflectra) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using or have a contraindication (harmful for) to methotrexate
   4. You have tried at least 3 months of or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   5. You meet ONE of the following:
      a. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
      b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

C. **If you have psoriatic arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Stelara, Xeljanz (immediate release/extended release), Otezla, Tremfya, Rinvoq, Skyrizi

D. **If you have ankylosing spondylitis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You have tried or have a contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug)
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Enbrel, Humira, Xeljanz (immediate release/extended release), Rinvoq

E. **If you have severe plaque psoriasis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
   4. You have tried or have a contraindication (harmful for) to ONE or more form of conventional therapies: PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
   5. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla

(Initial criteria continued on next page)
INFLIXIMAB-DYYB (NSA)

INITIAL CRITERIA (CONTINUED)

F. **If you have moderate to severe Crohn's disease, approval also requires:**
   1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   2. You have tried or have a contraindication (harmful for) to ONE conventional therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   3. You meet ONE of the following:
      a. You are 6 to 17 years of age AND have tried or have a contraindication (harmful for) to the following preferred immunomodulator: Humira
      b. You are 18 years of age or older AND have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Skyrizi

G. **If you have moderate to severe ulcerative colitis, approval also requires:**
   1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   2. You have tried or have a contraindication (harmful for) to ONE conventional therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   3. You meet ONE of the following:
      c. You are 6 to 17 years of age AND have tried or have a contraindication (harmful for) to the following preferred immunomodulator: Humira
      d. You are 18 years of age or older AND have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Xeljanz (immediate release/extended release), Rinvoq

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
INFLIXIMAB-DYYB (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named INFLIXIMAB-DYYB (Inflectra) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You are currently using or have a contraindication (harmful for) to methotrexate

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

D. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score while on therapy

E. If you have severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease OR you have experienced a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

Commercial Effective: 09/01/22
INOTUZUMAB OZOGAMICIN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INOTUZUMAB OZOGAMICIN</td>
<td>BESPONSA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named INOTUZUMAB OZOGAMICIN (Besponsa) requires the following rule(s) be met for approval:

A. You have relapsed or refractory B-cell pre-cursor acute lymphoblastic leukemia (ALL- type of blood and bone marrow cancer that affects white blood cells.)
B. You are 18 years of age or older
C. You have NOT received 6 cycles of Besponsa previously

Commercial Effective: 04/10/21
Our guideline named **IOBENGUANE IODINE 131 (Azedra)** requires the following rule(s) be met for approval:

A. You have unresectable (cannot be removed completely through surgery), locally advanced or metastatic pheochromocytoma (type of tumor that releases hormones) or paraganglioma (type of tumors)

B. You are 12 years of age or older

C. You require systemic anticancer therapy (cancer treatment that travels in the blood throughout the entire body)

D. The tumors are iobenguane scan positive (type of test that detects a tumor)

E. You have **NOT** previously received 1 dosimetric dose (measurement of how much radiation dose is absorbed by the body) and 2 therapeutic doses of Azedra

Commercial Effective: 07/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IPILIMUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPILIMUMAB</td>
<td>YERVOY</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named IPILIMUMAB (Yervoy) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be removed by surgery or has spread to other parts of the body)
   2. Cutaneous melanoma (a type of skin cancer)
   3. Advanced renal cell carcinoma (a type of kidney cancer)
   4. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (types of colon cancer)
   5. Hepatocellular carcinoma (a type of liver cancer)
   6. Metastatic or recurrent non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body or has returned)
   7. Unresectable (cannot be removed by surgery) malignant pleural mesothelioma (a tumor of the tissue that has spread and lines the lungs, stomach, heart, and other organs.)
   8. Unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC: a type of digestive cancer that cannot be removed by surgery or has spread to other parts of the body)
B. If you have unresectable or metastatic melanoma, approval also requires ONE of the following:
   1. You are 12 years of age or older AND Yervoy will be used as a single agent
   2. You are 18 years of age or older AND Yervoy will be used in combination with Opdivo (nivolumab)
C. If you have cutaneous melanoma, approval also requires:
   1. Yervoy will be used for adjuvant (add-on) treatment
   2. There is pathologic (disease) involvement of regional lymph nodes of more than 1mm
   3. You have undergone complete resection (surgery to completely remove cancer), including total lymphadenectomy (lymph glands are surgically removed)
D. If you have advanced renal cell carcinoma, approval also requires:
   1. Yervoy will be used in combination with Opdivo (nivolumab)
   2. You have intermediate or poor risk disease
   3. You have not received prior treatment for advanced renal cell carcinoma

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

E. If you have microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, approval also requires:
   1. You are 12 years of age or older
   2. Yervoy will be used in combination with Opdivo (nivolumab)
   3. You have disease progression (disease gets worse) following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan

F. If you have hepatocellular carcinoma, approval also requires:
   1. Yervoy will be used in combination with Opdivo (nivolumab)
   2. You have previously been treated with Nexavar (sorafenib)

G. If you have metastatic or recurrent non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your tumor does NOT have epidermal growth factor receptor (EGFR: type of protein) or anaplastic lymphoma kinase (ALK: type of protein) genomic tumor aberrations (changes in your gene structure)
   3. Yervoy will be used as first-line treatment
   4. You meet ONE of the following:
      a. For metastatic NSCLC, Yervoy will be used in combination with Opdivo (nivolumab) AND your tumor expresses programmed death-ligand 1 (PD-L1: type of protein) at greater than or equal to 1% as determined by an FDA (Food and Drug Administration)-approved test
      b. For metastatic or recurrent NSCLC, Yervoy will be used in combination with Opdivo (nivolumab) and 2 cycles of platinum-doublet chemotherapy (type of cancer medication)

H. If you have malignant pleural mesothelioma, approval also requires:
   1. You are 18 years of age or older
   2. Yervoy will be used as first line treatment in combination with Opdivo (nivolumab)

I. If you have unresectable advanced or metastatic esophageal squamous cell carcinoma, approval also requires:
   1. You are 18 years of age or older
   2. Yervoy will be used as first-line treatment in combination with Opdivo (nivolumab)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of unresectable or metastatic melanoma, advanced renal cell carcinoma, microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR) metastatic colorectal cancer, hepatocellular carcinoma, metastatic/recurrent non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, or unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) please refer to the Initial Criteria section.

Our guideline named IPILIMUMAB (Yervoy) requires the following rule(s) be met for renewal:
A. You have cutaneous melanoma (a type of skin cancer)
B. Yervoy will be used for adjuvant (add-on) treatment
C. You do not have any disease recurrence (defined as the appearance of one or more new melanoma lesions: local, regional or distant)

Commercial Effective: 07/18/22
Our guideline named **IRINOTECAN LIPOSOMAL (Onivyde)** requires the following rule(s) be met for approval:

A. You have metastatic adenocarcinoma of the pancreas (type of pancreas cancer that has spread)

B. You have experienced disease progression (disease has worsened) despite a trial of gemcitabine-based therapy (type of cancer drug)

C. Onivyde (irinotecan liposomal) will be used in combination with fluorouracil and leucovorin

---

**Commercial Effective: 07/01/20**
ISATUXIMAB-IRFC (NSA)

GUIDELINES FOR USE

Our guideline named ISATUXIMAB-IRFC (Sarclisa) requires the following rule(s) be met for approval:

A. You have multiple myeloma (type of white blood cell cancer) OR relapsed or refractory multiple myeloma (type of white blood cell cancer that has returned or no longer responds to treatment)

B. You are 18 years of age or older

C. **If you have multiple myeloma, approval also requires:**
   1. The requested medication will be used in combination with pomalidomide and dexamethasone
   2. You have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor (such as ixazomib, carfilzomib)

D. **If you have relapsed or refractory multiple myeloma, approval also requires:**
   1. The requested medication will be used in combination with carfilzomib and dexamethasone

E. You have received 1 to 3 prior lines of therapy

Commercial Effective: 05/01/21
Our guideline named **IXABEPILONE** requires the following rule(s) be met for approval:

A. You have metastatic (cancer that has spread to other parts of body) or locally advanced breast cancer

B. You meet **ONE** of the following:
   1. You had a trial of a chemotherapy (drugs used to treat cancer) regimen containing an anthracycline (doxorubicin or epirubicin), a taxane (paclitaxel or docetaxel), and Xeloda (capecitabine) **OR**
   2. You had a trial of a chemotherapy (drugs used to treat cancer) regimen containing an anthracycline (doxorubicin or epirubicin), and a taxane (paclitaxel or docetaxel) **AND** the requested medication is being used in combination with Xeloda (capecitabine)

**Commercial Effective: 07/01/20**
LETTERMOVIR IV (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LETTERMOVIR</td>
<td>PREVYMIS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named LETTERMOVIR IV (Prevymis) requires the following rule(s) be met for approval:

A. Prevymis will be used for prophylaxis (prevention) of cytomegalovirus infection (a type of viral infection) and disease
B. You are 18 years of age or older
C. You are a CMV (cytomegalovirus)-seropositive recipient [R+] of an allogeneic hematopoietic stem cell transplant (you have cells transplanted from a matching donor)
D. Prevymis will be started between Day 0 and Day 28 post-transplantation (before or after engraftment)
E. You are not receiving the medication beyond 100 days post-transplantation

Commercial Effective: 09/12/22
LEUPROLIDE MESYLATE (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEUPROLIDE MESYLATE</td>
<td>CAMCEVI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **LEUPROLIDE MESYLATE (Camcevi)** requires the following rule(s) be met for approval:

A. You have advanced prostate cancer (a type of cancer that has spread outside of the prostate gland)
B. You are 18 years of age or older

Commercial Effective: 10/01/22
GUIDELINES FOR USE

Our guideline named **LISOCABTAGENE MARALEUCEL (Breyanzi)** requires the following rule(s) be met for approval:

A. You have large B-cell lymphoma (LBCL: a type of immune system cancer), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B (types of cancer)

B. You have ONE of the following:
   1. You have refractory disease (disease did not respond to treatment) to first-line chemoimmunotherapy (cancer treatment) or relapse (disease has returned) within 12 months of first-line chemoimmunotherapy
   2. You have refractory (disease did not respond to treatment) disease to first-line chemoimmunotherapy (cancer treatment) or relapse (disease has returned) after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT: bone marrow transplant) due to comorbidities (other disease presenting together) or age
   3. You have relapsed (disease has returned) or refractory disease (disease did not respond to treatment) after two or more lines of systemic therapy (therapy that goes into the entire body)

C. You are 18 years of age or older

D. Therapy is prescribed by a Breyanzi-certified hematologist (blood specialist) or oncologist (tumor/ cancer doctor)

E. Breyanzi will be administered at a treatment center that is certified to administer Breyanzi

F. You have not received a previous trial of Breyanzi

G. You have not had any prior anti-CD19 therapy (a type of treatment such as Kymriah, Yescarta)

Commercial Effective: 10/01/22
Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

**LONCASTUXIMAB TESIRINE-LPYL (NSA)**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LONCASTUXIMAB TESIRINE-LPYL</td>
<td>ZYNLONTA</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **LONCASTUXIMAB TESIRINE-LPYL (Zynlonta)** requires the following rule(s) be met for approval:

A. You have relapsed or refractory large B-cell lymphoma (type of white blood cell cancer that has returned or is not responding to treatment), including diffuse large B-cell lymphoma (DLBCL), DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma

B. You are 18 years of age or older

C. You previously received two or more lines of systemic therapy (treatment that travels throughout the body)

Commercial Effective: 10/01/21
LU-177 VIPIVOTIDE TETRAXETAN (NSA)

GUIDELINES FOR USE

Our guideline named LU-177 VIPIVOTIDE TETRAXETAN (Pluvicto) requires the following rule(s) be met for approval:

A. You have metastatic castration-resistant prostate cancer (mCRPC: a type of prostate cancer that has spread to other parts of the body)
B. You are 18 years of age or older
C. Your cancer is prostate-specific membrane antigen (PSMA)-positive (a type of test)
D. You have been treated with androgen receptor (AR) pathway inhibition (such as enzalutamide, abiraterone) AND taxane-based chemotherapy (such as docetaxel, cabazitaxel)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named LUMASIRAN (Oxlumo) requires the following rule(s) be met for approval:

A. You have primary hyperoxaluria type 1 (PH1: a rare disorder in which buildup of a substance called oxalate is deposited in the kidneys and urinary tract)

Commercial Effective: 04/01/21
GUIDELINES FOR USE

Our guideline named LURBINECTEDIN (Zepzelca) requires the following rule(s) be met for approval:
A. You have metastatic small cell lung cancer (SCLC: type of lung cancer that has spread to other parts of the body)
B. You are 18 years of age or older
C. You had disease progression (worsening) on or after platinum-based chemotherapy (such as carboplatin or cisplatin)

Commercial Effective: 10/01/20
GUIDELINES FOR USE

Our guideline named **LUSPATERCEPT-AAMT (Reblozyl)** requires the following rule(s) be met for approval:

A. You have anemia (low amount of healthy red blood cells)
B. You are 18 years of age or older
C. You have ONE of the following conditions:
   1. Beta thalassemia (blood disorder that reduces the production of hemoglobin) and you require regular red blood cell (RBC) transfusions
   2. Myelodysplastic syndromes (group of blood disorders caused when production of blood cells is disrupted) with ring sideroblasts (cells that contain rings of iron deposits) (MDS-RS)
   3. Myelodysplastic/myeloproliferative neoplasm (group of disorders in which the bone marrow makes too many white blood cells) with ring sideroblasts and thrombocytosis (excess of blood clotting cells (platelets)) (MDS/MPN-RS-T)
D. **If you have myelodysplastic syndromes with ring sideroblasts (MDS-RS) OR myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T),** approval also requires:
   1. You are failing an erythropoiesis (red blood cell production) stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks

Commercial Effective: 05/01/20
LUTETIUM LU 177 DOTATATE (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUTETIUM LU 177 DOTATATE</td>
<td>LUTATHERA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named LUTETIUM LU 177 DOTATATE (Lutathera) requires the following rule(s) be met for approval:

A. You have somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs: type of hormone cancer in digestive tract)
B. You are 18 years of age or older
C. You will be treated with a long-acting octreotide (type of hormone) as maintenance therapy together with the requested medication
D. You have been previously treated with a long acting somatostatin analog (such as octreotide or lanreotide) before the request of this medication
E. You have NOT previously received 4 doses of Lutathera

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named MARGETUXIMAB-CMKB (Margenza) requires the following rule(s) be met for approval:

A. You have metastatic (cancer has spread to other parts of the body) HER2 (human epidermal growth factor receptor 2: type of protein found in breast cancer)-positive breast cancer
B. You are 18 years of age or older
C. Margenza will be used in combination with chemotherapy (such as Xeloda, Halaven, gemcitabine, Navelbine)
D. You have received two or more prior anti-HER2 regimens (such as Herceptin, Perjeta), at least one of which was for metastatic disease

Commercial Effective: 07/01/21
GUIDELINES FOR USE

Our guideline named MELPHALAN FLUFENAMIDE (Pepaxto) requires the following rule(s) be met for approval:

A. You have relapsed or refractory multiple myeloma (a type of blood cancer that has returned or is not responsive to treatment)
B. You are 18 years of age or older
C. Pepaxto will be used in combination with dexamethasone
D. You have received at least four prior lines of therapy
E. Your cancer is refractory (not responding to treatment) to at least one proteasome inhibitor (such as Velcade, Kyprolis), one immunomodulatory agent (such as Revlimid, Pomalyst), AND one CD38-directed monoclonal antibody (such as Darzalex)

Commercial Effective: 10/09/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named MEPOLIZUMAB (Nucala) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Severe asthma with an eosinophilic phenotype (inflammatory type)
   2. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus passages with small growths in the nose)
   3. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome (inflammation of blood vessels with high levels of a type of white blood cell)
   4. Hypereosinophilic syndrome (HES) (a rare blood disorder)

B. If you have severe asthma with an eosinophilic phenotype, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a doctor specializing in pulmonary (lung/breathing) medicine or allergy medicine
   3. You have a documented blood eosinophil level (type of white blood cell) of at least 150 cells/mcL within the past 12 months
   4. You are being treated with medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid

5. You have ONE of the following:
   a. Experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
   b. Poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      i. Daytime asthma symptoms more than twice per week
      ii. Any night waking due to asthma
      iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      iv. Any activity limitation due to asthma

*(Initial criteria continued on next page)*
MEPOLIZUMAB

INITIAL CRITERIA (CONTINUED)

6. You will NOT use Nucala concurrently (at the same time) with Xolair, Dupixent, or another anti-IL-5 biologic (such as Cinqair, Fasenra) when these are used for the treatment of asthma

C. If you have chronic rhinosinusitis with nasal polyps, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor) or allergist/immunologist
   3. Nucala will be used as add-on maintenance treatment
   4. You had a 90-day trial of ONE intranasal corticosteroid (such as mometasone, fluticasone, beclomethasone)

D. If you have eosinophilic granulomatosis with polyangiitis, approval also requires:
   1. You are 18 years of age or older

E. If you have hypereosinophilic syndrome, approval also requires:
   1. You are 12 years of age or older
   2. You have had HES for 6 months or more without an identifiable non-hematologic (not present in the blood) secondary cause

RENEWAL CRITERIA

NOTE: For the diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome) OR hypereosinophilic syndrome (HES), please refer to the Initial Criteria section.

Our guideline named MEPOLIZUMAB (Nucala) requires the following rule(s) be met for renewal:

D. You have ONE of the following diagnoses:
   1. Severe asthma with an eosinophilic phenotype (inflammatory type)
   2. Chronic rhinosinusitis with nasal polyps (CRSwNP; inflammation of nasal and sinus ways with small growths in the nose)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE
MEPOLIZUMAB

RENEWAL CRITERIA (CONTINUED)

E. If you have severe asthma with an eosinophilic phenotype, renewal also requires:
   1. You will continue to use an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroids
   2. You will NOT use Nucala concurrently (at the same time) with Xolair, Dupixent, or another anti-IL-5 biologic (such as Cinqair, Fasenra) when these are used for the treatment of asthma
   3. You have shown a clinical response as evidenced by ONE of the following:
      a. You have experienced a reduction in asthma exacerbation (worsening of symptoms) from baseline
      b. You have decreased use of rescue medications
      c. You have an increase in percent predicted FEV1 (amount of air you can forcefully exhale in one second) from pretreatment baseline (before starting Nucala)
      d. You have a reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing, etc.)

F. If you have chronic rhinosinusitis with nasal polyposis, renewal also requires:
   1. You have had a clinical benefit compared to baseline (before starting Nucala) (such as improvements in nasal congestion, sense of smell or size of polyps)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: SEE RENEWAL CRITERIA BELOW)

Our guideline named MINOCYCLINE HCL MICROSPHERES (Arestin) requires the following rule(s) be met for approval:
A. You have documentation of confirmed periodontitis (inflammation and infection of the gums)
B. You are age 18 years or older
C. The medication is prescribed by or given in consultation with an oral health care professional
D. You do not have a history of minocycline or tetracycline sensitivity or allergy
E. You do not have a history of candidiasis (a type of fungal infection) or active oral candidiasis
F. The requested medication will be administered by an oral health professional
G. The requested medication will be used as an adjunct (add-on therapy) to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing
H. The requested medication is not being used for acutely abscessed periodontal pocket (not used for short-term and sudden infection with pus-filled pocket)
I. The medication is not being used in an immunocompromised individual (your immune system is weakened), such as those immunocompromised by any of the following conditions:
   1. Uncontrolled diabetes mellitus
   2. Chemotherapy
   3. Radiation therapy
   4. HIV (human immunodeficiency virus) infection
J. The medication is not being used in the regeneration of alveolar bone (bone that has tooth sockets), either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants

RENEWAL CRITERIA

Our guideline named MINOCYCLINE HCL MICROSPHERES (Arestin) requires the following rule(s) be met for renewal:
A. You have documentation of periodontitis (inflammation and infection of the gums)
B. The medication will be used as an adjunct (add-on therapy) to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MITOMYCIN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MITOMYCIN</td>
<td>JELMYTO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named MITOMYCIN (Jelmyto) requires the following rule(s) be met for approval:

A. You have low grade Upper Tract Urothelial Cancer (LG-UTUC: type of cancer that grows in the upper part of the urinary system)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an oncologist (doctor who specializes in cancer) or urologist (doctor who specializes in the urinary tract and male reproductive organs)

RENEWAL CRITERIA

Our guideline named MITOMYCIN (Jelmyto) requires the following rule(s) be met for renewal:

A. You have low grade Upper Tract Urothelial Cancer (LG-UTUC: type of cancer that grows in the upper part of the urinary system)
B. You were reassessed at no sooner than 3 months after initiation of Jelmyto
C. You showed complete response at the time of assessment

Commercial Effective: 10/01/20
GUIDELINES FOR USE

Our guideline named **MITOXANTRONE** requires ONE of following rules be met for approval:

A. The medication is prescribed by or given in consultation with an oncologist (tumor/cancer doctor)

B. You have ONE of the following:
   1. Pain related to advanced refractory prostate cancer
   2. Acute nonlymphocytic leukemia (type of white blood cell cancer)
   3. Secondary progressive, progressive relapsing or worsening relapsing-remitting multiple sclerosis (disease where immune system attacks nerves)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named **MOGAMULIZUMAB-KPKC (Poteligeo)** requires the following rule(s) be met for approval:

A. You have Mycosis Fungoides or Sezary syndrome (types of blood cancers that affect the skin)
B. You are 18 years of age or older
C. You have relapsed or refractory disease (disease has returned or not responsive to therapy)
D. You have tried and failed at least one prior systemic therapy (treatment that travels in the blood throughout the body)

Commercial Effective: 04/10/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named MOMETASONE IMPLANT (Sinuva) requires the following rule(s) be met for approval:
A. You have nasal polyps (small growths inside the nose)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an otolaryngologist (ear, nose and throat doctor)
D. You previously had ethmoid sinus surgery (process to remove blockage in your sinuses)
E. You are a candidate for repeat ethmoid sinus surgery due to refractory moderate to severe symptoms (symptoms return and do not respond to surgery) of nasal obstruction, nasal congestion or nasal polyps in both ethmoid sinuses
F. You previously had a 90-day trial of ONE intranasal corticosteroid (such as fluticasone, beclomethasone, flunisolide, ciclesonide, mometasone)
G. You have not received 4 implants (2 per nostril) in your lifetime

RENEWAL CRITERIA

Our guideline named MOMETASONE IMPLANT (Sinuva) requires the following rule(s) be met for approval:
A. You have nasal polyps (small growths inside the nose)
B. You have ethmoid sinus polyps grade 1 or greater on any side
C. You do not have extensive ethmoid sinus polyp grade (grade 4 on at least one side) or extensive adhesions/synechiae (scar tissue) (grade 3 or 4)
D. You have not previously received 4 implants (2 per nostril) in your lifetime

Commercial Effective: 10/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

Moxetumomab Pasudotox (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxetumomab PASUDOTOX-TDFK</td>
<td>LUMOXITI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named Moxetumomab Pasudotox (Lumoxiti) requires the following rule(s) be met for approval:
A. You have hairy cell leukemia (HCL: type of blood and bone marrow cancer)
B. You are 18 years of age or older
C. You have relapsed or refractory disease (disease has returned or is not responsive to therapy)
D. You have received at least two prior systemic therapies, including treatment with a purine nucleoside analog (type of drug that treats certain blood cancers)
E. You have NOT previously received 6 cycles of Lumoxiti

Commercial Effective: 04/10/21
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NATALIZUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>NATALIZUMAB</td>
<td>TYSABRI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named NATALIZUMAB (Tysabri) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe Crohn’s disease (CD: a type of bowel disorder)
   2. A relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return) and active secondary progressive disease (advanced disease)

B. If you have moderate to severe Crohn’s disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You have tried or have a contraindication (harmful for) to ONE conventional agent, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Skyrizi (NOTE: Pharmaceutical samples from the prescriber or manufacturer assistance programs do not qualify.)

C. If you have a relapsing form of multiple sclerosis, approval also requires:
   1. You are 18 years of age or older
   2. The medication is being used as monotherapy (used by itself)
   3. You have tried TWO medications indicated for the treatment of multiple sclerosis (MS) (NOTE: The following medications are preferred and may also require prior authorization: Avonex, Copaxone/Glatiramer/Glatopa, Gilenya, Plegidry, Rebif, Betaseron, dimethyl fumarate, Mavenclad, Mayzent, Vumerity, Aubagio, Kesimpta)

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

Our guideline named NATALIZUMAB (Tysabri) requires the following rules be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   2. A relapsing form of multiple sclerosis (MS: a nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms goes away and returns), and active secondary progressive disease (advanced disease)

B. If you have moderate to severe Crohn’s disease, renewal also requires ONE of the following:
   1. If you have received at least 12 months of Tysabri therapy, renewal also requires that you have NOT received more than 3 months of corticosteroid within the past 12 months to control your Crohn's disease while on Tysabri
   2. If you have only received 6 months of Tysabri therapy, renewal also requires that you are NOT currently on corticosteroid therapy (you have slowly lowered the dose and stopped taking corticosteroids during the first 6 months of Tysabri therapy)

Commercial Effective: 09/01/22
**GUIDELINES FOR USE**

Our guideline named **NAXITAMAB-GQGK (Danyelza)** requires the following rule(s) be met for approval:

A. You have relapsed or refractory high-risk neuroblastoma (cancer that starts in early nerve cells that has returned or no longer responds to treatment) in the bone or bone marrow

B. You are 1 year of age or older

C. The requested medication will be used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF)

D. You have demonstrated a partial response, minor response, or stable disease to prior therapy

---

**Commercial Effective:** 04/10/21
GUIDELINES FOR USE

Our guideline named NECITUMUMAB (Portrazza) requires the following rule(s) be met for approval:
A. The medication will be used as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC; type of lung cancer that has spread to other parts of the body) in combination with gemcitabine and cisplatin

Commercial Effective: 04/10/21
GUIDELINES FOR USE

Our guideline named **NIVOLUMAB (Opdivo)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Unresectable or metastatic melanoma (type of skin cancer that has spread or cannot be completely removed with surgery)
2. Melanoma with lymph node involvement or metastatic disease (type of skin cancer that has spread to other parts of the body)
3. Resectable (tumors greater than or equal to 4 cm or node positive) non-small cell lung cancer (NSCLC: type of lung cancer that can be removed by surgery)
4. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
5. Recurrent non-small cell lung cancer (NSCLC: type of lung cancer that has returned)
6. Unresectable malignant pleural mesothelioma (tumor of the tissue that has spread and lines the lungs, stomach, heart, and other organs and cannot be removed by surgery)
7. Advanced renal cell carcinoma (RCC: type of kidney cancer)
8. Classical Hodgkin lymphoma (cHL: a type of immune system cancer)
9. Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN: type of head/neck cancer that has returned or spread to other parts of the body)
10. Urothelial carcinoma (UC: urinary system cancer)
11. Locally advanced or metastatic urothelial carcinoma (urinary system cancer that has spread to nearby tissue or lymph nodes or that has spread to other parts of the body)
12. Microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer (a type of digestive system cancer that has spread to other parts of the body)
13. Hepatocellular carcinoma (HCC: liver cancer)
14. Completely resected esophageal or gastroesophageal junction cancer (type of digestive system cancer that has been removed by surgery)
15. Unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC: type of digestive system cancer that cannot be removed by surgery, and has returned or has spread to other parts of the body)
16. Unresectable, advanced, or metastatic esophageal squamous cell carcinoma (ESCC: type of digestive system cancer that cannot be removed by surgery, and has spread to other parts of the body)
17. Advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (types of digestive system cancer that has spread to other parts of the body)

*(Criteria continued on next page)*
NIVOLUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

B. If you have unresectable or metastatic melanoma, approval also requires:
   1. You are 18 years of age or older
   2. Opdivo will be used alone OR in combination with Yervoy
   3. Opdivo will NOT be used at the same time with targeted therapy (BRAF inhibitors [such as Braftovi, Tafinlar], MEK inhibitors [such as Mekinist], and NTRK inhibitors [such as Vitrakvi, Rozlytrek])

C. If you have melanoma with lymph node involvement or metastatic disease, approval also requires:
   1. You are 18 years of age or older
   2. You have undergone complete resection (completely removed by surgery)
   3. Opdivo will be used as an adjuvant (add-on) treatment

D. If you have resectable (tumors greater than or equal to 4 cm or node positive) non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. Opdivo will be used in combination with platinum-doublet chemotherapy (such as carboplatin/paclitaxel, cisplatin/pemetrexed, cisplatin/gemcitabine) as neoadjuvant treatment (given before main treatment)

E. If you have metastatic non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. Your tumors express programmed death-ligand 1 (PD-L1: a type of protein greater than or equal to 1 percent) as determined by a Food and Drug Administration (FDA)-approved test, your tumor does NOT have epidermal growth factor receptor (EGFR: type of protein) or anaplastic lymphoma kinase (ALK: type of protein) genomic tumor aberrations (changes in your gene structure), and Opdivo will be used in combination with Yervoy as first-line treatment
      b. Your disease has worsened while on or after platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin), and you meet ONE of the following: i) your tumor does NOT have epidermal growth factor receptor (EGFR: type of protein) or anaplastic lymphoma kinase (ALK: type of protein) genomic tumor aberrations (changes in your gene structure), ii) your tumor has an ALK mutation, and your disease has worsened after an FDA-approved ALK-directed therapy (such as crizotinib, ceritinib), iii) your tumor has an EGFR mutation, and your disease has worsened after an FDA-approved EGFR-directed therapy (such as erlotinib, gefitinib, afatinib)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
NIVOLUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

c. Your disease has worsened while on or after platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin), and you meet ONE of the following:
   i. Your tumor does NOT have epidermal growth factor receptor (EGFR: type of protein) or anaplastic lymphoma kinase (ALK: type of protein) genomic tumor aberrations (changes in your gene structure)
   ii. Your tumor has an ALK mutation, and your disease has worsened after treatment with an FDA-approved ALK-directed therapy (such as crizotinib, ceritinib)
   iii. Your tumor has an EGFR mutation, and your disease has worsened after treatment with an FDA-approved EGFR-directed therapy (such as erlotinib, gefitinib, afatinib)

F. If you have recurrent non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your tumor does NOT have epidermal growth factor receptor (EGFR: type of protein) or anaplastic lymphoma kinase (ALK: type of protein) genomic tumor aberrations (changes in your gene structure)
   3. Opdivo will be used in combination with Yervoy AND 2 cycles of platinum-doublet chemotherapy (such as carboplatin/pemetrexed, cisplatin/pemetrexed, carboplatin/paclitaxel) as first-line treatment

G. If you have unresectable malignant pleural mesothelioma, approval also requires:
   1. You are 18 years of age or older
   2. Opdivo will be used in combination with Yervoy as first line treatment

H. If you have advanced renal cell carcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. You have intermediate or poor risk disease and Opdivo will used in combination with Yervoy as first-line treatment
      b. Opdivo will be used in combination with Cabometyx as first-line treatment
      c. You have received one prior anti-angiogenic therapy (drugs that stop tumors from growing their own blood vessels such as Sutent, Votrient, Cabometyx) and Opdivo will be used by itself

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

I. If you have classical Hodgkin lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. Your disease has relapsed or worsened after receiving ONE of the following:
      a. Autologous hematopoietic stem cell transplantation (cells from your own body are used) and Adcetris (brentuximab vedotin)
      b. Three or more lines of systemic therapy (treatment that targets the entire body) that includes autologous hematopoietic stem cell transplantation

J. If you have recurrent or metastatic squamous cell carcinoma of the head and neck, approval also requires:
   1. You are 18 years of age or older
   2. Your disease has worsened on or after treatment with a platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)

K. If you have urothelial carcinoma, approval also requires:
   1. You are 18 years of age or older
   2. Opdivo will be used as an adjuvant (add-on) treatment
   3. You are at high risk of recurrence after undergoing radical resection (tumor removal) of urothelial carcinoma

L. If you have locally advanced or metastatic urothelial carcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. Your disease has worsened during or after treatment with a platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
      b. Your disease has worsened within 12 months of neoadjuvant (given before main treatment) or adjuvant (add-on) treatment with platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)

M. If you have microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, approval also requires:
   1. You are 12 years of age or older
   2. You will be using Opdivo by itself OR in combination with Yervoy
   3. Your disease has worsened after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan

N. If you have hepatocellular carcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You will be using Opdivo in combination with Yervoy
   3. You have been previously treated with Nexavar

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

O. If you have completely resected esophageal or gastroesophageal junction cancer, approval also requires:
   1. You are 18 years of age or older
   2. Opdivo will be used as an adjuvant (add-on) treatment
   3. You have a residual pathologic disease (disease is still present) and have received neoadjuvant chemoradiotherapy (CRT: cancer medications given before surgery)

P. If you have unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You have previously received treatment with fluoropyrimidine- and platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin)

Q. If you have unresectable, advanced, or metastatic esophageal squamous cell carcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following criteria:
      a. You will be using Opdivo as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
      b. You will be using Opdivo as first-line treatment in combination with ipilimumab

R. If you have advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You will be using Opdivo in combination with fluoropyrimidine and platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)

Commercial Effective: 07/18/22
GUIDELINES FOR USE

Our guideline named NIVOLUMAB-RELATLIMAB-RMBW (Opdualag) requires the following rule(s) be met for approval:

A. You have unresectable or metastatic melanoma (a type of skin cancer that cannot be removed by surgery or has spread to other parts of the body)

B. You are 12 years of age or older

Commercial Effective: 07/01/22
NUSINERSEN (NSA)

Guidelines for Use

Initial Criteria (Note: For Renewal Criteria See Below)

Our guideline named NUSINERSEN (Spinraza) requires the following rule(s) be met for approval:

A. You have Spinal muscular atrophy (SMA: genetic disorder where your muscles become weak and break down)
B. Your diagnosis of spinal muscular atrophy (SMA) is confirmed by documentation of a gene mutation analysis indicating mutations or deletions of both alleles of the survival motor neuron 1 (SMN1: type of protein in spinal cord) gene (such as homozygous deletions of SMN1, homozygous mutations of SMN1, compound heterozygous mutations in SMN1 [deletion of SMN1 on one allele and point mutation of SMN1 on the other allele])
C. The requested medication is prescribed by or given in consultation with a neuromuscular (nerve and muscle) specialist or spinal muscular atrophy (SMA) specialist at a SMA Specialty Center
D. If you are presymptomatic (symptoms have not yet appeared), approval also requires:
   1. There is documentation showing you have up to three copies of survival motor neuron 2 (SMN2: type of protein in spinal cord) based on screening done when you were a newborn
E. If you are symptomatic (symptoms have appeared), approval also requires:
   1. The onset of spinal muscular atrophy (SMA) symptoms occurred before 20 years of age
   2. There is documentation showing you had a baseline motor function assessment by a neuromuscular (nerve and muscle) specialist or SMA specialist
   3. If you previously had gene therapy, you had less than expected clinical benefit with gene therapy

Renewal Criteria

Our guideline named NUSINERSEN (Spinraza) requires the following rule(s) be met for renewal:

A. You have spinal muscular atrophy (SMA: genetic disorder where your muscles become weak and break down)
B. You meet ONE of the following:
   1. You have improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline. Some types of motor assessment tests include Hammersmith Infant Neurological Examination (HINE), Hammersmith Functional Motor Scale - Expanded (HFMSE) and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
   2. You have improved, maintained, or demonstrated less than expected decline in other muscle function such as pulmonary (lung/breathing) function

Commercial Effective: 09/07/20

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
OBINUTUZUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OBINUTUZUMAB</td>
<td>GAZYVA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **OBINUTUZUMAB (Gazyva)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Chronic lymphocytic leukemia (CLL: type of blood and bone marrow cancer)
   2. Follicular lymphoma (FL: type of cancer with abnormal immune cells)
   3. Stage II bulky, III or IV follicular lymphoma

B. **If you have chronic lymphocytic leukemia, approval also requires:**
   1. You have not received previous treatment for chronic lymphocytic leukemia
   2. The requested medication will be used in combination with chlorambucil

C. **If you have follicular lymphoma, approval also requires:**
   1. You have relapsed after or are refractory to (your disease has returned or is resistant to) a regimen containing RituXan (rituximab)
   2. The requested medication will be used in combination with bendamustine for the initial six cycles OR as monotherapy (the only drug used in treatment) thereafter

D. **If you have stage II bulky, III or IV follicular lymphoma, approval also requires:**
   1. You are 18 years of age or older
   2. You have not received previous treatment for stage II bulky, III or IV follicular lymphoma
   3. The requested medication will be used in combination with chemotherapy for the initial six or eight cycles [bendamustine; CHOP (cyclophosphamide, daunorubicin, vincristine, prednisone or prednisolone); CVP (cyclophosphamide, vincristine, prednisone or prednisolone)] OR as monotherapy (the only drug used in treatment) thereafter

Commercial Effective: 04/10/21
Our guideline named OCRELIZUMAB (Ocrevus) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Primary progressive multiple sclerosis (type of disease where body attacks its own nerves and it slowly gets worse)
   2. Relapsing form of multiple sclerosis (type of disease where body attacks its own nerves and symptoms return after treatment) which includes clinically isolated syndrome (occurs once), relapsing-remitting disease (periods of symptoms and no symptoms), and active secondary progressive disease (advanced disease)

B. If you have primary progressive multiple sclerosis (PPMS), approval also requires:
   1. You are 18 years of age or older

C. If you have a relapsing form of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. You have previously tried any TWO agents indicated for the treatment of multiple sclerosis (MS) (Please note: The following agents are preferred and may also require prior authorization: Avonex, Copaxone/Glatiramer/Glatopa, Gilenya, Plegridy, Rebif, Betaseron, dimethyl fumarate, Mavenclad, Mayzent, Vumerity, Aubagio, Kesimpta)
      b. You show signs of severe disease requiring high-efficacy disease modifying therapy (DMT) such as high lesion (affected areas) volume and/or count, walking disability, or rapid decline

Commercial Effective: 01/01/21
GUIDELINES FOR USE

Our guideline named OFATUMUMAB (Arzerra) requires the following rule(s) be met for approval:

A. You have chronic lymphocytic leukemia (CLL: type of blood and bone marrow cancer)

B. If you have previously untreated chronic lymphocytic leukemia, approval also requires:
   1. You have not received previous treatment for chronic lymphocytic leukemia
   2. Fludara (fludarabine)-based therapy is considered inappropriate for you
   3. The requested medication will be used in combination with chlorambucil

C. If you have relapsed chronic lymphocytic leukemia (type of blood and bone marrow cancer that has returned), approval also requires:
   1. The requested medication will be used in combination with Fludara (fludarabine) and cyclophosphamide

D. If you are requesting extended treatment of chronic lymphocytic leukemia, approval also requires:
   1. You are in complete or partial response
   2. You have received at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia

E. If you have refractory chronic lymphocytic leukemia, approval also requires:
   1. You are refractory (non-responsive) to Fludara (fludarabine) and Campath (alemtuzumab)

Commercial Effective: 04/10/21
GUIDELINES FOR USE

Our guideline named OLARATUMAB (Lartruvo) requires the following rule(s) be met for approval:
A. You have soft tissue sarcoma (STS: type of cancer that starts in soft tissues like muscles/tendons)
B. The request is for continuation of Lartruvo therapy (you are currently on Lartruvo)
C. The requested medication will be used in combination with doxorubicin for the first 8 cycles
D. The histologic subtype of sarcoma (the type of tissue cancer such as undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumors) may be appropriately treated with an anthracycline-containing regimen (a treatment plan that contains a specific type of cancer drug)
E. You are not responsive to curative treatment with radiotherapy or surgery

Commercial Effective: 04/10/21
OMALIZUMAB

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OMALIZUMAB** (Xolair) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe persistent asthma
   2. Nasal polyps (small growths in the nose)
   3. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe persistent asthma, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary (relating to lungs/breathing) medicine
   3. You have a positive skin prick or blood test such as ELISA or FEIA (type of blood test to identify what you're allergic to) to a perennial aeroallergen (airborne particles that cause allergies year-round)
   4. You have a documented baseline IgE (type of antibody that is produced by your immune system if you have an allergy) serum level greater than or equal to 30 IU/mL
   5. You are being treated with medium, high-dose, or maximally tolerated inhaled corticosteroid AND at least one other maintenance medication such as long-acting inhaled beta2-agonist (such as salmeterol or formoterol), long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid
   6. You have ONE of the following:
      a. Experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
      b. Poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
         i. Daytime asthma symptoms more than twice per week
         ii. Any night waking due to asthma
         iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
         iv. Any activity limitation due to asthma
   7. You will NOT use Xolair concurrently (at the same time) with Dupixent or an anti-IL5 biologic (such as Nucala, Cinqair, Fasenra) when these are used for treatment of asthma

(Initial criteria continued on next page)
OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

C. If you have nasal polyps, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor) or an allergist/immunologist
   3. Xolair will be used as add-on maintenance treatment
   4. You had a previous 90-day trial of ONE intranasal corticosteroid

D. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), approval also requires:
   1. You are 12 years of age or older
   2. Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary (relating to lungs/breathing) medicine
   3. You still experience hives on most days of the week for at least 6 weeks
   4. You have tried a high dose H1 antihistamine (type of allergy medication such as four-fold dosing of Clarinex or Xyzal) AND leukotriene antagonist (type of allergy medication such as montelukast) for at least 2 weeks

RENEWAL CRITERIA

Our guideline named OMALIZUMAB (Xolair) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe persistent asthma
   2. Nasal polyps (small growths in the nose)
   3. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe persistent asthma, renewal also requires:
   1. You will continue to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid
   2. You will NOT use Xolair concurrently (at the same time) with Dupixent or an anti-IL5 biologic (such as Nucala, Cinqair, Fasenra) when these are used for treatment of asthma

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE
OMALIZUMAB

RENEWAL CRITERIA (CONTINUED)

3. You have shown a clinical response as evidenced by ONE of the following:
   a. Reduction in asthma exacerbation (worsening of symptoms) from baseline
   b. Decreased use of rescue medications
   c. Increase in percent predicted FEV1 (amount of air you can forcefully exhale) from baseline before treatment
   d. Reduction in severity or frequency of asthma-related symptoms which may include wheezing, shortness of breath, or coughing

C. If you have nasal polyps, renewal also requires:
   1. You have had a clinical benefit compared to baseline (before starting Xolair) (such as improvements in nasal congestion, sense of smell, size of polyps)

D. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), renewal also requires:
   1. Therapy is prescribed by or in consultation with an allergist or immunologist (immune system doctor)

Commercial Effective: 07/01/22
ONASEMNOGENE ABEPARVOVEC-XIOI (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ONASEMNOGENE ABEPARVOVEC-XIOI</td>
<td>ZOLGENSMA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **ONASEMNOGENE ABEPARVOVEC-XIOI (Zolgensma)** requires the following rule(s) be met for approval:

A. You have spinal muscular atrophy (SMA: genetic disorder where your muscles become weak and break down)
B. You are less than 2 years of age
C. The requested medication is prescribed by or given in consultation with a neuromuscular (nerve and muscle) specialist or spinal muscular atrophy (SMA) specialist at a SMA Specialty Center
D. You have documentation of gene mutation analysis with bi-allelic survival motor neuron 1 (SMN1: type of protein in spinal cord) mutations such as deletions and/or point mutations
E. You do NOT have anti-adeno-associated virus vector (anti-AAV9) antibody titers (amount of a type of immune system cells in blood) greater than 1:50 as determined by an enzyme linked immunosorbent assay (ELISA: type of lab test)
F. You do NOT have advanced spinal muscular atrophy (SMA) such as complete paralysis of the limbs or permanent ventilator dependence

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named PACLITAXEL (Abraxane) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic breast cancer (breast cancer that has spread to other parts of the body)
   2. Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC: cancer that is in the advanced stage or that has spread to other parts of the body)
   3. Small Cell Lung Cancer (SCLC)
   4. Metastatic adenocarcinoma of the pancreas (pancreas cancer that has spread to other parts of the body)

B. If you have metastatic breast cancer, approval also requires:
   1. You have tried a chemotherapy regimen (cancer-treating medications) containing an anthracycline (cancer drug such as doxorubicin or epirubicin) or paclitaxel

C. If you have metastatic adenocarcinoma of the pancreas, approval also requires:
   1. The requested medication will be used in combination with gemcitabine

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PALIVIZUMAB (Synagis) requires the following rule(s) be met for approval:

A. You are less than 12 months old or less than 24 months at the start of respiratory syncytial virus (RSV: type of lung and respiratory tract infection) season (mid-September to mid-May)

B. **If you are less than 12 months old, you must meet ONE of the following:**
   1. You have chronic lung disease of prematurity (a condition where you were born at less than 32 weeks and required more than 21% of additional oxygen for at least the first 28 days after birth)
   2. You are profoundly immunocompromised during RSV season (your body cannot fight off infections)
   3. You have received a solid-organ transplant during RSV season
   4. You have congenital (starting from birth) heart disease conditions at birth such as: acyanotic heart disease (blood from the left side to the right side of the heart due to a hole in the heart walls) where you need medication to control chronic heart failure and will require heart surgical procedures; moderate to severe pulmonary hypertension (high blood pressure in the lungs); or cyanotic heart defect (low blood oxygen level) and the requested medication is prescribed by or given in consultation with a pediatric cardiologist (a heart doctor for children)
   5. You have congenital (starting from birth) abnormalities of the lung airways or a neuromuscular (nerve-muscle) disorder that affects respiratory (lung/breathing) secretions
   6. You were born premature at less than 29 weeks (gestational age)
   7. You are an American Navajo, American White Mountain Apache, or Alaska Native infant born prematurely

C. **If you are less than 24 months old, you must meet ONE of the following:**
   1. You are profoundly immunocompromised during RSV season (a condition where your body cannot fight off infections)
   2. You have chronic lung disease of prematurity and need medical support within 6 months before the start of the second respiratory syncytial virus (RSV: type of lung and respiratory tract infection) season. Medical support includes oxygen, bronchodilator (drug that helps you breathe), diuretic (drug that makes you urinate), or chronic steroid therapy
   3. You have received a solid-organ transplant during RSV season

CONTINUED ON NEXT PAGE
PALIVIZUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named PALIVIZUMAB (Synagis) requires the following rule(s) be met for renewal:
A. You are under 24 months old
B. You meet ONE of the following:
   1. You received cardiopulmonary bypass surgery (type of heart and lung surgery) during respiratory syncytial virus (RSV: type of lung and respiratory tract infection) prevention season
   2. This request is for a second year of coverage and you have chronic lung disease of prematurity and need medical support during the 6 months before the start of the second RSV season. Medical support includes oxygen, bronchodilator (drug that helps you breathe), diuretic (drug that makes you urinate), or chronic steroid therapy

Commercial Effective: 10/01/21
PANITUMUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PANITUMUMAB</td>
<td>VECTIBIX</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named PANITUMUMAB (Vectibix) requires the following rule(s) be met for approval:

A. You have metastatic colorectal cancer (mCRC: a type of digestive cancer that has spread to other parts of the body)

B. Your cancer is wild-type RAS (defined as wild-type in both the KRAS gene and NRAS gene) (types of gene), as determined by a Food and Drug Administration (FDA)-approved test for this use

C. You meet ONE of the following:
   1. Vectibix will be used as first-line therapy (initial treatment) AND in combination with FOLFOX (treatment regimen containing leucovorin calcium [folinic acid], fluorouracil, oxaliplatin)
   2. Vectibix will be used as monotherapy (one drug) AND you have disease progression (worsening of disease) after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy (drugs used to treat cancer)

Commercial Effective: 04/11/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PASIREOTIDE PAMOATE (Signifor LAR) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Cushing's disease (a type of hormone disorder)
   2. Acromegaly (a type of hormone disorder)

B. If you have Cushing's disease, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
   2. You have undergone non-curative pituitary surgery (surgery to remove a tumor in the hormone gland) or pituitary surgery is not an option for you
   3. You have tried or have a contraindication (harmful for) to oral ketoconazole

C. If you have acromegaly, approval also requires:
   1. You have had an inadequate response to surgery and/or surgery is not an option for you
   2. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
   3. You have tried or have a contraindication (harmful for) to TWO somatostatin analogs such as octreotide or lanreotide

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named PASIREOTIDE PAMOATE (Signifor LAR) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Cushing's disease (a type of hormone disorder)
   2. Acromegaly (a type of hormone disorder)

B. If you have Cushing's disease, renewal also requires:
   1. You continue to have improvement of Cushing's disease (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
   2. You continue to tolerate Signifor LAR

C. If you have acromegaly, renewal also requires:
   1. You have a reduction, normalization or maintenance of IGF-1 (insulin-like growth factor: a growth hormone) levels based on age and gender
   2. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

Commercial Effective: 10/01/22
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PATISIRAN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PATISIRAN SODIUM, LIPID COMPLEX</td>
<td>ONPATTRO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PATISIRAN (Onpattro) requires the following rule(s) be met for approval:

A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve damage/pain)

B. You are 18 years of age or older

C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor), cardiologist (a type of heart doctor), hATTR specialist, or medical geneticist (doctor who treats gene disorders)

D. You have a documented diagnosis of hereditary TTR amyloidosis (hATTR) as confirmed by ONE of the following:
   1. Biopsy (surgical removal of a sample) of tissue/organ to confirm amyloid (abnormal protein that can build up in any tissue or organ) presence AND chemical typing to confirm the presence of TTR (transthyretin) protein
   2. DNA genetic sequencing (lab test for genes) to confirm hATTR mutation

E. You have familial amyloidotic polyneuropathy (FAP) stage 1 or 2 OR up to polyneuropathy disability (PND) stage Illb polyneuropathy

F. You had a trial of or contraindication (harmful for) to the preferred medication: Amvuttra

RENEWAL CRITERIA

Our guideline named PATISIRAN (Onpattro) requires the following rule(s) be met for renewal:

A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve damage/pain)

B. You have not progressed to familial amyloidotic polyneuropathy (FAP) stage 3 OR polyneuropathy disability (PND) stage IV polyneuropathy as evidenced by functional decline such as being wheelchair-bound or bedridden

Commercial Effective: 10/01/22
GUIDELINES FOR USE

Our guideline named PEGAPTANIB (Macugen) requires the following rule(s) be met for approval:
1. You have neovascular (wet) age-related macular degeneration (a chronic eye disorder that causes blurred vision or a blind spot in your visual field)
2. The medication is prescribed by or given in consultation with an ophthalmologist (eye doctor) and/or retina specialist

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PEGLOTICASE (Krystexxa)** requires the following rules be met for approval:

A. You have chronic gout that is refractory to conventional therapy (resistant to standard treatments)
B. You are 18 years of age or older
C. You have symptomatic gout as shown by ONE of the following:
   1. At least 3 or more gout flares in the previous 18 months
   2. History of at least 1 gout tophus (uric acid crystallizes in joints like hands/feet)
   3. Gouty arthritis (severe pain and inflammation in joints due to gout)
D. You had a baseline serum uric acid levels of at least 8 mg/dL while on conventional gout medications such as allopurinol, lesinurad
E. You do not have glucose-6-phosphate dehydrogenase (G6PD) deficiency (you are missing an enzyme that helps red blood cells work properly)
F. You will not be on urate-lowering therapy (such as xanthine oxidase inhibitors, febuxostat, probenecid, lesinurad) at the same time as using pegloticase
G. You have experienced failure, contraindication (harmful for), intolerance (side effects) or inadequate response (drug did not work) to previous therapy with a maximum tolerated dose for TWO conventional (standard) gout medications for at least 3 months (such as allopurinol, probenecid, lesinurad)
H. Krystexxa will be co-administered (given with) with weekly oral methotrexate 15mg and folic acid, unless contraindicated (harmful for)

RENEWAL CRITERIA

Our guideline named **PEGLOTICASE (Krystexxa)** requires a sustained serum uric level below 6 mg/dL for renewal.

---

**Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.**

Revised: 9/16/2022
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEMBROLIZUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEMBROLIZUMAB</td>
<td>KEYTRUDA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named PEMBROLIZUMAB (Keytruda) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Unresectable or metastatic melanoma (type of skin cancer that has spread to other parts of the body or cannot be completely removed with surgery)
2. Stage IIB, IIC, or III melanoma following complete resection (type of skin cancer after surgical removal)
3. Non-small cell lung cancer
4. Head and neck squamous cell carcinoma (type of neck cancer)
5. Classical Hodgkin lymphoma (type of immune system cancer)
6. Primary mediastinal large B-cell lymphoma (type of immune system cancer)
7. Locally advanced or metastatic (disease has spread to other parts of the body) urothelial carcinoma (type of urinary system cancer)
8. Unresectable or metastatic tumor that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) (type of cancer with genetic abnormalities that cannot be removed by surgery or has spread to other parts of the body) as determined by an FDA-approved test
9. Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC: type of colon or rectal cancer with genetic abnormalities that cannot be removed by surgery or has spread to other parts of the body) as determined by an FDA-approved test
10. Locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2: type of protein that promotes cancer cells) -positive gastric or gastroesophageal junction (GEJ: type of cancer in the stomach/lower part of throat that cannot be surgically removed or has spread to other parts of the body) adenocarcinoma
11. Locally advanced or metastatic esophageal or gastroesophageal junction (GEJ: type of throat/esophagus/stomach cancer)
12. Persistent, recurrent or metastatic cervical cancer
13. Hepatocellular carcinoma (liver cancer)
14. Recurrent locally advanced or metastatic Merkel cell carcinoma (MCC: type of skin cancer)
15. Renal cell carcinoma (kidney cancer)
16. Advanced endometrial carcinoma (type of cancer that starts in the uterus)
17. Bladder cancer

(Criteria continued on next page)
PEMBROLIZUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

18. Unresectable or metastatic solid tumors (type of cancer that cannot be removed with surgery or has spread to other parts of the body)
19. Recurrent or metastatic OR locally advanced cutaneous squamous cell carcinoma (cSCC: a type of skin cancer that has returned or has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes)
20. High-risk early-stage triple-negative breast cancer (TNBC) (type of breast cancer that does not have three receptors)
21. Locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) (type of breast cancer that does not have three receptors and cannot be removed with surgery or has spread to other parts of the body)

B. If you have unresectable or metastatic melanoma, approval also requires:
   1. Keytruda will NOT be used at the same time with a targeted therapy (BRAF inhibitors [such as Braftovi, Tafinlar], MEK inhibitors [such as Mekinist], and NTRK inhibitors [such as Vitrakvi, Rozlytrek])

C. If you have Stage IIB, IIC, or III melanoma after complete surgical removal, approval also requires:
   1. You are 12 years of age or older
   2. The requested drug will be used as add-on (adjuvant) treatment

D. If you have metastatic nonsquamous non-small cell lung cancer, approval also requires:
   1. You have not received prior systemic chemotherapy treatment (therapy that is given into the bloodstream) for metastatic NSCLC (it is being used as first-line treatment)
   2. The medication is used in combination with pemetrexed and platinum chemotherapy
   3. You do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations (types of gene mutations)

E. If you have metastatic squamous non-small cell lung cancer, approval also requires:
   1. You have not received prior systemic chemotherapy treatment (therapy that is given into the bloodstream) for metastatic NSCLC (it is being used as first-line treatment)
   2. The medication is used in combination with carboplatin and either paclitaxel or paclitaxel protein-bound

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
F. If you have non-small cell lung cancer, approval also requires:
   1. You have not received prior systemic chemotherapy treatment (therapy that is given into
      the bloodstream) for NSCLC (it is being used as first-line treatment)
   2. The medication will be given as a single agent (not given in combination with
      chemotherapy)
   3. Non-small cell lung cancer tumors have programmed death-ligand 1 Tumor Proportion
      Score greater than or equal to 1% (you have a certain amount of a type of protein that is
      present in lung cancer) as determined by a Food and Drug Administration (FDA)-
      approved test
   4. You do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma
      kinase (ALK) genomic tumor aberrations (types of gene mutations)
   5. You meet ONE of the following:
      a. You have stage III non-small cell lung cancer AND are not a candidate for surgical
         resection (removal) or definitive chemoradiation
      b. You have metastatic non-small cell lung cancer (cancer that has spread to other
         parts of the body)

G. If you have metastatic non-small cell lung cancer, approval also requires:
   1. The medication will be given as a single agent (it is not given in combination with
      chemotherapy)
   2. Non-small cell lung cancer tumors have programmed death-ligand 1 Tumor Proportion
      Score greater than or equal to 1% (you have a certain amount of a type of protein that is
      present in lung cancer) as determined by a Food and Drug Administration (FDA)-
      approved test
   3. You experienced disease progression (disease has gotten worse) on or after treatment
      with platinum-containing chemotherapy such as cisplatin, carboplatin, oxaliplatin
   4. You meet ONE of the following:
      a. You do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma
         kinase (ALK) genomic tumor aberrations (gene mutations)
      b. You have an anaplastic lymphoma kinase (ALK) genomic tumor aberration (gene
         mutation) AND experienced disease progression (has gotten worse) on or after ALK-
         directed therapy such as Xalkori (crizotinib) or Zykadia (ceritinib)
      c. You have an epidermal growth factor receptor (EGFR) genomic tumor aberration
         (gene mutation) AND experienced disease progression (has gotten worse) on or
         after EGFR-directed therapy such as Tarceva (erlotinib), Iressa (gefitinib) or Gilotrif
         (afatinib)

(Criteria continued on next page)
H. If you have metastatic or unresectable, recurrent head and neck squamous cell carcinoma, approval also requires:
   1. The medication is used as a first line treatment
   2. You meet ONE of the following:
      a. The medication will be given in combination with platinum and fluorouracil (FU)
      b. The medication will be given as a single agent AND the tumors have PD-L1 (a type of protein with a Combined Positive Score greater than or equal to 1) as determined by a Food and Drug Administration (FDA)-approved test

I. If you have recurrent or metastatic head and neck squamous cell carcinoma, approval also requires:
   1. You experienced disease progression (has gotten worse) on or after treatment with platinum-containing chemotherapy such as cisplatin, carboplatin, oxaliplatin
   2. The medication will be given as a single agent

J. If you have classical Hodgkin lymphoma, approval also requires ONE of the following:
   1. You are 18 years of age or older AND have relapsed (disease has returned) or refractory classical Hodgkin lymphoma (disease is resistant to treatment)
   2. You have refractory classical Hodgkins lymphoma or relapsed (disease has returned) after 2 or more prior lines of therapy

K. If you have primary mediastinal large B-cell lymphoma, approval also requires ONE of the following:
   1. You have refractory primary mediastinal large B-cell lymphoma (type of immune system cancer that is resistant to treatment)
   2. You have relapsed (disease has returned) after 2 or more prior lines of therapy

L. If you have locally advanced or metastatic urothelial carcinoma, approval also requires ONE of the following:
   1. You are not eligible for any platinum-containing chemotherapy such as cisplatin, carboplatin, oxaliplatin
   2. You experienced disease progression (has gotten worse) on or after treatment with platinum-containing chemotherapy such as cisplatin, carboplatin, oxaliplatin
   3. You experienced disease progression (has gotten worse) within 12 months of neoadjuvant or adjuvant (add-on) treatment with platinum-containing chemotherapy such as cisplatin, carboplatin, oxaliplatin

(Criteria continued on next page)
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEMBROLIZUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

M. If you have bladder cancer, approval also requires:
   1. You have Bacillus Calmette-Guerin (BCG; a type of anti-cancer treatment)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (a group of abnormal cells that have not spread) with or without papillary tumors
   2. You are ineligible for or have chosen not to undergo cystectomy (surgery to remove part of or all of the urinary bladder)

N. If you have unresectable or metastatic tumor that is microsatellite instability-high or mismatch repair deficient, approval also requires:
   1. You have a solid tumor that has progressed (gotten worse) after using prior treatment and have no satisfactory alternative treatment options

O. If you have locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma, approval also requires:
   1. The requested medication is being used as first-line treatment
   2. The requested medication will be used in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy

P. If you have locally advanced or metastatic esophageal or gastroesophageal junction carcinoma, approval also requires:
   1. Your tumors are not amenable (responsive) to surgical resection (removal) or definitive chemoradiation
   2. Keytruda will be used in combination with platinum- and fluoropyrimidine-based chemotherapy OR Keytruda will be used as a single agent after one or more prior lines of systemic therapy for patients with squamous cell histology that express PD-L1 (programmed death-ligand 1: type of protein with a Combined Positive Score greater than or equal to 10) as determined by an FDA-approved test

Q. If you have cervical cancer, approval also requires ONE of the following:
   1. You have persistent, recurrent, or metastatic cervical cancer; Keytruda will be used in combination with chemotherapy, and your tumors express PD-L1 (CPS at least 1) as determined by a Food and Drug Administration (FDA)-approved test
   2. You have recurrent or metastatic cervical cancer; Keytruda will be used as a single agent, you have experienced disease progression (has gotten worse) on or after chemotherapy; and your tumors have PD-L1 (a type of protein with a Combined Positive Score greater than or equal to 1) as determined by a Food and Drug Administration (FDA)-approved test

R. If you have hepatocellular carcinoma, approval also requires:
   1. You have previously been treated with sorafenib

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
PEMBROLIZUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

S. If you have renal cell carcinoma, approval also requires ONE of the following:
   1. You have advanced renal cell carcinoma; you are 18 years of age or older and have not
      received prior systemic chemotherapy treatment (therapy that travels throughout the
      bloodstream) for renal cell carcinoma (it is used as first line treatment), and Keytruda will
      be used in combination with axitinib or lenvatinib
   2. Keytruda will be used as adjuvant (add-on) treatment and your cancer is at intermediate-
      high or high risk of recurrence (returning) following nephrectomy (surgical removal of the
      kidney), or following nephrectomy and resection (surgical removal) of metastatic lesions
      (abnormal area of tissue)

T. If you have advanced endometrial carcinoma, approval also requires:
   1. You meet ONE of the following:
      a. You are using Keytruda in combination with lenvatinib (Lenvima), AND you do not
         have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
         biomarkers (characteristics that help determine what type of cancer you have and
         what treatment options there are for it)
      b. You are using Keytruda as a single agent, AND you have MSI-H or dMMR
         biomarkers
   2. You experienced disease progression following prior systemic therapy (disease has
      gotten worse after previous treatment)
   3. You are not a candidate for curative surgery or radiation

U. If you have unresectable or metastatic solid tumors, approval also requires:
   1. Your solid tumors are tumor mutational burden-high (TMB-H: high number of changes
      found in the genes of the cancer cells) [at least 10 mutations/megabase], as determined
      by a Food Drug Administration (FDA)-approved test
   2. Your disease has worsened following prior treatment and you have no alternative
      treatment options

V. If you have recurrent or metastatic OR locally advanced cutaneous squamous cell
   carcinoma, approval also requires:
   1. Your disease is not curable by surgery or radiation

W. If you have high-risk early-stage triple-negative breast cancer, approval also requires:
   1. The medication will be used in combination with chemotherapy as neoadjuvant
      treatment, and then continued as a single agent as adjuvant treatment after surgery

X. If you have locally recurrent unresectable or metastatic triple-negative breast cancer,
   approval also requires:
   1. The medication is used in combination with chemotherapy
   2. You have tumors that have PD-L1 (programmed death-ligand 1; a type of protein with a
      Combined Positive Score greater than or equal to 10) as determined by a Food and
      Drug Administration (FDA)-approved test
GUIDELINES FOR USE

Our guideline named Pemetrexed (Alimta, Pemfexy) requires the following rule(s) be met for approval:

A. You have one of the following diagnoses:
   1. Locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to nearby tissue/lymph nodes or other part of the body)
   2. Metastatic, non-squamous, non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
   3. Recurrent, metastatic non-squamous, non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
   4. Malignant pleural mesothelioma (a type of cancer)

B. If you have locally advanced or metastatic, non-squamous, non-small cell lung cancer, approval also requires ONE of the following:
   1. The requested medication is being used in combination with cisplatin for initial treatment
   2. The requested medication is being used as a single agent, maintenance therapy AND your disease has not progressed (gotten worse) after four cycles of platinum-based first-line chemotherapy

C. If you have metastatic, non-squamous, non-small cell lung cancer, approval also requires:
   1. The requested medication is being used for initial (starting) treatment
   2. The requested medication is being used in combination with pembrolizumab and platinum chemotherapy
   3. You do NOT have EGFR (Epidermal growth factor receptor) or ALK (anaplastic lymphoma kinase) genomic tumor aberrations (types of gene mutations)

D. If you have recurrent, metastatic non-squamous, non-small cell lung cancer, approval also requires:
   1. The requested medication is being used as a single agent
   2. You have received prior chemotherapy

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

E. If you have malignant pleural mesothelioma, approval also requires:
   1. The requested medication is being used in combination with cisplatin for initial (starting) treatment
   2. Your disease is unresectable (cannot be completely removed by surgery) OR you are not a candidate for curative surgery

Commercial Effective: 07/18/22
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEMETREXED DITROMETHAMINE (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEMETREXED</td>
<td>PEMETREXED DITROMETHAMINE</td>
</tr>
<tr>
<td>DITROMETHAMINE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named PEMETREXED DITROMETHAMINE requires the following rule(s) be met for approval:

A. You have one of the following diagnoses:
   1. Locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to nearby tissue/lymph nodes or other part of the body)
   2. Recurrent, metastatic non-squamous, non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
   3. Malignant pleural mesothelioma (a type of cancer)

B. If you have locally advanced or metastatic, non-squamous, non-small cell lung cancer, approval also requires ONE of the following:
   1. The requested medication is being used in combination with cisplatin for initial treatment
   2. The requested medication is being used as a single agent, maintenance therapy AND your disease has not progressed (gotten worse) after four cycles of platinum-based first-line chemotherapy

C. If you have recurrent, metastatic non-squamous, non-small cell lung cancer, approval also requires:
   1. The requested medication is being used as a single agent
   2. You have received prior chemotherapy

D. If you have malignant pleural mesothelioma, approval also requires:
   1. The requested medication is being used in combination with cisplatin for initial (starting) treatment
   2. Your disease is unresectable (cannot be completely removed by surgery) OR you are not a candidate for curative surgery

Commercial Effective: 10/01/22
PERTUZUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PERTUZUMAB</td>
<td>PERJETA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named PERTUZUMAB (Perjeta) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic breast cancer (breast cancer that has spread to other body parts)
   2. Locally advanced, inflammatory, or early stage breast cancer (breast cancer defined as either greater than 2 cm in diameter or node positive)
   3. Early breast cancer at high risk of recurrence (returning)

B. **If you have metastatic breast cancer, approval also requires:**
   1. Your breast cancer is HER2-positive (higher than normal levels of a protein called human epidermal growth factor receptor 2)
   2. You have not received prior therapy with an anti-HER2 agent (drug that works against a protein called human epidermal growth factor receptor 2) or chemotherapy for metastatic disease (cancer treatment for disease that has spread to other parts of the body)
   3. The requested medication will be used in combination with trastuzumab and docetaxel

C. **If you have locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive), approval also requires:**
   1. Your breast cancer is HER2-positive (higher than normal levels of a protein called human epidermal growth factor receptor 2)
   2. The requested medication will be used in the neoadjuvant setting (given before surgery)
   3. The requested medication will be used in combination with trastuzumab and chemotherapy (cancer drug treatment such as paclitaxel, carboplatin, or cyclophosphamide) as part of a complete drug regimen for early breast cancer

D. **If you have early breast cancer at a high risk of recurrence, approval also requires:**
   1. Your breast cancer is HER2-positive (higher than normal levels of a protein called human epidermal growth factor receptor 2)
   2. The requested medication will be used in the adjuvant setting (given as add-on treatment)
   3. The requested medication will be used in combination with trastuzumab and chemotherapy (cancer drug treatment such as paclitaxel, carboplatin, or cyclophosphamide)

Commercial Effective: 04/10/21
PERTUZUMAB-TRASTUZUMAB-HY-ZZXF (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PERTUZUMAB-TRASTUZUMAB-HY-ZZXF</td>
<td>PHESGO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named PERTUZUMAB-TRASTUZUMAB-HY-ZZXF (Phesgo) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Locally advanced, inflammatory, or early breast cancer (tumor is greater than 2 cm in diameter or node positive)
   2. Early breast cancer at high risk of recurrence (returning)
   3. Metastatic breast cancer (breast cancer has spread to other parts of the body)

B. If you have locally advanced, inflammatory or early breast cancer (tumor is greater than 2 cm in diameter or node positive), approval also requires:
   1. Your breast cancer is HER2-positive
   2. The requested medication will be used in combination with chemotherapy as part of a complete treatment regimen for early breast cancer in the neoadjuvant setting (given before surgery)

C. If you have early breast cancer at high risk of recurrence, approval also requires:
   1. Your breast cancer is HER2-positive
   2. The requested medication will be used in combination with chemotherapy in the adjuvant setting (given as add-on treatment)

D. If you have metastatic breast cancer, approval also requires:
   1. Your breast cancer is HER2-positive
   2. You have not previously received anti-HER2 therapy or chemotherapy for metastatic disease
   3. The requested medication is being used in combination with docetaxel

Commercial Effective: 01/01/21
GUIDELINES FOR USE

Our guideline named **PLERIXAFOR (Mozobil)** requires you meet the following rule(s) for approval:

A. You have Non-Hodgkin's lymphoma (cancer of a part of the immune system called the lymph system) or multiple myeloma (cancer that forms in a type of white blood cell called a plasma cell)

B. The medication is prescribed by or given in consultation with a hematologist or oncologist (blood or cancer doctor)

Commercial Effective: 07/01/20
POLATUZUMAB VEDOTIN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>POLATUZUMAB VEDOTIN-PIIQ</td>
<td>POLIVY</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named POLATUZUMAB VEDOTIN (Polivy) requires the following rule(s) be met for approval:

A. You have relapsed or refractory diffuse large B-cell lymphoma (a type of cancer that affects your white blood cells and returns or resistant to treatment)
B. You are at least 18 years old
C. The requested drug will be used in combination with bendamustine and a rituximab product (type of cancer drug)
D. You have had at least two prior therapies.
E. You are not a candidate for autologous hematopoietic stem cell transplant (cells transferred from your own body)

Commercial Effective: 04/10/21
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PORFIMER</td>
<td>PHOTOFRIN</td>
</tr>
<tr>
<td>SODIUM</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **PORFIMER (Photofrin)** requires that the drug is being used for one of the following conditions:

A. The reduction of blockage and palliation of symptoms (treatment focused on relief from the symptoms and stress of a serious illness) in patients with completely or partially obstructing endobronchial non-small cell lung cancer (NSCLC) or,

B. Treatment of microinvasive endobronchial non-small cell lung cancer (a type of lung cancer that involves airway blockage) where surgery and radiation therapy cannot be used; or

C. Helping to lessen your symptoms with completely obstructing or partially obstructing esophageal cancer, where in the opinion of your physician, you cannot be treated with Nd:YAG laser therapy (a high intensity laser that can be used to remove cancer) or,

D. The ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy (removal of precancerous cells of the esophagus and you did not have surgical treatment for esophageal cancer)

Commercial Effective: 07/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRALATREXATE</td>
<td>FOLOTYN</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named PRALATREXATE (Folotyn) requires a diagnosis of relapsed or refractory peripheral T-cell lymphoma (a type of white blood cell cancer that returns or does not fully respond to treatment).

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named RAMUCIRUMAB (Cyramza) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Advanced or metastatic (cancer that has spread to other parts of the body), gastric cancer or gastro-esophageal junction adenocarcinoma (cancer of the stomach or cancer of the esophagus [tube that connects mouth and stomach])
   2. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of your body)
   3. Metastatic colorectal cancer (type of rectum cancer that has spread to other parts of the body)
   4. Hepatocellular carcinoma (type of liver cancer)

B. If you have advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma, approval also requires:
   1. The requested medication will be used as a single agent or in combination with paclitaxel
   2. You have experienced disease progression (disease has worsened) on or after prior fluoropyrimidine-containing chemotherapy (examples include fluorouracil [5-FU], capecitabine, floxuridine) OR platinum-containing chemotherapy (examples include cisplatin, oxaliplatin, carboplatin)

C. If you have metastatic non-small cell lung cancer (NSCLC), approval also requires ONE of the following:
   1. The requested medication will be used in combination with docetaxel and you meet ONE of the following:
      a. You have experienced disease progression (disease has worsened) on or after platinum-based chemotherapy (cisplatin, oxaliplatin, carboplatin)
      b. You have an epidermal growth factor receptor (EGFR: type of protein) or anaplastic lymphoma kinase (ALK : type of enzyme) genomic tumor abnormality AND your disease has gotten worse on an Food and Drug Administration (FDA)-approved therapy (examples include Tarceva, Gilotrif, Xalkori, or Zykdia) prior to receiving Cyramza
   2. The requested medication will be used in combination with erlotinib as first-line treatment AND your tumors have epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 (L858R) substitution mutations

(Criteria continued on next page)
D. If you have metastatic colorectal cancer, approval also requires:
   1. The requested medication will be used in combination with FOLFIRI (drug combination of irinotecan, folinic acid, and 5-fluorouracil)
   2. You have experienced disease progression (disease has worsened) on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (such as 5-fluorouracil or capecitabine)

E. If you have hepatocellular carcinoma, approval also requires:
   1. The requested medication will be used as a single agent
   2. You have an alpha fetoprotein (AFP) greater than or equal to 400 ng/mL
   3. You have been treated with sorafenib (Nexavar)

Commercial Effective: 07/01/20
RANIBIZUMAB-LUCENTIS (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>RANIBIZUMAB</td>
<td>LUCENTIS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RANIBIZUMAB (Lucentis) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Neovascular (wet) age-related macular degeneration (AMD: a type of eye disease)
   2. Diabetic macular edema (DME: a type of eye condition caused by high blood sugar)
   3. Diabetic retinopathy (DR: a type of eye condition caused by high blood sugar)
   4. Macular edema following retinal vein occlusion (a type of eye condition)
   5. Myopic choroidal neovascularization (mCNV: a type of eye condition)

B. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist

C. **If you have diabetic macular edema, approval also requires:**
   1. You will NOT use Lucentis concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Vabysmo)

D. **If you have neovascular (wet) age-related macular degeneration, approval also requires:**
   1. You had a trial of or contraindication (harmful for) to the preferred medication: Byooviz
   2. You will NOT use Lucentis concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Susvimo, Beovu)

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

NOTE: For the diagnoses of diabetic retinopathy, macular edema following retinal vein occlusion, or myopic choroidal neovascularization, please refer to the initial criteria section.

Our guideline named RANIBIZUMAB (Lucentis) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Diabetic macular edema (DME: a type of eye condition caused by high blood sugar)
   2. Neovascular (wet) age-related macular degeneration (AMD: a type of eye disease)
B. If you have diabetic macular edema, renewal also requires:
   1. You have maintenance or improvement of visual acuity (vision clarity or sharpness)
   2. You will NOT use Lucentis concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Vabysmo)
C. If you have neovascular (wet) age-related macular degeneration, renewal also requires:
   1. You have maintenance or improvement of visual acuity (vision clarity or sharpness)
   2. You will NOT use Lucentis concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Susvimo, Beovu)

Commercial Effective: 10/01/22
RANIBIZUMAB-NUNA (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>RANIBIZUMAB-NUNA</td>
<td>BYOOVIZ</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RANIBIZUMAB-NUNA (Byooviz) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Neovascular (wet) age-related macular degeneration (nAMD: a type of eye disease)
   2. Macular edema following retinal vein occlusion (RVO: a type of eye condition)
   3. Myopic choroidal neovascularization (mCNV: a type of eye condition)

B. If the request is for neovascular (wet) age-related macular degeneration, approval also requires:
   1. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist
   2. You will NOT use Byooviz concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Beovu, Eylea, Lucentis)

C. If the request is for macular edema following retinal vein occlusion, approval also requires:
   1. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist

D. If the request is for myopic choroidal neovascularization, approval also requires:
   1. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist

RENEWAL CRITERIA

NOTE: For the diagnoses of macular edema following retinal vein occlusion (RVO), or myopic choroidal neovascularization (MCN), please refer to the Initial Criteria section.

Our guideline named RANIBIZUMAB-NUNA (Byooviz) requires the following rule(s) be met for renewal:

A. You have neovascular (wet) age-related macular degeneration (nAMD: a type of eye disease)
B. You have maintenance or improvement of visual acuity (vision clarity or sharpness)
C. You will NOT use Byooviz concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such Beovu, Eylea, Lucentis)

Commercial Effective: 07/18/22
RANIBIZUMAB-SUSVIMO (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>RANIBIZUMAB,</td>
<td>SUSVIMO</td>
</tr>
<tr>
<td>RANIBIZUMAB/INIT</td>
<td></td>
</tr>
<tr>
<td>FILL NEEDLE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RANIBIZUMAB (Susvimo) requires the following rule(s) be met for approval:

A. You have neovascular (wet) age-related macular degeneration (AMD: a type of eye disease)
B. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist
C. You have previously responded to at least TWO intravitreal (into the eye) injections of a vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis, Beovu)
D. You will NOT use Susvimo concurrently (at the same time) with other intravitreal VEGF inhibitors (such as Eylea, Lucentis, Beovu)

RENEWAL CRITERIA

Our guideline named RANIBIZUMAB (Susvimo) requires the following rule(s) be met for renewal:

A. You have neovascular (wet) age-related macular degeneration (AMD: a type of eye disease)
B. You have maintenance or improvement of visual acuity (vision clarity or sharpness)
C. You will NOT use Susvimo concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea, Lucentis, Beovu)

Commercial Effective: 09/01/22
RAVULIZUMAB-CWVZ (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAVULIZUMAB-CWVZ</td>
<td>ULTOMIRIS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RAVULIZUMAB-CWVZ (Ultomiris) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
   2. Atypical hemolytic uremic syndrome (aHUS: a rare blood disorder)
   3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)

B. If you have paroxysmal nocturnal hemoglobinuria (PNH), approval also requires:
   1. You are one month of age or older
   2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
   3. You have documented confirmation of PNH by flow cytometry (a type of lab test) demonstrating ALL of the following:
      a. At least 2 different GPI-protein deficiencies (missing a certain type of protein such as CD55, CD59) on at least 2 cell lineages (such as erythrocytes [red blood cells], granulocytes [a type of white blood cell])
      b. PNH granulocyte clone size of 10 percent or greater
   4. You are not using concurrent (at the same time) complement inhibitor therapy (such as Soliris or Empaveli)
   5. You meet ONE of the following:
      a. You are transitioning from Soliris to Ultomiris
      b. You have documented evidence of intravascular hemolysis (blood cells break down within your blood stream) (such as lactate dehydrogenase [LDH: type of enzyme] level of at least 1.5 times the upper limit of normal, hemoglobinuria [type of blood protein in urine]) AND presence of at least one PNH-related sign or symptom (such as a history of blood transfusion [adding blood to your body] due to PNH, symptoms of anemia [low red blood cell level], history of major adverse vascular event from thromboembolism [blood clot])

C. If you have atypical hemolytic uremic syndrome, approval also requires:
   1. You are one month of age or older

(Initial criteria continued on next page)
RAVULIZUMAB-CWVZ (NSA)

INITIAL CRITERIA (CONTINUED)

D. If you have generalized myasthenia gravis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. Your diagnosis is confirmed by a positive serologic test for anti-acetylcholine receptor (AChR) antibody (an indicator of myasthenia gravis)
   4. You have Myasthenia Gravis Foundation of America class II, III, or IV (types of severity of disease)
   5. You had a trial of or contraindication (harmful for) to ONE corticosteroid (such as prednisone)
   6. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
      b. You had a trial of or contraindication (harmful for) to ONE non-steroidal immunosuppressive therapy while on chronic plasmapheresis or plasma exchange (types of blood therapy)

RENEWAL CRITERIA

Our guideline named RAVULIZUMAB-CWVZ (Ultomiris) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
   2. Atypical hemolytic uremic syndrome (aHUS: a rare blood disorder)
   3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
B. If you have paroxysmal nocturnal hemoglobinuria, renewal also requires:
   1. You have had clinical benefit compared to baseline (before you started treatment) (such as reduction in number of blood transfusions [adding blood to your body]), improvement/stabilization of lactate dehydrogenase [type of enzyme] and hemoglobin [type of protein in red blood cells] levels)
   2. You are not using concurrent (at the same time) complement inhibitor therapy (such as Soliris or Empaveli)

(Reaward criteria continued on next page)

CONTINUED ON NEXT PAGE
RAVULIZUMAB-CWVZ (NSA)

RENEWAL CRITERIA (CONTINUED)

C. If you have generalized myasthenia gravis, renewal also requires:
   1. You have had clinical benefit compared to baseline according to validated gMG instruments (such as Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)

Commercial Effective: 10/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RESLIZUMAB (Cinqair) requires the following rule(s) be met for approval:

A. You have severe asthma with an eosinophilic phenotype (inflammatory type of asthma where there is a high number of a type of white blood cell)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a physician specializing in pulmonary (lung/breathing) medicine or allergy medicine
D. You have a documented blood eosinophil level (type of white blood cell) of at least 150 cells/mcL within the past 12 months
E. You are being treated with medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid plus at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid
F. You have ONE of the following:
   1. Experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
   2. Poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      a. Daytime asthma symptoms more than twice per week
      b. Any night waking due to asthma
      c. Use of short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      d. Any activity limitation due to asthma
G. You will NOT use Cinqair concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Fasenra) when these are used for the treatment of asthma
H. You had a trial of or contraindication (medical reasons why you cannot use) to TWO of the following: Fasenra, Nucala, or Dupixent

CONTINUED ON NEXT PAGE
RESLIZUMAB (NSA)

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named RESLIZUMAB (Cinqair) requires the following rule(s) be met for renewal:

A. You will continue to use an inhaled corticosteroid (ICS) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as tiotropium), a leukotriene receptor antagonist (such as montelukast), theophylline, or oral corticosteroid

B. You will NOT use Cinqair concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Fasenra) when these are used for the treatment of asthma

C. You have shown a clinical response as evidenced by ONE of the following:

1. Reduction in asthma exacerbation (worsening of symptoms) from baseline
2. Decreased use of rescue medications
3. Increase in percent predicted FEV1 (type of lung test) from pretreatment baseline
4. Reduction in severity or frequency of asthma-related symptoms such as wheezing, shortness of breath, coughing, etc.

Commercial Effective: 07/01/22
RISANKIZUMAB-RZAA

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RISANKIZUMAB-RZAA (Skyrizi) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe Crohn’s disease (CD: a type of bowel disorder)

B. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
   4. You have tried or have a contraindication (harmful for) to one or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. If you have moderate to severe Crohn’s disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

Our guideline named RISANKIZUMAB-RZAA (Skyrizi) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)

B. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

C. If you have psoriatic arthritis, renewal also requires:
   1. You experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Commercial Effective: 09/12/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named RITUXIMAB (Rituxan) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   3. Previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL: a type of blood cancer), Burkitt lymphoma (BL: a type of blood cancer), Burkitt-like lymphoma (BLL: a type of blood cancer), or mature B-cell acute leukemia (B-AL: a type of blood cancer)
   4. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
   5. Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) (a condition that affects the blood vessels)
   6. Microscopic polyangiitis (MPA: a condition that affects the blood vessels)
   7. Moderate to severe pemphigus vulgaris (PV: a type of skin condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using or have a contraindication (harmful for) to methotrexate
   4. You have tried at least 3 months of treatment with or have a contraindication (harmful for) to ONE DMARD (disease modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   5. You meet ONE of the following:
      a. You have tried or have a contraindication (harmful for) to any TWO of the following preferred immunomodulators (class of drugs): Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
      b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. If you have non-Hodgkin's lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)

(Initial criteria continued on next page)
INITIAL CRITERIA (CONTINUED)

D. If you have previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia, approval also requires:
   1. You are 6 months of age or older
   2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
   3. The requested medication will be used in combination with chemotherapy

E. If you have chronic lymphocytic leukemia, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
   3. You are currently using chemotherapy at the same time with the requested medication

F. If you have granulomatosis with polyangiitis (Wegener’s granulomatosis) or microscopic polyangiitis, approval also requires:
   1. You are 2 years of age or older
   2. You are currently on glucocorticoids (steroids such as methylprednisolone or prednisone) along with the requested medication

G. If you have moderate to severe pemphigus vulgaris, approval also requires:
   1. You are 18 years of age or older

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

NOTE: For the diagnoses of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) (Wegener’s granulomatosis), microscopic polyangiitis (MPA), and moderate to severe pemphigus vulgaris (PV), please refer to the Initial Criteria section.

Our guideline named RITUXIMAB (Rituxan) requires the following rule(s) be met for renewal:
A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count from baseline while on therapy for renewal

Commercial Effective: 03/14/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RITUXIMAB-ABBS (Truxima) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Non-Hodgkin's lymphoma (NHL: a type of blood cancer)
   2. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
   3. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   4. Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) (a condition that affects the blood vessels)
   5. Microscopic polyangiitis (MPA: a condition that affects the blood vessels)

B. If you have non-Hodgkin's lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with an oncologist (a type of cancer doctor)

C. If you have chronic lymphocytic leukemia, approval also requires:
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with an oncologist (a type of cancer doctor)

D. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using or have a contraindication (harmful for) to methotrexate
   4. You had a trial of at least 3 months or a contraindication (harmful for) to treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial criteria continued on next page)
INITIAL CRITERIA (CONTINUED)

5. You meet ONE of the following:
   a. You had a trial of or contraindication (harmful for) to any TWO of the following preferred immunomodulators: Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
   b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

   NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

E. If you have granulomatosis with polyangiitis (Wegner's granulomatosis) or microscopic polyangiitis, approval also requires:
   1. You are 18 years of age or older
   2. You are currently on glucocorticoids (steroids such as methylprednisolone or prednisone) with requested medication

RENEWAL CRITERIA

Our guideline named RITUXIMAB-ABBS (Truxima) requires the following rule(s) be met for renewal:
A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Commercial Effective: 03/14/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RITUXIMAB-ARRX (Riabni) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Non-Hodgkin's lymphoma (NHL: type of blood cancer)
   2. Chronic lymphocytic leukemia (CLL: type of blood and bone marrow cancer)
   3. Granulomatosis with polyangiitis (GPA or Wegener's granulomatosis: a condition that causes inflammation of the blood vessels)
   4. Microscopic polyangiitis (MPA: blood vessel inflammation, which can damage organ systems)
   5. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

B. If you have non-Hodgkin's lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an oncologist (cancer/tumor doctor)

C. If you have chronic lymphocytic leukemia, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used in combination with fludarabine and cyclophosphamide (FC)
   3. Therapy is prescribed by or in consultation with an oncologist (cancer/tumor doctor)

D. If you have granulomatosis with polyangiitis or microscopic polyangiitis, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used with glucocorticoids steroids (such as methylprednisolone, prednisone)

(Initial criteria continued on next page)
E. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using or have a contraindication (harmful for) to methotrexate
   4. You have tried or have a contraindication to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   5. You meet ONE of the following:
      a. You have tried or have a contraindication (harmful for) to any TWO of the following preferred medications: Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
      b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

RENEWAL CRITERIA

NOTE: For the diagnoses of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), Wegener’s granulomatosis (WG), or microscopic polyangiitis (MPA), please refer to the Initial Criteria section.

Our guideline named RITUXIMAB-ARRX (Riabni) requires the following rule(s) be met for renewal:
A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
B. You have experienced 20% or greater improvement in tender joint count or swollen joint count from baseline while on therapy

Commercial Effective: 07/18/22
GUIDELINES FOR USE

Our guideline named RITUXIMAB AND HYALURONIDASE HUMAN - SQ (Rituxan Hycela) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnosis:
   1. Follicular Lymphoma (FL: type of cancer that affects a type of white blood cells)
   2. Diffuse Large B-cell Lymphoma (DLBCL: cancer that affects specific immune system cells)
   3. Chronic Lymphocytic Leukemia (blood and bone marrow cancer) in adult patients who have received or will receive at least one full dose of a rituximab product by intravenous infusion (given into the veins) before starting requested medication

B. If you have Follicular Lymphoma (FL), approval also requires ONE of the following:
   1. The medication will be used as a single agent if you have relapsed or refractory Follicular Lymphoma (cancer that has returned or does not fully respond to treatment)
   2. The medication will be used in combination with first line chemotherapy if you have previously untreated Follicular Lymphoma
   3. The medication will be used as a single-agent for maintenance therapy if you have achieved a complete or partial response to rituximab in combination with chemotherapy
   4. The medication will be used as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy if you have non-progressing (does not get worse, including stable disease) Follicular Lymphoma

C. If you have Diffuse Large B-cell Lymphoma (DLBCL) approval also requires ONE of the following:
   1. The medication will be used in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), or other anthracycline-based chemotherapy regimens for previously untreated Diffuse Large B-cell Lymphoma (DLBCL)

D. If you have Chronic Lymphocytic Leukemia (CLL), approval also requires ONE of the following:
   1. The medication will be used in combination with fludarabine and cyclophosphamide (FC)

Commercial Effective: 07/01/20
RITUXIMAB-PVVR (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>RITUXIMAB-PVVR</td>
<td>RUXIENCE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RITUXIMAB-PVVR (Ruxience) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Non-Hodgkin's lymphoma (NHL: a type of blood cancer)
   2. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
   3. Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) (a condition that affects the blood vessels)
   4. Microscopic polyangiitis (MPA: a condition that affects the blood vessels)
   5. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

B. You are 18 years of age or older

C. If you have non-Hodgkin's lymphoma, approval also requires:
   1. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)

D. If you have chronic lymphocytic leukemia, approval also requires:
   1. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
   2. The requested medication will be used in combination with chemotherapy

E. If you have granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis, approval also requires:
   1. You are using glucocorticoids (steroids such as methylprednisolone or prednisone) at the same time with the requested medication

G. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   2. You are currently using methotrexate, unless you have a contraindication (harmful for)
   3. You had a trial of or contraindication to (harmful for) at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

4. You meet ONE of the following:
   a. You had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Enbrel, Humira, Rinvoq, Xeljanz (immediate release/extended release)
   b. You have tried any tumor necrosis factor (TNF) inhibitor (such as Humira, Enbrel) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq, Xeljanz) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

NOTE: For the diagnoses of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) Wegener's granulomatosis), and microscopic polyangiitis (MPA), please refer to the Initial Criteria section.

Our guideline named RITUXIMAB-PVVR (Ruxience) requires the following rule(s) be met for renewal:
   A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   B. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

Commercial Effective: 03/14/22
GUIDELINES FOR USE

Our guideline named ROMIDEPSIN (Istodax) requires the following rule(s) be met for approval:

A. You have cutaneous T-cell lymphoma (CTCL: type of cancer that affects a certain type of immune system cells) also known as Mycosis Fungoides/Sezary Syndrome

B. You are 18 years of age or older

C. You meet ONE of the following:
   1. You had a trial of Zolinza (vorinostat) unless there is a medical reason why you cannot (contraindication) AND you are not able to tolerate oral medications
   2. You have tried at least one form of systemic therapy (such as retinoids, interferon, denileukin diftitox, methotrexate, liposomal doxorubicin, gemcitabine, chlorambucil) AND you are able to tolerate oral medications

Commercial Effective: 08/30/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ROMIPLOSTIM (Nplate) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Immune thrombocytopenia (ITP: your immune system attacks blood cells that prevent bleeding)
   2. Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS: you have been acutely exposed to myelosuppressive doses of radiation)

B. If you have immune thrombocytopenia (ITP), approval also requires:
   1. You are 1 year of age or older
   2. You have previously tried or have a contraindication to (medical reason why you cannot use) corticosteroids or immunoglobulins, OR you had an insufficient response to a splenectomy (surgical removal of spleen)
   3. Therapy is prescribed by or given in consultation with a hematologist (blood specialist) or immunologist (allergy/immune system doctor)
   4. If you are between 1 and 17 years old, approval also requires:
      a. You had immune thrombocytopenia (ITP) for at least 6 months

RENEWAL CRITERIA

Our guideline named ROMIPLOSTIM (Nplate) requires the following rule(s) be met for renewal:

A. You have immune thrombocytopenia (ITP: your immune system attacks blood cells that prevent bleeding)

B. You had a clinical response, as defined by an increase in platelet count to at least 50 X 10^9/L (at least 50,000 per microliter)

Commercial Effective: 03/01/21
Our guideline named **ROMOSOZUMAB (Evenity)** requires the following rule(s) be met for approval:

A. You have postmenopausal osteoporosis (weak and brittle bones)
B. You have not received a total of 12 months or more of Evenity therapy.
C. You meet **ONE** of the following criteria:
   1. You are at high risk for fractures defined as **ONE** of the following:
      a. History of osteoporotic (fragility, low trauma) fracture(s)
      b. 2 or more risk factors for fracture such as history of multiple recent low trauma fractures, bone marrow density [BMD] T-score (measurement of how high your risk for osteoporosis is) less than or equal to -2.5, corticosteroid use, or use of gonadotropin-releasing hormone [GnRH] analogs such as nafarelin, etc.
      c. No prior treatment for osteoporosis **AND** FRAX score (test for your risk of fractures) greater than or equal to 20% for any major fracture **OR** greater than or equal to 3% for hip fracture
   2. You are unable to use oral therapy. Reasons include upper gastrointestinal [GI] problems - unable to tolerate oral medication, lower GI problems - unable to absorb oral medications, trouble remembering to take oral medications or coordinating an oral bisphosphonate with other oral medications or their daily routine
   3. You had an adequate trial of, intolerance to, or a contraindication to (medical reason why you cannot use) bisphosphonates such as Fosamax, Actonel, Boniva

Commercial Effective: 07/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SACITUZUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SACITUZUMAB</td>
<td>TRODELVY</td>
</tr>
<tr>
<td>GOVITECAN-HZIY</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named SACITUZUMAB (Trodelvy) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable locally advanced (the cancer has spread from where it started to nearby tissue or lymph nodes and cannot be surgically removed) OR metastatic triple negative breast cancer (mTNBC: breast cancer that has spread to other parts of the body and does not have estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 [HER2: type of protein])
   2. Locally advanced or metastatic (disease has spread to other parts of the body) urothelial cancer (mUC: type of urinary system cancer)

B. You are 18 years of age or older

C. If you have unresectable locally advanced or metastatic triple negative breast cancer, approval also requires:
   1. You have previously tried two or more previous systemic therapies (treatment that targets the entire body by traveling throughout your bloodstream), at least one of them for metastatic disease (disease that has spread to other parts of the body)

D. If you have locally advanced or metastatic urothelial cancer (mUC), approval also requires:
   1. You have previously received a platinum-containing chemotherapy (such as cisplatin, carboplatin) and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor (such as atezolizumab, avelumab, cemiplimab-rwlc, durvalumab)

Commercial Effective: 06/01/21
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEBELIPASE ALFA (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEBELIPASE ALFA</td>
<td>KANUMA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SEBELIPASE ALFA (Kanuma) requires the following rule(s) be met for approval:

A. You have lysosomal acid lipase (LAL) deficiency (inherited condition where your body cannot break down and use fats and cholesterol), as confirmed by the presence of clinical features such as hepatomegaly (enlarged liver), elevated serum transaminases (types of enzymes), dyslipidemia (abnormal levels of fats), splenomegaly (enlarge spleen)

B. The medication is prescribed by or given in consultation with an endocrinologist (hormone doctor), hepatologist (liver specialist), gastroenterologist (digestive system doctor), medical geneticist, or lipidologist (cholesterol management specialist)

C. You meet ONE of the following:
   1. A blood test indicating low or absent levels of lysosomal acid lipase enzyme activity
   2. A dried blood spot test indicating low or absent lysosomal acid lipase enzyme activity
   3. A genetic test indicating the bi-allelic presence of altered LIPA gene(s) (you have a change in a gene that provides instructions for producing an enzyme called lysosomal acid lipase)

RENEWAL CRITERIA

Our guideline named SEBELIPASE ALFA (Kanuma) requires the following rule(s) be met for renewal:

A. You have lysosomal acid lipase (LAL) deficiency (inherited condition where your body cannot break down and use fats and cholesterol) presenting after the first 6 months of life and not considered rapidly progressive (getting worse)

B. You have documented improvement in ONE of the following clinical parameters associated with lysosomal acid lipase (LAL) deficiency during the past 6 months:
   1. A relative reduction from baseline in any one of the following lipid levels (fat lab measurements such as LDL-c, Non-HDL-c, or triglycerides)
   2. Normalization of aspartate aminotransferase (AST: type of liver enzyme) based on age- and gender-specific normal ranges
   3. A decrease in liver fat content compared to baseline assessed by abdominal imaging such as multi-echo gradient echo [MEGE] MRI

Commercial Effective: 07/01/20
SELEXIPAG

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SELEXIPAG (Uptravi) requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
C. You have documented confirmatory pulmonary arterial hypertension diagnosis based on right heart catheterization (a test used to measure how well your heart is pumping) with the following lab values:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
D. You have New York Heart Association-World Health Organization (NYHA-WHO) Functional Class II-IV symptoms (classification system for heart failure)
E. If you have WHO Functional Class II or III symptoms, approval also requires:
   1. You had a trial of or contraindication (harmful for) to TWO of the following agents from different drug classes:
      a. Oral endothelin receptor antagonist (such as Tracleer, Letairis, Opsumit)
      b. Oral phosphodiesterase-5 inhibitor (such as Adcirca or Revatio)
      c. Oral cGMP stimulator (such as Adempas)
F. If you have WHO Functional Class III symptoms with evidence of rapid progression/poor prognosis, or WHO Functional Class IV symptoms, approval also requires:
   1. You had a trial of or contraindication (harmful for) to ONE intravenous or subcutaneous prostacyclin (such as Flolan/Veletri or Remodulin)

RENEWAL CRITERIA

Our guideline named SELEXIPAG (Uptravi) requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition)
B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance
   2. You have a stable 6-minute walk distance from baseline AND your World Health Organization (WHO) functional class (classification system for heart failure) has remained stable or improved

Commercial Effective: 04/01/22

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SILTUXIMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SILTUXIMAB</td>
<td>SYLVANT</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named SILTUXIMAB (Sylvant) requires the following rule(s) be met for approval:
A. You have multi-centric Castleman’s disease (MCD: disease that affects the lymph nodes and related tissues)
B. You are negative for both human immunodeficiency virus (HIV) and human herpes virus-8 (HHV-8)

Commercial Effective: 07/01/20
SIROLIMUS PROTEIN-BOUND (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIROLIMUS PROTEIN-BOUND</td>
<td>FYARRO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **SIROLIMUS PROTEIN-BOUND (Fyarro)** requires the following rule(s) be met for approval:

A. You have locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa: a type of rare tumor, that cannot be completely removed with surgery and has spread to nearby tissue or lymph nodes, or that has spread to other parts of the body)

B. You are 18 years of age or older

Commercial Effective: 04/01/22
GUIDELINES FOR USE

Our guideline named **SPESOLIMAB-SBZO (SPEVIGO)** requires the following rule(s) be met for approval:

A. The request is for treatment of a generalized pustular psoriasis (GPP: a type of skin condition) flare
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
D. You have sterile, macroscopically visible pustules (blisters with non-infectious pus that can be seen with the naked eye) on non-acral skin (skin in areas of the body such as arms and legs)
E. You have not received more than one dose in the previous 30 days and that dose was not within the last 7 days

Commercial Effective: 10/01/22
SUFENTANIL (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUFENTANIL CITRATE</td>
<td>DSUVIA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named SUFENTANIL (Dsuvia) requires the following rule(s) be met for approval:
A. You have acute pain (sudden and severe pain)
B. You are 18 years of age or older
C. Your pain is severe enough to require an opioid analgesic for which alternative treatments are inadequate. Alternative treatments that may be inadequate include non-opioid analgesic products or opioid combination products
D. Your treatment center is a Dsuvia Risk Evaluation and Mitigation Strategy (REMS) certified medically supervised healthcare setting, such as a hospital, surgical center, or emergency department

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named **SUTIMLIMAB-JOME (Enjaymo)** requires the following rule(s) be met for approval:

A. You have cold agglutinin disease (CAD: a rare type of blood condition)
B. You are 18 years of age or older

Commercial Effective: 07/01/22
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TAFASITAMAB-CXIX (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAFASITAMAB-CXIX</td>
<td>MONJUVI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **TAFASITAMAB-CXIX (Monjuvi)** requires the following rule(s) be met for approval:

A. You have relapsed or refractory diffuse large B-cell lymphoma (DLBCL: type of white blood cancer that has returned or did not respond to previous treatment)
B. You are 18 years of age or older
C. The requested medication will be used in combination with lenalidomide
D. You are not eligible for autologous stem cell transplant (ASCT: stem cell transplant transferred from your own body)

Commercial Effective: 04/10/21
TAGRAXOFUSP-ERZS (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAGRAXOFUSP-ERZS</td>
<td>ELZONRIS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **TAGRAXOFUSP-ERZS (Elzonris)** requires the following rule(s) be met for approval:

A. You have blastic plasmacytoid dendritic cell neoplasm (BPDCN: aggressive and rare disease of the bone marrow and blood that can affect multiple organs)

B. You are 2 years of age or older

Commercial Effective: 07/01/20
TALIMOGENE LAHERPAREPVEC (NSA)

GUIDELINES FOR USE

Our guideline for TALIMOGENE LAHERPAREPVEC (Imlygic) requires the following rule(s) be met for approval:

A. You have unresectable melanoma (type of skin cancer that cannot be removed with surgery)
B. Your melanoma lesions are recurrent after initial surgery (cancer returns after surgery)
C. You do not have a history of primary or acquired immunodeficient states (conditions that weaken your immune system), leukemia (type of white blood cell cancer), lymphoma (type of cancer affecting immune system), or Acquired Immunodeficiency Syndrome (AIDS)
D. You are not currently receiving immunosuppressive therapy (treatment that weakens your immune system)
E. You are not receiving concurrent medical therapy for the treatment of melanoma including pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), dabrafenib (Tafinlar), trametinib (Mekinist), vemurafenib (Zelboraf), interleukin-2, interferon, dacarbazine, temozolomide (Temodar), paclitaxel, carboplatin, imatinib (Gleevec), melphalan (Alkeran), imiquimod, or radiation therapy
F. The request is for Imlygic to be injected into cutaneous, subcutaneous, and/or nodal lesions (injected into the skin layers) that are visible, palpable (can be felt), or detectable by ultrasound guidance

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named **TEBENTAFUSP-TEBN (Kimmtrak)** requires the following rule(s) be met for approval:

A. You have unresectable or metastatic uveal melanoma (a type of eye cancer that is unable to be removed by surgery or has spread to other parts of the body)
B. You are 18 years of age or older
C. You are HLA-A*02:01-positive (a complex of genes)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TEMOZOLOMIDE (Temodar) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Anaplastic astrocytoma (type of brain tumor)
   2. Glioblastoma multiforme (type of tumor affecting brain or spine)
   4. Metastatic melanoma (type of skin cancer)

B. If you have metastatic melanoma, approval also requires:
   1. You are not concurrently (at the same time) using an immunosuppressive therapy (treatment that lowers the activity of the body’s immune system) or a medical therapy for the treatment of melanoma

RENEWAL CRITERIA

NOTE: For the diagnoses of Anaplastic astrocytoma, Glioblastoma multiforme, or Small cell lung cancer (SCLC), please refer to the Initial Criteria section.

Our guideline named TEMOZOLOMIDE (Temodar) requires the following rule(s) be met for renewal:

A. You have metastatic melanoma (type of skin cancer)
B. You are not concurrently (at the same time) using an immunosuppressive therapy (treatment that lowers the activity of the body’s immune system) or a medical therapy for the treatment of melanoma

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named **TEMSIROLIMUS (Torisel)** requires the following rule(s) be met for approval:

A. You have advanced renal cell carcinoma (RCC: type of kidney cancer).

Commercial Effective: 07/01/20
TEPROTUMUMAB-TRBW (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEPROTUMUMAB-TRBW</td>
<td>TEPEZZA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named TEPROTUMUMAB-TRBW (Tepezza) requires the following rule(s) be met for approval:

A. You have thyroid eye disease (a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TEZEPELUMAB-EKKO (Tezspire)** requires the following rule(s) be met for approval:

A. You have severe asthma (a type of lung condition)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a doctor specializing in allergy or pulmonary (lung/breathing) medicine
D. You are being treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid [such as triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as salmeterol, formoterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), or theophylline
E. You meet ONE of the following:
   1. You experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room visit within the past 12 months
   2. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      i. Daytime asthma symptoms more than twice per week
      ii. Any night waking due to asthma
      iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      iv. Any activity limitation due to asthma
F. You will NOT use Tezspire concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Cinquair, Fasenra) when used for the treatment of asthma
G. **If you have severe asthma with an eosinophilic phenotype (type of inflammatory asthma), approval also requires:**
   1. You have a documented blood eosinophil level of at least 150 cells/mcL within the last 12 months
   2. You had a trial of or contraindication (harmful for) to TWO of the following: Fasenra, Nucala, Dupixent

*(Initial criteria continued on next page)*

CONTINUED ON NEXT PAGE
TEZEPELUMAB-EKKO (NSA)

INITIAL CRITERIA (CONTINUED)

H. If you have severe oral corticosteroid-dependent asthma, approval also requires:
   1. You had a trial of or contraindication (harmful for) to Dupixent
I. If you have severe allergic asthma, approval also requires:
   1. You had a trial of or contraindication (harmful for) to Xolair

RENEWAL CRITERIA

Our guideline named TEZEPELUMAB-EKKO (Tezspire) requires the following rule(s) be met for renewal:
A. You will continue to use an inhaled corticosteroid (ICS, such as triamcinolone acetonide, beclomethasone) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), long-acting muscarinic antagonist (such as tiotropium), leukotriene receptor antagonist (such as montelukast), or theophylline
B. You have shown a clinical response as evidenced by ONE of the following:
   1. Reduction in asthma exacerbation (worsening of symptoms) from baseline
   2. Decreased use of rescue medications
   3. Increase in percent predicted FEV1 (amount of air exhaled in one second) from pretreatment baseline
   4. Reduction in severity or frequency of asthma-related symptoms such as wheezing, shortness of breath, coughing, etc.
C. You will NOT use Tezspire concurrently (at the same time) with Xolair, Dupixent, or another anti-IL5 biologic (such as Nucala, Cinqair, Fasenra) when used for the treatment of asthma

Commercial Effective: 07/01/22
THYROTROPIN ALFA FOR INJECTION (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>THYROTROPIN ALFA FOR INJECTION</td>
<td>THYROGEN</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **THYROTROPIN ALFA FOR INJECTION (Thyrogen)** requires that the requested product is being used as adjunctive (add-on) treatment for radioiodine ablation of thyroid tissue remnants for thyroid cancer without evidence of metastatic disease (used to destroy thyroid tissue that is left over after using another treatment and you have no signs of the disease spreading in body)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TILDRAKIZUMAB-ASMN (Ilumya) requires the following rule(s) be met for approval:

A. You are 18 years of age or older
B. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
D. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
E. You have tried or have a contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine
F. You have tried or have a contraindication (harmful for) to any TWO of the following preferred immunomodulators: Cosentyx, Humira, Stelara, Tremfya, Skyrizi, Enbrel, Otezla

The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

Our guideline named TILDRAKIZUMAB-ASMN (Ilumya) requires the following rule(s) be met for renewal:

A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
B. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

Commercial Effective: 03/14/22
Our guideline named **TISAGENLECLEUCEL (Kymriah)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. B-cell precursor acute lymphoblastic leukemia (ALL: a type of blood cancer)
   2. Relapsed or refractory diffuse large B-cell lymphoma (DLBCL: a type of blood cancer that has returned or did not respond to treatment) not otherwise specified, high grade B-cell lymphoma (a type of blood cell cancer), or DLBCL arising from follicular lymphoma (FL: type of blood cancer) such as transformed follicular lymphoma
   3. Relapsed or refractory follicular lymphoma (FL: a type of blood cancer that has returned or did not respond to treatment)

B. **If you have B-cell precursor acute lymphoblastic leukemia, approval also requires:**
   1. You are 25 years of age or younger
   2. Therapy is prescribed by a Kymriah-certified hematologist (blood specialist) or oncologist (tumor/cancer doctor)
   3. Kymriah will be administered at a treatment center that is certified to administer Kymriah
   4. You have not had a previous trial of Kymriah
   5. You have not received prior anti-CD19 therapy (a type of treatment such as Breyanzi, Yescarta)
   6. You have ONE of the following criteria:
      a. You are in second or greater bone marrow relapse (disease returns)
      b. You are currently in bone marrow relapse after having undergone allogeneic stem cell transplantation (SCT: donor cells are from another person)
      c. You have not achieved minimal residual disease (MRD) negative complete remission after two cycles of a standard chemotherapy regimen (you have primary refractory disease)
      d. You have not achieved complete remission after one cycle of standard chemotherapy for relapsed leukemia (chemorefractory relapsed leukemia)
      e. You have Philadelphia chromosome positive (Ph+; type of gene mutation) acute lymphoblastic leukemia and meet ONE of the following:
         i. You had a trial of 2 or more tyrosine kinase inhibitors (TKIs)
         ii. You are unable to tolerate TKI therapy
         iii. You have a contraindication (harmful for) to TKI therapy
      f. You are not eligible for allogeneic stem cell transplantation (SCT)

*(Criteria continued on next page)*

CONTINUED ON NEXT PAGE
TISAGENLECLEUCEL (NSA)

GUIDELINES FOR USE (CONTINUED)

C. If you have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma, or DLBCL arising from follicular lymphoma [transformed follicular lymphoma], approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by a Kymriah-certified hematologist (blood specialist) or oncologist (tumor/cancer doctor)
   3. Kymriah will be administered at a treatment center that is certified to administer Kymriah
   4. You have not had a previous trial of Kymriah
   5. You have not received prior anti-CD19 therapy (a type of treatment such as Breyanzi, Yescarta)
   6. You are refractory (disease did not respond to treatment) or have had disease progression (gotten worse) after two or more lines of systemic therapy including rituximab and an anthracycline
   7. You had disease progression or relapsed (disease worsens or returns) after autologous hematopoietic stem cell transplantation (ASCT) OR you are not eligible for ASCT

D. If you have relapsed or refractory follicular lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by a Kymriah-certified hematologist (blood specialist) or oncologist (tumor/cancer doctor)
   3. Kymriah will be administered at a treatment center that is certified to administer Kymriah
   4. You have not had a previous trial of Kymriah
   5. You have not received prior anti-CD19 therapy (a type of treatment such as Breyanzi, Yescarta)
   6. You previously received two or more lines of systemic therapy

Commercial Effective: 10/01/22
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TISOTUMAB VEDOTIN-TFTV (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TISOTUMAB VEDOTIN-TFTV</td>
<td>TIVDAK</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named TISOTUMAB VEDOTIN-TFTV (Tivdak) requires the following rule(s) be met for approval:
A. You have recurrent or metastatic (cancer that has returned or spread to other parts of the body) cervical cancer
B. You are 18 years of age or older
C. You had disease progression on or after chemotherapy (drugs used to treat cancer)

Commercial Effective: 01/01/22
TOCILIZUMAB – IV (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOCILIZUMAB - IV</td>
<td>ACTEMRA - IV</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named TOCILIZUMAB - IV (Actemra - IV) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Giant cell arteritis (GCA: a type of inflammatory condition)
   3. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)
   5. Schimeric antigen receptor (CAR) T cell-induced severe or life-threatening Cytokine Release Syndrome (CRS: inflammatory response that can be triggered by a variety of factors such as infections and certain drugs)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, sulfasalazine
   4. You had a trial of or contraindication (harmful for) to the preferred medication: Humira

C. **If you have giant cell arteritis, approval also requires:**
   1. You are 18 years of age or older

D. **If you have polyarticular juvenile idiopathic arthritis, approval also requires:**
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, sulfasalazine
   4. You had a trial of or contraindication (harmful for) to the preferred medication: Humira

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
TOCILIZUMAB – IV (NSA)

INITIAL CRITERIA (CONTINUED)

E. If you have systemic juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune
      system doctor), dermatologist (skin doctor), or immunologist (immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying
      antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine,
      sulfasalazine

F. For the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-
   threatening cytokine release syndrome (CRS), approval also requires:
   1. You are 2 years of age or older

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance
program) will not be considered when evaluating the medical condition or prior prescription
history for drugs that require prior authorization.

RENEWAL CRITERIA

Our guideline named TOCILIZUMAB - IV (Actemra - IV) requires the following rule(s) be met
for renewal:
A. You have ONE of the following diagnoses:
   1. Giant cell arteritis (GCA: a type of inflammatory condition)
   2. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   3. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis or polyarticular juvenile
   idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count
      or swollen joint count while on therapy

C. If you have systemic juvenile idiopathic arthritis, renewal also requires ONE of the
   following:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count
      or swollen joint count while on therapy
   2. You have shown maintained or improved systemic inflammatory disease (such as
      fevers, pain, rash, arthritis)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named TRABECTEDIN (Yondelis) requires the following rule(s) be met for approval:
A. You have unresectable or metastatic liposarcoma or leiomyosarcoma (cancer of the fat cells or muscles that cannot be removed with surgery or has spread to other parts of body).
B. You have previously received therapy with an anthracycline-containing regimen such as doxorubicin.

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named TRASTUZUMAB-ANNS (Kanjinti) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Breast cancer
   2. Metastatic breast cancer (breast cancer that has spread to other parts of body)
   3. Metastatic gastric or gastroesophageal junction adenocarcinoma (cancer in the stomach and/or throat that has spread to other parts of the body)
B. If you have breast cancer, approval also requires:
   1. You have HER2-positive tumor (type of protein found in breast cancer) as detected by a Food and Drug Administration (FDA)-approved test
   2. The request is for adjuvant (add-on) therapy
   3. You meet ONE of the following:
      a. The requested medication is being used as part of a treatment plan that includes doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
      b. The requested medication is being used as part of a treatment plan with docetaxel and carboplatin
      c. The requested medication is being used as a single agent following multi-modality anthracycline based therapy (therapy using a class of cancer drug that combines more than one method of treatment) such as daunorubicin, doxorubicin, idarubicin, epirubicin, or valrubicin
C. If you have metastatic breast cancer, approval also requires:
   1. You have HER2-positive tumor (type of protein found in breast cancer) as detected by a Food and Drug Administration (FDA)-approved test
   2. You meet ONE of the following:
      a. The requested medication is being used in combination with paclitaxel for first-line treatment
      b. The requested medication is being used as a single agent if you have previously received ONE or more chemotherapy regimens for metastatic disease (disease has spread to other parts of the body)

(Criteria continued on next page)
D. If you have metastatic gastric or gastroesophageal junction adenocarcinoma (cancer in the stomach and/or throat that has spread to other parts of the body), approval also requires:
   1. You have HER2-positive tumor (you have a type of protein present in breast cancer) as detected by a Food and Drug Administration (FDA)-approved test
   2. The requested medication is being used in combination with cisplatin and capecitabine or 5-fluorouracil
   3. You have not received prior treatment for metastatic disease (disease has spread to other parts of the body)

Commercial Effective: 04/10/21
GUIDELINES FOR USE

Our guideline named TRASTUZUMAB-DKST (Ogivri) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Breast cancer
   2. Metastatic breast cancer (cancer has spread to other parts of the body)
   3. Metastatic gastric or gastroesophageal junction adenocarcinoma (type of cancer in the stomach and/or lower throat that has spread to other parts of the body)

B. If you have breast cancer, approval also requires:
   1. You have HER2-positive tumor (type of protein found in breast cancer) as detected by a Food and Drug Administration (FDA)-approved test
   2. The request is for adjuvant (add-on) therapy
   3. You meet ONE of the following:
      a. The requested medication is being used as part of a treatment plan that includes doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
      b. The requested medication is being used as part of a treatment plan with docetaxel and carboplatin
      c. The requested medication is being used as a single agent following multi-modality anthracycline based therapy (therapy using a class of cancer drug that combines more than one method of treatment) such as daunorubicin, doxorubicin, idarubicin, epirubicin, or valrubicin

C. If you have metastatic breast cancer, approval also requires:
   1. You have HER2-positive metastatic breast cancer (you have a type of protein found in breast cancer) as detected by a Food and Drug Administration (FDA)-approved test
   2. You meet ONE of the following:
      a. The requested medication is being used in combination with paclitaxel for first-line treatment
      b. The requested medication is being used as a single agent if you have previously received ONE or more chemotherapy regimens for metastatic disease (disease has spread to other parts of the body)

D. If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:
   1. You have HER2-positive metastatic cancer (you have a type of protein and the cancer has spread to other parts of the body) as detected by a Food and Drug Administration-(FDA)-approved test
   2. The requested medication is being used in combination with cisplatin and capecitabine or 5-fluorouracil
   3. You have not received prior treatment for metastatic disease (disease has spread to other parts of the body)
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

Commercial Effective: 04/10/21
TRASTUZUMAB-DTTB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRASTUZUMAB-DTTB</td>
<td>ONTRUZANT</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named TRASTUZUMAB-DTTB (Ontruzant) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Breast cancer
   2. Metastatic breast cancer (breast cancer that has spread to other parts of the body)
   3. Metastatic gastric or gastroesophageal junction adenocarcinoma (cancer in the stomach and/or throat that has spread to other parts of the body)

B. If you have breast cancer, approval also requires:
   1. The request is for adjuvant (add-on) therapy
   2. You have HER2-positive tumor (type of protein present in breast cancer) as detected by a Food and Drug Administration (FDA)-approved test
   3. You meet ONE of the following:
      a. The requested medication is being used as part of a treatment plan that contains doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
      b. The requested medication is being used as part of a treatment plan with docetaxel and carboplatin
      c. The requested medication is being used as a single agent following multi-modality anthracycline based therapy (therapy using a class of cancer drug that combines more than one method of treatment) such as daunorubicin, doxorubicin, idarubicin, epirubicin, or valrubicin
   4. You previously tried ONE of the following preferred agents unless there is a medical reason why you cannot (contraindication): Kanjinti, Trazimera, or Ogivri

C. If you have metastatic breast cancer, approval also requires:
   3. You have HER2-positive tumor (type of protein present in breast cancer) as detected by a Food and Drug Administration-approved test
   4. You meet ONE of the following:
      a. The requested medication is being used in combination with paclitaxel for first-line treatment
      b. The requested medication is being used as a single agent if you have previously received ONE or more chemotherapy regimens for metastatic disease (disease has spread to other parts of the body)
   5. You previously tried ONE of the following preferred agents unless there is a medical reason why you cannot (contraindication): Kanjinti, Trazimera, or Ogivri

(Criteria continued on next page)
TRASTUZUMAB-DTTB (NSA)

GUIDELINES FOR USE (CONTINUED)

D. If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:
   1. You have HER2-positive tumor (type of protein present in stomach cancer) as detected by a Food and Drug Administration-approved test
   2. The requested medication is being used in combination with cisplatin and capecitabine or 5-fluorouracil
   3. You have not received prior treatment for metastatic disease (disease has spread to other parts of the body)

Commercial Effective: 04/10/21
GUIDELINES FOR USE

Our guideline named TRASTUZUMAB/TRASTUZUMAB-HYALURONIDASE (Herceptin, Herceptin Hylecta) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic breast cancer (breast cancer that has spread to other parts of the body)
   2. Breast cancer
   3. Metastatic gastric or gastroesophageal junction adenocarcinoma (cancer in the stomach and/or lower throat that has spread to other parts of the body)

B. If you have metastatic breast cancer, approval also requires:
   1. You have HER2-positive tumor (type of protein found in breast cancer) as detected by a Food and Drug Administration (FDA)-approved test
   2. You meet ONE of the following:
      a. The requested medication is being used in combination with paclitaxel for first-line treatment
      b. The requested medication is being used as a single agent if you have previously tried chemotherapy for metastatic disease (disease has spread to other areas of body)
   3. If you are requesting Herceptin Hylecta, you must be 18 years of age or older
   4. You previously tried ONE of the following preferred agents unless there is a medical reason why you cannot (contraindication): Kanjinti, Trazimera, or Ogivri

C. If you have breast cancer, approval also requires:
   1. The request is for adjuvant therapy (add-on therapy to main treatment)
   2. You have HER2-overexpressing (HER2-positive: a type of breast cancer gene) tumor as detected by a Food and Drug Administration (FDA)-approved test
   3. You meet ONE of the following:
      a. The requested medication is being used as part of a treatment plan that includes doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
      b. The requested medication is being used as part of a treatment plan with docetaxel and carboplatin
      c. The requested medication is being used as a single agent following multi-modality anthracycline based therapy (therapy using a class of cancer drug that combines more than one method of treatment) such as daunorubicin, doxorubicin, idarubicin, epirubicin, or valrubicin

(Criteria continued on next page)
TRASTUZUMAB/TRASTUZUMAB-HYALURONIDASE (NSA)

GUIDELINES FOR USE (CONTINUED)

4. You previously tried ONE of the following preferred agents unless there is a medical reason why you cannot (contraindication): Kanjinti, Trazimera, or Ogivri

5. If you are requesting Herceptin Hylecta, you must be 18 years of age or older

D. If you have metastatic gastric or gastroesophageal junction adenocarcinoma (stomach-throat cancer that has spread), approval also requires:
   1. The request is for Herceptin (not Herceptin Hylecta)
   2. You have HER2-overexpressing (HER2-positive: a type of breast cancer gene) metastatic breast cancer as detected by a Food and Drug Administration (FDA)-approved test
   3. The requested medication is being used in combination with cisplatin and capecitabine or 5-fluorouracil
   4. You have not received prior treatment for metastatic disease (disease has spread to other parts of the body)

Commercial Effective: 04/10/21
Our guideline named TRASTUZUMAB-PKRB (Herzuma) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Breast cancer
   2. Metastatic breast cancer (breast cancer that has spread to other parts of the body)
   3. Metastatic gastric or gastroesophageal junction adenocarcinoma (cancer in the stomach and/or lower throat that has spread to other parts of the body)

B. **If you have breast cancer, approval also requires:**
   1. You have HER2-positive tumor (type of protein found in breast cancer) as detected by a Food and Drug Administration (FDA)-approved test
   2. The request is for adjuvant (add-on) treatment
   3. You meet ONE of the following:
      a. The requested medication is being used as part of a treatment plan that includes doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
      b. The requested medication is being used as part of a treatment plan with docetaxel and carboplatin
      c. The requested medication is being used as a single agent following multi-modality anthracycline based therapy (therapy using a class of cancer drug that combines more than one method of treatment) such as daunorubicin, doxorubicin, idarubicin, epirubicin, or valrubicin
   4. You previously tried ONE of the following preferred agents unless there is a medical reason why you cannot (contraindication): Kanjinti, Trazimera, or Ogivri

C. **If you have metastatic breast cancer, approval also requires:**
   1. You have HER2-positive tumor (type of protein found in breast cancer) as detected by a Food and Drug Administration (FDA)-approved test
   2. You meet ONE of the following:
      a. The requested medication is being used in combination with paclitaxel for first-line treatment
      b. The requested medication is being used as a single agent if you have previously received ONE or more chemotherapy regimens for metastatic disease (disease has spread to other parts of the body)
   3. You previously tried ONE of the following preferred agents unless there is a medical reason why you cannot (contraindication): Kanjinti, Trazimera, or Ogivri

*(Criteria continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

D. If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:
   1. You have HER2-positive tumor (type of protein found in stomach cancer) as detected by a Food and Drug Administration (FDA)-approved test
   2. The requested medication is being used in combination with cisplatin and capecitabine or 5-fluorouracil
   3. You have not received prior treatment for metastatic disease (disease has spread to other parts of the body)

Commercial Effective: 04/10/21
GUIDELINES FOR USE

Our guideline named TRASTUZUMAB-QYYP (Trazimera) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Breast cancer
   2. Metastatic breast cancer (breast cancer that has spread to other parts of the body)
   3. Metastatic gastric or gastroesophageal junction adenocarcinoma (cancer in the stomach and/or throat that has spread to other parts of the body)

B. If you have breast cancer, approval also requires:
   1. The request is for adjuvant (add-on) therapy
   2. You have HER2-positive tumor (type of protein present in breast cancer) as detected by a Food and Drug Administration-approved test
   3. You meet ONE of the following:
      a. The requested medication is being used as part of a treatment plan that contains doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
      b. The requested medication is being used as part of a treatment plan with docetaxel and carboplatin
      c. The requested medication is being used as a single agent following multi-modality anthracycline based therapy (therapy using a class of cancer drug that combines more than one method of treatment) such as daunorubicin, doxorubicin, idarubicin, epirubicin, or valrubicin

C. If you have metastatic breast cancer, approval also requires:
   1. You have HER2-positive tumor (type of protein present in breast cancer) as detected by a Food and Drug Administration-approved test
   2. You meet ONE of the following:
      a. The requested medication is being used in combination with paclitaxel for first-line treatment
      b. The requested medication is being used as a single agent if you have previously received ONE or more chemotherapy regimens for metastatic disease (disease has spread to other parts of the body)

(Criteria continued on next page)
TRASTUZUMAB-QYYP (NSA)

GUIDELINES FOR USE (CONTINUED)

D. If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:
   1. You have HER2-positive tumor (type of protein present in stomach cancer) as detected by a Food and Drug Administration-approved test
   2. The requested medication is being used in combination with cisplatin and capecitabine or 5-fluorouracil
   3. You have not received prior treatment for metastatic disease (disease has spread to other parts of the body)

Commercial Effective: 04/10/21
GUIDELINES FOR USE

Our guideline named TRILACICLIB (Cosela) requires the following rule(s) be met for approval:

A. You have extensive-stage small cell lung cancer
B. You are 18 years of age or older
C. Cosela is being used to decrease the incidence of chemotherapy-induced myelosuppression (decreased bone marrow activity causing fewer red blood cells, white blood cells, and platelets)
D. Cosela will be given prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

Commercial Effective: 07/01/21
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named USTEKINUMAB (Stelara) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (PsA: a type of skin and joint condition)
   2. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   4. Moderate to severe active ulcerative colitis (UC: a type of digestive disorder)

B. If you have moderate to severe plaque psoriasis OR moderate to severe plaque psoriasis
   with co-existent psoriatic arthritis, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions
      (rashes) affecting the hands, feet, genital area, or face
   4. You have tried or have a contraindication (harmful for) to ONE or more forms of standard
      therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B),
      topical corticosteroids, calcipotriene, acitretin, methotrexate, or cyclosporine

C. If you have psoriatic arthritis without co-existent plaque psoriasis, approval also
   requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system
      doctor) OR dermatologist (type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying
      antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or
      sulfasalazine

D. If you have moderate to severe Crohn's disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats
      digestive conditions)
   3. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as
      corticosteroids (budesonide, methylprednisolone), azathioprine, mercaptopurine,
      methotrexate, or mesalamine

(Initial criteria continued on next page)
E. If you have moderate to severe active ulcerative colitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

RENEWAL CRITERIA

Our guideline named USTEKINUMAB (Stelara) requires the following rules be met for renewal:
A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (PsA: a type of skin and joint condition)
   2. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
B. If you have psoriatic arthritis without co-existent plaque psoriasis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
C. If you have moderate to severe plaque psoriasis OR moderate to severe plaque psoriasis with co-existent psoriatic arthritis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

Commercial Effective: 08/29/22
VEDOLIZUMAB (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEDOLIZUMAB</td>
<td>ENTYVIO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named VEDOLIZUMAB (Entyvio) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe Crohn's disease (CD: type of bowel disorder)
   2. Moderate to severe ulcerative colitis (UC: type of digestive disorder)

B. You are 18 years of age or older

C. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

D. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

E. If you have moderate to severe Crohn's disease, approval also requires:
   1. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Skyrizi, Stelara

F. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You have tried or have a contraindication (harmful for) to TWO of the following preferred immunomodulators: Humira, Stelara, Xeljanz/XR, Rinvoq

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

Our guideline named VEDOLIZUMAB (Entyvio) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe Crohn's disease (CD: type of bowel disorder)
   2. Moderate to severe ulcerative colitis (UC: type of digestive disorder)

Commercial Effective: 09/01/22
Our guideline named VESTRONIDASE ALFA-VJBK (Mepsevii) requires the following rule(s) be met for approval:

A. You have Mucopolysaccharidosis VII (MPS VII, Sly syndrome: genetic metabolism disorder that does not allow the body to break down a certain chemical)

B. The requested medication is prescribed by or given in consultation with a physician specializing in genetic or metabolic disorders

C. You have a documented urinary GAG (glycosaminoglycan: type of chemical that builds up when your body cannot break it down) level of greater than three times the upper level of normal based on the laboratory test

D. Your diagnosis of Mucopolysaccharidosis VII is confirmed by documentation of beta-glucuronidase enzyme activity deficiency (you don't have a protein that breaks down a chemical) or genetic testing

E. You have at least ONE of the following clinical signs of Mucopolysaccharidosis VII:
   1. Enlarged liver and spleen
   2. Joint limitations
   3. Airway obstructions or pulmonary (lung/breathing) dysfunction

F. You have not undergone successful bone marrow or stem cell treatment for Mucopolysaccharidosis VII

G. You have limitation in mobility, but you still have ambulatory (walking) capacity for the six-minute walk test (6MWT) to be measured and evaluated

Our guideline named VESTRONIDASE ALFA-VJBK (Mepsevii) requires the following rule(s) be met for renewal:

A. You have Mucopolysaccharidosis VII (MPS VII, Sly syndrome: genetic metabolism disorder that does not allow the body to break down a certain chemical)

B. You have improved, maintained, or demonstrated less than expected decline in ambulatory (walking) ability based on a six-minute walk test compared to baseline

Commercial Effective: 07/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>VILTOLARSEN (NSA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic</td>
</tr>
<tr>
<td>VILTOLARSEN</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named VILTOLARSEN (Viltepso) requires the following rule(s) be met for approval:

A. You have Duchenne muscular dystrophy (DMD: inherited disorder where your muscles get weaker over time)
B. You have documented genetic testing that confirms you have a mutation (change in DNA that make up your gene) in the DMD gene that is responsive to exon 53 skipping (a process that allows a protein to still function with sections of faulty genetic code)
C. Therapy is prescribed by or given in consultation with a neurologist (brain, spinal cord, nervous system doctor) specializing in treatment of Duchenne muscular dystrophy at a DMD treatment center
D. You are ambulatory (able to move and walk)
E. You are currently receiving treatment with corticosteroids (such as prednisone or prednisolone) unless there is a medical reason why you cannot (contraindication)

RENEWAL CRITERIA

Our guideline named VILTOLARSEN (Viltepso) requires ONE of the following rule(s) be met for renewal:

A. You have maintained or demonstrated less than expected decline in ambulatory ability (ability to move and walk) based on muscle function assessments (such as the 6-minute walk test)
B. You have maintained or demonstrated less than expected decline in other muscle function (such as pulmonary [lung] or cardiac [heart] function)

Commercial Effective: 01/01/21
VINCRISTINE LIPOSOMAL (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>VINCRISTINE SULFATE LIPOSOMAL</td>
<td>MARQIBO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **VINCRISTINE SULFATE LIPOSOMAL (Marqibo)** requires the following rule(s) be met for approval:

A. You have Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (a type of cancer that does not have a certain gene mutation)

B. You meet ONE of the following criteria:
   1. You have experienced a relapse (disease returns) two or more times
   2. You have experienced disease progression after treatment with two or more anti-leukemia therapies

Commercial Effective: 07/01/20
Our guideline named **VORETIGENE NEPARVOVEC-RZYL (Luxturna)** requires the following rule(s) be met for approval:

A. You have confirmed biallelic RPE65 mutation-associated retinal dystrophy (loss of vision in one or both eyes due to a gene mutation)

B. You are 3 years of age or older

C. Your diagnosis of biallelic RPE65 (type of gene) mutation-associated retinal dystrophy is confirmed by documentation of genetic testing

D. The requested medication is prescribed by or given in consultation with an ophthalmologist (eye doctor) or retinal specialist

E. You have a visual acuity of 20/60 or worse or a visual field less than 20 degrees in any meridian in both eyes

F. You have enough retinal cells as demonstrated by sufficient retinal thickness

G. You do **NOT** have pre-existing eye conditions that may lead to blindness independently of RPE65 (type of gene)-mutation associated retinal dystrophy. Pre-existing eye conditions may include leukemia (type of cancer) with Central Nervous System/optic nerve involvement, macular edema (fluid buildup in the eye) or cytomegalovirus retinitis (inflammation of the retina of the eye that can lead to blindness)

H. You have **NOT** previously received gene therapy (including Luxturna) for the treatment of vision loss

I. The procedure and administration of Luxturna will be completed at a designated specialty Luxturna treatment center
VUTRISIRAN (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>VUTRISIRAN SODIUM</td>
<td>AMVUTTRA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named VUTRISIRAN (Amvuttra) requires the following rule(s) be met for approval:
A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve damage/pain)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor), cardiologist (a type of heart doctor), hATTR specialist, or medical geneticist (doctor who treats gene disorders)
D. You have a documented diagnosis of hereditary TTR amyloidosis (hATTR) as confirmed by ONE of the following:
   1. Biopsy (removal of cells from the body for examination) of tissue/organ to confirm amyloid (type of abnormal protein) presence AND chemical typing to confirm the presence of TTR (transthyretin) protein
   2. DNA genetic sequencing (type of lab test) to confirm hATTR mutation
E. You have familial amyloidotic polyneuropathy (FAP) stage 1 or 2 OR up to polyneuropathy disability (PND) stage IIIb polyneuropathy (widespread nerve pain/damage)

RENEWAL CRITERIA

Our guideline named VUTRISIRAN (Amvuttra) requires the following rule(s) be met for renewal:
A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve damage/pain)
B. You have not progressed to familial amyloidotic polyneuropathy (FAP) stage 3 OR polyneuropathy disability (PND) stage IV polyneuropathy (widespread nerve pain/damage) as shown by functional decline (such as being wheelchair-bound or bedridden)

Commercial Effective: 07/18/22
ZIV-AFLIBERCEPT (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIV-AFLIBERCEPT</td>
<td>ZALTRAP</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **ZIV-AFLIBERCEPT** requires the following rule(s) be met for approval:

A. You have metastatic colorectal cancer (cancer has spread in body)
B. You previously had a trial of an oxaliplatin-containing regimen (such as FOLFOX)
C. You will be using the requested medication with fluorouracil, leucovorin, irinotecan (FOLFIRI) at the same time

Commercial Effective: 07/01/20
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INDEX

A

ABATACEPT/MALTOSE - IV (NSA) .................. 3
ABECMA (NSA) ..................................118
ABOBOTULINUM TOXIN A (NSA) ................ 44
ABRAXANE (NSA) ..................................188
ACTEMRA - IV (NSA) ...............................259
ADAKVEO (NSA) ......................................68
ADCCRTIS (NSA) .................................... 49
ADO-TRASTUZUMAB EMTANSINE (NSA) .......  6
ADUCANUMAB-AVWA (NSA) .....................  7
ADUHELM (NSA) .....................................  7
AFAMELANOTIDE (NSA) ............................  9
AFLIBERCEPT (NSA) ..................................10
AGALSIDASE BETA (NSA) .............................12
AMILTuzumab (NSA) ..................................14
ALGLUCOSIDASE ALFA (NSA) .................... 15
ALIMTA (NSA) .........................................203
ALIQOPA ............................................... 67
ALYMSYS (NSA) ....................................... 39
AMivantamab-Vmjw (NSA) ..........................16
AMONDYS-45 (NSA) ....................................61
ANVUTTRA (NSA) ......................................282
ANIFROLUMAB-FNIA (NSA) ....................... 17
ARESTIN (NSA) ........................................ 163
ARZERRA (NSA) ........................................ 182
ASCENV ............................................... 119
ASPARGINASE (ERWINIA CHRYSAN) (NSA) .... 18
ASPARLAS (NSA) ....................................... 57
ATEZOLIZUMAB (NSA) ...............................19
AVALGUCOSIDASE ALFA-NGPT (NSA) ......... 22
AVASTIN (NSA) .........................................32, 35
AVELUMAB (NSA) ...................................... 23
AVSOLA (NSA) ..........................................133
AXICABTAGENE CILOLEUCEL (NSA) .......... 24
AZEDRA (NSA) ..........................................142

B

BAVENCIO (NSA) ........................................ 23
BELANTAMAB MAFODOTIN-BLMF (NSA) ....... 26
BELEODAQ (NSA) .......................................29
BELIMUMAB (IV) (NSA) ............................. 27
BELINSTAT (NSA) .......................................29
BENLYSTA (IV) (NSA) ............................... 27
BENRALIZUMAB (NSA) .............................. 30
BEOVU (NSA) .......................................... 53
BESPONSA (NSA) ......................................141

BEVACIZUMAB (NSA) .................................32, 35
BEVACIZUMAB-BVZR (NSA) ....................... 37
BEVACIZUMAB-MALY (NSA) ....................... 39
BIVIGAM (COMMERCIAL, NSA) .................119
BLENREP (NSA) .........................................26
BLINATUMOMAB (NSA) .............................. 41
BLINCYTO (NSA) .........................................41
BORTezOMIB (NSA) .....................................43
BOTOX (NSA) ............................................. 44
BOTOX COSMETIC (NSA) ............................ 44
BRENTUXIMAB VEDOTIN (NSA) ................... 49
BREXUCABTAGENE AUTOLEUCEL (NSA) ....... 51
BREYANZI (NSA) .........................................151
BRINEURA (NSA) ..........................................63
BROLUCIZUMAB-DLL (NSA) ....................... 53
BREXUCABTAGENE AUTOLEUCEL (NSA) ....... 51
BREXUCABTAGENE AUTOLEUCEL (NSA) ....... 51
BUROSUMAB-TWZA (NSA) .......................... 55
BYOOVIZ (NSA) .........................................216

C

CALASPARGASE PEGOL-MKNL (NSA) .............  57
CAMCEVI (NSA) .........................................150
CANAKINUMAB/PF (NSA) ..........................  58
CARFILZOMIB (NSA) ....................................60
CARIMUNE NF NANO FILTERED (COMMERCIAL, NSA) ........................................ 119
CARVKYTI (NSA) ..........................................66
CASIMEREN (NSA) ....................................... 61
CEMPLIMAB-RWLC (NSA) ...........................  62
CEREZyme (NSA) .........................................90
CELIPONASE ALFA (NSA) ...........................  63
CETUXIMAB (NSA) ......................................  64
CILTACABTAGENE AUTOLEUCEL (NSA) .........  66
CINQAIR (NSA) ..........................................221
COPANLISIB ..............................................  67
COSELA (NSA) .......................................... 274
CRIZANLIZUMAB-TMCA (NSA) ...................... 68
CRYSVITA (NSA) ......................................... 55
CUTAQUIG ............................................... 119
CUVITRU ............................................... 119
CYRAMZA (NSA) .........................................212

D

DANYELZA (NSA) .......................................171
DARATUMUMAB ...........................................69
DARATUMUMAB-HYALURONIDASE-FIHJ (NSA) .... 70

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
STANDARD NON-SELF-ADMINISTERED DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

G

GAMASTAN S-D (COMMERCIAL, NSA) ........................................ 119
GAMIFANT (NSA) ................................................................... 88
GAMMAGARD LIQUID (COMMERCIAL, NSA) ...................... 119
GAMMAGARD S-D (COMMERCIAL, NSA) ......................... 119
GAMMAKER (COMMERCIAL, NSA) ........................................ 119
GAMMAPLEX (COMMERCIAL, NSA) ...................................... 119
GAMUNEX-C (COMMERCIAL, NSA) ..................................... 119
GAZYVA (NSA) ...................................................................... 180
GEL-ONE (NSA) ................................................................. 114
GEMTUZUMAB OZOGAMICIN (NSA) ................................. 104
GENVISC 850 (NSA) ........................................................... 114
GIVLAARI (NSA) ................................................................. 105
GIVOSIRAN (NSA) ............................................................... 105
GOLIMUB - IV (NSA) ............................................................. 106
GOLDIORSN (NSA) ............................................................... 109
GONADOTROPIN RELEASING HORMONE (GNRH) AGONIST (NSA) .................................................. 110
GOSERELIN ACETATE (NSA) ................................................ 110

H

HALAVEN (NSA) .................................................................. 94
HERCEPTIN (NSA) ................................................................ 268
HERCEPTIN HYLECTA (NSA) ................................................. 268
HERZUMA (NSA) ................................................................. 270
HISTRELIN ACETATE (NSA) .................................................. 110
HIZENTRA (COMMERCIAL, NSA) ....................................... 119
HYALGAN (NSA) .................................................................. 114
HYALURONATE SODIUM (NSA) ........................................... 114
HYALURONATE SODIUM, STABILIZED (NSA) ................. 114
HYALURONATE, MODIFIED, NON-CROSSLINK (NSA) .... 114
HYDROXY-PROGESTERONE CAPROATE (GENERIC FOR DELALUTIN) (NSA) .............................................. 116
HYDROXYPROGESTERONE CAPROATE (NSA) .................. 116
HYLAN G-F 20 (NSA) ......................................................... 114
HYMOVIS (NSA) ................................................................. 114
HYQVIA (COMMERCIAL, NSA) ........................................... 119

I

IBALIZUMAB-UIYK (NSA) ..................................................... 117
IDECABTAGENE VICLEUCEL (NSA) ..................................... 118

F

FABRAZYME (NSA) ............................................................... 12
FAM-TRASTUZUMAB DERUXTECAN-NXKI (NSA) ............ 100
FARICIMAB-SVOA (NSA) ...................................................... 102
FASENRA (NSA) ................................................................. 30

DARZALEX (NSA) ................................................................. 69
DARZALEX FASPRO (NSA) .................................................. 70
DAUNORUBICIN/CYTARABINE LIPOsome (NSA) ............. 72
DENOSUMAB-PROLIA (NSA) .............................................. 73
DENOSUMAB-XGEVA (NSA) .............................................. 75
DIFELIKEFALIN ACETATE (NSA) ....................................... 76
DINUTUXIMAB (NSA) .......................................................... 77
DOSTARLIMAB-GXLY (NSA) .............................................. 78
DSUVIA (NSA) ..................................................................... 243
DUROLANE (NSA) ................................................................ 114
DURVALUMAB (NSA) .......................................................... 79
DYSPORT (NSA) ................................................................... 44

E

ECALLANTIDE (NSA) ........................................................... 80
ECULIZUMAB (NSA) ............................................................ 81
EDARAVONE (NSA) ............................................................. 84
EFGRATIGIMOD ALFA-FCAB (NSA) ................................. 85
ELEYSO (NSA) ..................................................................... 90
ELOSULFAE ALFA (NSA) .................................................... 86
ELOTUZUMAB (NSA) ........................................................... 87
ELZONRI (NSA) ................................................................... 246
EMAPALUMAB-LZSG (NSA) ............................................... 88
EMPLICITI (NSA) ............................................................... 87
ENFORTUMAB VEDOTIN-EJFV (NSA) ............................. 89
ENHERTU (NSA) .................................................................. 100
ENJAYMO (NSA) ................................................................. 244
ENTYVIO (NSA) ................................................................... 277

ENZYME REPLACEMENT THERAPY: GAUCHER
DISEASE (NSA) ................................................................. 90
EPOPROSTENOL SODIUM (GLYCINE) (NSA) ................. 91
EPOPROSTENOL SODIUM (NSA) ....................................... 91
EPTINEZUMAB-JJM (NSA) .................................................. 92
ERBITUX (NSA) .................................................................. 64
ERIBULIN MESYLATE (NSA) .............................................. 94
ERWINAZE (NSA) ............................................................... 98
ESKETAMINE (NSA) ............................................................. 95
ETEL-Calgetide (NSA) ........................................................ 97
ETEPLIRSEN (NSA) ............................................................ 98
EUFLEXXA (NSA) ............................................................... 114
EVENITY (NSA) ................................................................. 236
EVINACUMAB-DGNB ........................................................ 99
EVKEEZA .......................................................................... 99
EXONDYS 51 (NSA) ............................................................ 98
EYLEA (NSA) ..................................................................... 10

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/16/2022
## Standard Non-Self-Administered Drug Formulary

**Prior Authorization Guidelines**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>IG/G/Hyaluronidase, Recombinant (Commercial, NSA)</td>
<td>119</td>
</tr>
<tr>
<td>Ilaris (NSA)</td>
<td>58</td>
</tr>
<tr>
<td>I lumy (Commercial, NSA)</td>
<td>255</td>
</tr>
<tr>
<td>Imfinzi (NSA)</td>
<td>79</td>
</tr>
<tr>
<td>IgGlucerase (NSA)</td>
<td>90</td>
</tr>
<tr>
<td>Imlygic (NSA)</td>
<td>247</td>
</tr>
<tr>
<td>Immunoglobulin G(IgG)/Gly/IGA Ov50</td>
<td>119</td>
</tr>
<tr>
<td>Immunoglobulin G(IgG)-Hipp/Maltose</td>
<td>119</td>
</tr>
<tr>
<td>IMmunoglobulin G(IgG)-IFAS/Glycine</td>
<td>119</td>
</tr>
<tr>
<td>Immune Glob, Gam Caprylate (Commercial, NSA)</td>
<td>119</td>
</tr>
<tr>
<td>Immune Globulin (Human)-Klhw</td>
<td>119</td>
</tr>
<tr>
<td>Immune Globulin (Human)-Slra</td>
<td>119</td>
</tr>
<tr>
<td>Immune Globulin / Maltose (Commercial, NSA)</td>
<td>119</td>
</tr>
<tr>
<td>Immune Globulin Intravenous (Commercial, NSA)</td>
<td>119</td>
</tr>
<tr>
<td>Inclisiran Sodium (NSA)</td>
<td>122</td>
</tr>
<tr>
<td>Incobotulinum Toxin A (NSA)</td>
<td>44</td>
</tr>
<tr>
<td>Nebilizumab-Cdon (NSA)</td>
<td>124</td>
</tr>
<tr>
<td>Inflecta (NSA)</td>
<td>137</td>
</tr>
<tr>
<td>Infliximab (NSA)</td>
<td>125</td>
</tr>
<tr>
<td>Infliximab-Abda (NSA)</td>
<td>129</td>
</tr>
<tr>
<td>Infliximab-Axq (NSA)</td>
<td>133</td>
</tr>
<tr>
<td>Infliximab-DyYb (NSA)</td>
<td>137</td>
</tr>
<tr>
<td>Notuzumab Ozogamicin (NSA)</td>
<td>141</td>
</tr>
<tr>
<td>Obenguane-I 131 (NSA)</td>
<td>142</td>
</tr>
<tr>
<td>Pilumumab (NSA)</td>
<td>143</td>
</tr>
<tr>
<td>Irinotecan Liposomal (NSA)</td>
<td>146</td>
</tr>
<tr>
<td>Isatuximab-IRfC (NSA)</td>
<td>147</td>
</tr>
<tr>
<td>Istopax (NSA)</td>
<td>234</td>
</tr>
<tr>
<td>Ixabepilone (NSA)</td>
<td>148</td>
</tr>
<tr>
<td>Ixempra (NSA)</td>
<td>148</td>
</tr>
<tr>
<td>Jelmyto (NSA)</td>
<td>164</td>
</tr>
<tr>
<td>Jemperli (NSA)</td>
<td>78</td>
</tr>
<tr>
<td>KAdycyla (NSA)</td>
<td>6</td>
</tr>
<tr>
<td>Kalbitor (NSA)</td>
<td>80</td>
</tr>
<tr>
<td>Kanjinti (NSA)</td>
<td>262</td>
</tr>
<tr>
<td>Kanuma (NSA)</td>
<td>238</td>
</tr>
<tr>
<td>Keytruda (NSA)</td>
<td>197</td>
</tr>
<tr>
<td>Kimmtrak (NSA)</td>
<td>248</td>
</tr>
<tr>
<td>Korsuva (NSA)</td>
<td>76</td>
</tr>
<tr>
<td>Krystexxa (NSA)</td>
<td>196</td>
</tr>
<tr>
<td>Kymriah (NSA)</td>
<td>256</td>
</tr>
<tr>
<td>Kyprolis (NSA)</td>
<td>60</td>
</tr>
<tr>
<td>Lartruvo (NSA)</td>
<td>183</td>
</tr>
<tr>
<td>Lemptada (NSA)</td>
<td>14</td>
</tr>
<tr>
<td>Leqvio (NSA)</td>
<td>122</td>
</tr>
<tr>
<td>Leterminovir (NSA)</td>
<td>149</td>
</tr>
<tr>
<td>Leuprolide Acetate (NSA)</td>
<td>110</td>
</tr>
<tr>
<td>Leuprolide Mesylate (NSA)</td>
<td>150</td>
</tr>
<tr>
<td>Libtayo (NSA)</td>
<td>62</td>
</tr>
<tr>
<td>LisoCanogene Maraleucel (NSA)</td>
<td>151</td>
</tr>
<tr>
<td>Loncastuximab Tisirine-Lpyp (NSA)</td>
<td>152</td>
</tr>
<tr>
<td>Lu-177 Vipivotide Tetraxetan (NSA)</td>
<td>153</td>
</tr>
<tr>
<td>Luctenisc (NSA)</td>
<td>214</td>
</tr>
<tr>
<td>Lumisinor Sodium (NSA)</td>
<td>154</td>
</tr>
<tr>
<td>Lumizyme (NSA)</td>
<td>15</td>
</tr>
<tr>
<td>LumoXi (NSA)</td>
<td>168</td>
</tr>
<tr>
<td>Luponeta (NSA)</td>
<td>110</td>
</tr>
<tr>
<td>Lupron Depot (NSA)</td>
<td>110</td>
</tr>
<tr>
<td>Lupron Depot-Ped (NSA)</td>
<td>110</td>
</tr>
<tr>
<td>Lurbinectedin (NSA)</td>
<td>155</td>
</tr>
<tr>
<td>Luspatercept-amt (NSA)</td>
<td>156</td>
</tr>
<tr>
<td>Lutathera (NSA)</td>
<td>157</td>
</tr>
<tr>
<td>Lutetium Lu 177 Dotate (NSA)</td>
<td>157</td>
</tr>
<tr>
<td>Luxturna (NSA)</td>
<td>281</td>
</tr>
<tr>
<td>MAcugen (NSA)</td>
<td>195</td>
</tr>
<tr>
<td>Makena (NSA)</td>
<td>116</td>
</tr>
<tr>
<td>Marginza (NSA)</td>
<td>158</td>
</tr>
<tr>
<td>Marginuximab-Cmkb (NSA)</td>
<td>158</td>
</tr>
<tr>
<td>Marqibo (NSA)</td>
<td>280</td>
</tr>
<tr>
<td>Melphanal Flufenamide HCl (NSA)</td>
<td>159</td>
</tr>
<tr>
<td>Mepolizumab</td>
<td>160</td>
</tr>
<tr>
<td>Mepsevii (NSA)</td>
<td>278</td>
</tr>
<tr>
<td>Minocycline Hcl Microspheres (NSA)</td>
<td>163</td>
</tr>
<tr>
<td>Mitomycin (NSA)</td>
<td>164</td>
</tr>
<tr>
<td>Mitoxantrone Hcl (NSA)</td>
<td>165</td>
</tr>
<tr>
<td>Mogamulizumab-Kpc (NSA)</td>
<td>166</td>
</tr>
<tr>
<td>Mometasone Furoate (NSA)</td>
<td>167</td>
</tr>
<tr>
<td>Monjui (NSA)</td>
<td>245</td>
</tr>
<tr>
<td>Monovisc (NSA)</td>
<td>114</td>
</tr>
<tr>
<td>Moxetumomab Pasudotox-Tdfk (NSA)</td>
<td>168</td>
</tr>
<tr>
<td>Mozobil (NSA)</td>
<td>208</td>
</tr>
<tr>
<td>Mylotarg (NSA)</td>
<td>104</td>
</tr>
<tr>
<td>Myobloc (NSA)</td>
<td>44</td>
</tr>
<tr>
<td>Natalizumab (NSA)</td>
<td>169</td>
</tr>
<tr>
<td>Naxitamab-GqGk (NSA)</td>
<td>171</td>
</tr>
<tr>
<td>Necitumumab (NSA)</td>
<td>172</td>
</tr>
<tr>
<td>Nexviazyme (NSA)</td>
<td>22</td>
</tr>
</tbody>
</table>

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 9/16/2022  Page 286 of 289
Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnost, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB (NSA) ............................................. 173
NIVOLUMAB-RELATLIMAB-RMBW (NSA) .......... 178
NOVANTRONE (NSA) ....................................... 165
NPLATE (NSA) ............................................. 235
NUCALA .................................................. 160
NUSINERSEN (NSA) ...................................... 179

O
OBINUTUZUMAB (NSA) .................................. 180
OCRELIZUMAB (NSA) ................................... 181
OCREVUS (NSA) .......................................... 181
OCTAGAM (COMMERCIAL, NSA) ................. 119
OFATUMUMAB (NSA) .................................... 182
OGIVRI (NSA) ............................................ 264
OLARATUMAB (NSA) ..................................... 183
OMALIZUMAB ........................................... 184
ONABOTULINUM TOXIN A (NSA) .................. 184
ONASEMNOGENE ABEPARVOVEC-XIOI (NSA) . 187
ONCASPAR (NSA) ........................................ 18
ONIVYDE (NSA) .......................................... 146
ONPATTRO (NSA) .......................................... 194
ONTRUZANT (NSA) ...................................... 266
OPDIVO (NSA) ............................................ 173
OPDUALAG(NSA). ....................................... 178
ORENICA - IV (NSA) .................................... 3
ORTHOVISC (NSA) ....................................... 114
OXLUMO (NSA) .......................................... 154

P
PACLITAXEL PROTEIN-BOUND (NSA) .......... 188
PADCEV (NSA) ........................................ 89
PALIVIZUMAB (NSA) ................................... 189
PANITUMUMAB (NSA) .................................. 191
PANZYG (NSA) ........................................... 119
PARSABIV (NSA) ......................................... 97
PASIREOTIDE PAMOATE (NSA) .................... 192
PATISIRAN SODIUM, LIPID COMPLEX (NSA) . 194
PEGAPTANIB SODIUM (NSA) ......................... 195
PEGASPARAGASE (NSA) ................................ 18
PEGLOTICASE (NSA) ..................................... 196
PEMBROLIZUMAB (NSA) ................................ 197
PEMBCX (PEMBCX) (NSA) .......................... 203
PEMETREXED (PEMFEXY) (NSA) .................. 203
PEMETREXED DISODIUM (NSA) .................... 203
PEMETREXED DITROMETHAMINE (NSA) ....... 205
PEMFEXY (NSA) ......................................... 203
PEPAKTOE (NSA) ....................................... 159
PERJETA (NSA) .......................................... 206
PERTUZUMAB (NSA) .................................. 206
PERTUZUMAB-TRASTUZUMAB-HY-ZXXF (NSA). 207
PHESGO (NSA) .......................................... 207
PHOTOFIRIN (NSA) ..................................... 210
PLERIXAFOR (NSA) ..................................... 208
PLUVICTO (NSA) ........................................ 153
POLATUZUMAB VEDOTIN-PIIQ (NSA) .......... 209
POLIVY (NSA) ........................................... 209
PORFIMER SODIUM (NSA) ........................... 210
PORTRAZZA (NSA) ..................................... 172
POTELIGEO (NSA) ...................................... 166
PRLATREXATE (NSA) .................................... 211
PREVYMIS (NSA) ....................................... 149
PRIVIGEN (COMMERCIAL, NSA) ................. 119
PROBUPHINE (NSA) .................................... 54
PROLIA (NSA) .......................................... 73

R
RADICAVA (NSA) ........................................ 84
RAMUCIRUMAB (NSA) .................................. 212
RANIBIZUMAB (LUCENTIS) (NSA) ............... 214
RANIBIZUMAB (SUSVIMO) (NSA) ................. 217
RANIBIZUMAB/INIT FILL NEEDLE (NSA) ....... 217
RANIBIZUMAB-NUNA (NSA) ......................... 216
RAVULIZUMAB-CWVZ (NSA) ....................... 218
REBLOZYL (NSA) ....................................... 156
REMICADE (NSA) ...................................... 125
RENFLEXIS (NSA) ....................................... 129
RESLIZUMAB (NSA) .................................... 221
RIABNI (NSA) ........................................... 229
RIMABOTULINUM TOXIN B (NSA) ............... 44
RISANKIZUMAB-RZA .................................. 223
RITUXAN (NSA) ......................................... 225
RITUXAN HYCELA (NSA) ............................ 231
RITUXIMAB (NSA) ...................................... 225
RITUXIMAB/HYALURONIDASE, HUMAN - SQ (NSA). 231
RITUXIMAB-ABB (NSA) ................................ 227
RITUXIMAB-ARR (NSA) ................................ 229
RITUXIMAB-PVVR (NSA) ............................. 232
ROMIDEPSIN (NSA) .................................... 234
ROMIPLOSTIM (NSA) ................................... 235
ROMOSOZUMAB-AQQG (NSA) ..................... 236
RUXIENOE (NSA) ....................................... 232
RYBREVANT (NSA) ..................................... 16

S
SACITUZUMAB GOVITECAN-HZIY (NSA) ........ 237
SAPHNELO (NSA) ....................................... 17
SARCISIA (NSA) ........................................ 147
SCENESSE (NSA) ....................................... 9
SEBELIPASE ALFA (NSA) ............................ 238
SELEXIPAG ............................................. 239
SIGNIFOR LAR (NSA) .................................. 192
SILTUXIMAB (NSA) .................................... 240
SIMPOLI ARIA - IV (NSA) ......................... 106

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
<table>
<thead>
<tr>
<th>Drug Name (NSA)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAFASITAMAB-CXIX</td>
<td>245</td>
</tr>
<tr>
<td>TAGRAXOFUSP-ERZS</td>
<td>246</td>
</tr>
<tr>
<td>TALIGLUCERASE ALFA</td>
<td>90</td>
</tr>
<tr>
<td>TALIMOGENE LAHERPAREPVEC</td>
<td>247</td>
</tr>
<tr>
<td>TEBENTAFUSP-TEBN</td>
<td>248</td>
</tr>
<tr>
<td>TECARTUS</td>
<td>51</td>
</tr>
<tr>
<td>TECENTRIQ</td>
<td>19</td>
</tr>
<tr>
<td>TEMODAR</td>
<td>249</td>
</tr>
<tr>
<td>TEMOZOLOMIDE</td>
<td>249</td>
</tr>
<tr>
<td>TEMSIROLIMUS</td>
<td>250</td>
</tr>
<tr>
<td>TEPREXO (NSA)</td>
<td>251</td>
</tr>
<tr>
<td>TEPROVIO (NSA)</td>
<td>252</td>
</tr>
<tr>
<td>THYMOXIN</td>
<td>253</td>
</tr>
<tr>
<td>THYROTROPIN ALFA</td>
<td>254</td>
</tr>
<tr>
<td>TILDRAKIZUMAB-ASMS (COMMERCIAL, NSA)</td>
<td>255</td>
</tr>
<tr>
<td>TISAGENLEUCEL</td>
<td>256</td>
</tr>
<tr>
<td>TISOTUMAB VEDOTIN-TFTV</td>
<td>258</td>
</tr>
<tr>
<td>TIVDAK</td>
<td>258</td>
</tr>
<tr>
<td>TOCILIZUMAB - IV (NSA)</td>
<td>259</td>
</tr>
<tr>
<td>TORKENEL (NSA)</td>
<td>260</td>
</tr>
<tr>
<td>TRADECETIN (NSA)</td>
<td>261</td>
</tr>
<tr>
<td>TRASTZUMAB (NSA)</td>
<td>268</td>
</tr>
<tr>
<td>TRASTZUMAB-ANNS (NSA)</td>
<td>262</td>
</tr>
<tr>
<td>TRASTZUMAB-DKST (NSA)</td>
<td>264</td>
</tr>
<tr>
<td>TRASTZUMAB-DTPT (NSA)</td>
<td>266</td>
</tr>
<tr>
<td>TRASTZUMAB-HYALURONIDASE-OYHER (NSA)</td>
<td>268</td>
</tr>
<tr>
<td>TRASTZUMAB-PKR (NSA)</td>
<td>270</td>
</tr>
<tr>
<td>TRASTZUMAB-QYYP (NSA)</td>
<td>272</td>
</tr>
<tr>
<td>TRAZIMERA (NSA)</td>
<td>272</td>
</tr>
<tr>
<td>TRELSTAR (NSA)</td>
<td>110</td>
</tr>
<tr>
<td>TRILACICLID DIHYDROCHLORIDE (NSA)</td>
<td>274</td>
</tr>
<tr>
<td>TRILURON (NSA)</td>
<td>111</td>
</tr>
<tr>
<td>TRIPLODUR (NSA)</td>
<td>110</td>
</tr>
<tr>
<td>TRIPROLEIN PAMOATE (NSA)</td>
<td>110</td>
</tr>
<tr>
<td>TRIVISC (NSA)</td>
<td>114</td>
</tr>
<tr>
<td>TRODELY (NSA)</td>
<td>237</td>
</tr>
<tr>
<td>TROGARZO (NSA)</td>
<td>117</td>
</tr>
<tr>
<td>TRUXIMA (NSA)</td>
<td>227</td>
</tr>
<tr>
<td>TYSABRI (NSA)</td>
<td>169</td>
</tr>
<tr>
<td>ULTOMIRIS (NSA)</td>
<td>218</td>
</tr>
<tr>
<td>UNITUXIN (NSA)</td>
<td>77</td>
</tr>
<tr>
<td>UPLIZNA (NSA)</td>
<td>124</td>
</tr>
<tr>
<td>UPTRAVI</td>
<td>239</td>
</tr>
<tr>
<td>USTEKINUMAB (NSA)</td>
<td>275</td>
</tr>
<tr>
<td>VABYSMO (NSA)</td>
<td>102</td>
</tr>
<tr>
<td>VANTAS (NSA)</td>
<td>110</td>
</tr>
<tr>
<td>VECTIBIX (NSA)</td>
<td>191</td>
</tr>
<tr>
<td>VEDOLIZUMAB (NSA)</td>
<td>277</td>
</tr>
<tr>
<td>VELAGLUCERASE ALFA (NSA)</td>
<td>90</td>
</tr>
<tr>
<td>VELCADE (NSA)</td>
<td>43</td>
</tr>
<tr>
<td>VELETRI (NSA)</td>
<td>91</td>
</tr>
<tr>
<td>VESTRONDASE ALFA-VJBK (NSA)</td>
<td>278</td>
</tr>
<tr>
<td>VILEPSO (NSA)</td>
<td>279</td>
</tr>
<tr>
<td>VILTOLARSEN (NSA)</td>
<td>279</td>
</tr>
<tr>
<td>VIMIZIM (NSA)</td>
<td>86</td>
</tr>
<tr>
<td>VINCRISEINE SULFATE LIPOSOMAL (NSA)</td>
<td>280</td>
</tr>
<tr>
<td>VISCO-3 (NSA)</td>
<td>114</td>
</tr>
<tr>
<td>VORETIGENE NPARVOPVE-RZL (NSA)</td>
<td>281</td>
</tr>
<tr>
<td>VPRIV (NSA)</td>
<td>90</td>
</tr>
<tr>
<td>VUTRISIRAN SODIUM (NSA)</td>
<td>282</td>
</tr>
<tr>
<td>VYEPITI (NSA)</td>
<td>92</td>
</tr>
<tr>
<td>VYONDS-S3 (NSA)</td>
<td>109</td>
</tr>
<tr>
<td>VYVAGART (NSA)</td>
<td>85</td>
</tr>
<tr>
<td>VYXEOS (NSA)</td>
<td>72</td>
</tr>
</tbody>
</table>

X

<table>
<thead>
<tr>
<th>Drug Name (NSA)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>XEMEBIFY</td>
<td>119</td>
</tr>
<tr>
<td>XEOMIN (NSA)</td>
<td>44</td>
</tr>
<tr>
<td>XGEVA (NSA)</td>
<td>75</td>
</tr>
<tr>
<td>XOLAIR</td>
<td>184</td>
</tr>
</tbody>
</table>

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
Drugs listed in this document do not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>Y</th>
<th>Z</th>
</tr>
</thead>
<tbody>
<tr>
<td>YERVOY (NSA)</td>
<td>ZALTRAP (NSA)</td>
</tr>
<tr>
<td>YESCARTA (NSA)</td>
<td>ZEPZELCA (NSA)</td>
</tr>
<tr>
<td>YONDELIS (NSA)</td>
<td>ZIRABEV (NSA)</td>
</tr>
<tr>
<td>............................</td>
<td>............................</td>
</tr>
<tr>
<td>143</td>
<td>283</td>
</tr>
<tr>
<td>24</td>
<td>155</td>
</tr>
<tr>
<td>261</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>283</td>
</tr>
<tr>
<td></td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>187</td>
</tr>
<tr>
<td></td>
<td>152</td>
</tr>
</tbody>
</table>